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Organic acids, including L- and D-lactate, explain most but not the entire elevated anion 
gap in diarrhea-associated metabolic acidosis.  Also, D-lactate has been implicated in the 
neurological symptoms associated with this condition.  Less-common organic compounds may 
influence the anion gap and neurological symptoms.  This research aimed to characterize and 
attempt to identify a previously unidentified compound, Compound X, first noted in diarrheic 
acidotic calves with elevated anion gap (Omole, 1999). 
High performance liquid chromatography (HPLC) was used to measure Compound X in 
biological fluids from diarrheic and healthy calves; diarrheic piglets, foals, and human infants; 
and calves experimentally infused with saline or acid.  Attempts were made to identify 
Compound X using HPLC with tandem and Fourier-transform mass spectrometry.   
Compound X was significantly higher in diarrheic calf serum (p<0.001) and lower in 
feces (p<0.001) and rumen fluid (p<0.001) than those fluids from healthy calves.  Compound X 
in serum from acid-infused calves (median peak area ratio = 1.5 – 1.9) was lower than that of 
diarrheic calves (median = 4.8) and only slightly greater than that of healthy calves (median = 
1.2).  Serum Compound X correlated with serum D-lactate in diarrheic and healthy calves 
combined; however, no such correlation was observed in acid-infused calves.  Conversely, a 
relationship between Compound X and neurological disturbance was present in acid-infused 
calves, but not in diarrheic calves.  In other species, Compound X was highest in diarrheic infants 
and lowest in diarrheic piglets.  Although mass spectrometry and database library searches 
revealed several compounds as putative matches for Compound X, none of the compounds made 
sense within the context of acidosis and mammalian biological fluids.  Therefore, the identity of 
Compound X remains unknown. 
Compound X has been established as a ubiquitous compound(s) present in the biological 
fluids of mammals.  Compound X may be a normal intestinal compound or bacterial metabolite 
that crosses the intestinal epithelium during diarrhea.  In spite of this, Compound X was 
associated with the neurological manifestations of D-lactic acidosis.  Compound X`s identity was 
not determined, and some reasons for this and future directions are discussed.           
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Diarrhea is a significant health problem affecting humans and domestic animals 
worldwide.  The World Health Organization has reported that approximately 2.5 billion cases of 
diarrhea occur in children less than five years of age each year, causing 1.5 million deaths in this 
population (The United Nations Children's Fund (UNICEF)/World Health Organization (WHO), 
2009).  The primary sequelae of diarrhea include dehydration and metabolic acidosis, almost 
regardless of diarrheal etiology (Grove-White & White, 1993).  Diarrhea-associated metabolic 
acidosis was historically associated with L-lactate production; however, D-lactate has been 
reported as a significant contributor to metabolic acidosis in diarrheic calves (Ewaschuk, Naylor, 
Chirino-Trejo, & Zello, 2004; Ewaschuk, Naylor, Palmer, Whiting, & Zello, 2004; Lorenz & 
Vogt, 2006; Omole, Nappert, Naylor, & Zello, 2001) and humans with short bowel syndrome 
(Azhar & Beach, 2002; Zhang, Jiang, Jiang, Cao, & Li, 2003).  One way of classifying metabolic 
acidoses uses the anion gap, which is the difference between commonly measured plasma cations 
and commonly measured plasma anions (Ewaschuk, Naylor, & Zello, 2003).  Thus, the anion gap 
represents the unmeasured anions present in a biological fluid, such as serum or urine (Ewaschuk 
et al., 2003).   In diarrhea, D-and L-lactate explain some, but not all, of the increase in anion gap. 
In 1999, Omole (Omole, 1999) used high performance liquid chromatography (HPLC) to 
measure D- and L-lactic acids, as well as pyruvic and acetic acids, in diarrheic and healthy calf 
serum.  He observed an unidentified peak, termed Compound X, on the chromatograms and 
found Compound X to be higher in the diarrheic group and to correlate with the anion gap 
(Omole, 1999).  It was suggested that Compound X was an organic acid, or a compound with 
properties similar to organic acids, that contributed to the anion gap (Omole, 1999). 
Ewaschuck (Ewaschuk, 2004) measured D- and L-lactate in diarrheic calves, as well as 
three diarrheic monogastric species – human infants, piglets, and foals.  Compound X was not 
studied, however diarrheic human infants presented with elevated anion gap that was not 
attributable to increased D- or L-lactate (Ewaschuk, 2004).  Ewaschuk (Ewaschuk, 2004) 
concluded that another organic acid was responsible for the elevated anion gap, although there 
was no mention of Compound X (Ewaschuk, 2004). 
Metabolic acidosis has also been associated with effects on the central nervous system.  In 
calves, metabolic acidosis has been correlated with depression scores (Nakagawa, Suzuki, & 
Taguchi, 2007).  Some research has suggested a role for D-lactate in acidosis-related neurologic 
disturbance (Abeysekara, Naylor, Wassef, Isak, & Zello, 2007; Lorenz & Vogt, 2006).  In 
humans, D-lactic acidosis has been associated with neurological symptoms, including slurred 
speech, ataxia, and severe lethargy (Uchida et al., 2004; Zhang, 2000), as well as memory loss 
and disorientation (Narula, El Shafei, Ramaiah, & Schmitz, 2000).  One hypothesis regarding the 
mechanism of neurologic disturbance in D-lactic acidosis is that unknown toxic compounds 
produced along with D-lactate, and not D-lactate per se, are responsible for the observed signs 
(Uribarri, Oh, & Carroll, 1998).   
 Diarrhea and its sequelae have devastating consequences to human and animal welfare, 
along with significant economic effects to the health care system and agricultural sector.  
Diarrhea-associated metabolic acidosis and the associated neurological manifestations remain 
incompletely understood.  There are potentially unknown metabolites, produced by the body or 
by intestinal bacteria, that contribute to the elevated anion gap in diarrheic animals (Omole, 1999) 
and human infants (Ewaschuk, 2004), and the mechanism of neurological manifestations from 
metabolic acidosis are unknown.  For these reasons, unidentified compounds associated with 
diarrhea and metabolic acidosis must be examined to elucidate their potentially significant roles 
in these conditions.        
 
1.2. Objectives 
 This study aimed to characterize the role of the unknown Compound X, first noted by 
Omole (Omole, 1999), in diarrhea-associated metabolic acidosis.  The first objective was to 
determine if Compound X was related to diarrheal illness, D-lactic acidosis, or acidosis-related 
neurological disturbance.  The second objective was to determine the origin of Compound X.  
The third objective was to determine whether or not Compound X is present in other diarrheic 
animals.  The final objective was to determine the identity of Compound X.  
2 
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2. LITERATURE REVIEW 
2.1 Diarrhea 
Diarrhea is a significant health problem affecting humans and domestic animals 
worldwide.  The World Health Organization has reported that approximately 2.5 billion cases of 
diarrhea occur in children under five years of age each year, causing 1.5 million deaths in this 
population (The United Nations Children's Fund (UNICEF)/World Health Organization (WHO), 
2009).  In cattle, although mortality rates from diarrhea have declined, diarrhea remains the most 
common neonatal ailment and is responsible for significant economic loss to livestock producers 
(Ewaschuk, Naylor, Chirino-Trejo et al., 2004).   
Diarrhea can be caused by osmotic, secretory, exudative, or motility factors, operating 
alone or in combination (Field, 2003).  Osmotic diarrhea occurs when ingested solutes remain 
unabsorbed by the intestinal epithelium, drawing water and ions into the intestinal lumen in 
excess of the colon’s capacity for reabsorption (Field, 2003).  Secretory diarrhea can be caused 
by bacterial enterotoxins, bile acids, hormones, or inflammatory mediators that create aberrant 
ion transport in which electrolytes and water move from the intestinal epithelium into the lumen 
and overwhelm the colon’s absorptive capacity (Field, 2003; Sellin, 2001).  Exudative diarrhea 
refers to the leakage of water, electrolytes, mucus, and protein from intestinal lymph and blood 
vessels into the intestinal lumen secondary to intestinal epithelial impairment, such as disrupted 
tight junctions (Field, 2003).  Intestinal motility-related diarrhea can result from increased 
motility, as in hyperthyroidism, as well as decreased motility, which can lead to diarrhea due to 
intestinal bacterial overgrowth (Field, 2003; Sellin, 2001).   
Diarrhea of a secretory and osmotic nature, often due to rotavirus infection or 
enterotoxigenic Escherichia coli (ETEC) infection, occurs more frequently and causes more 
mortality than the other types of diarrhea in humans (Baldi, Bianco, Nardone, Pilotto, & Zamparo, 
2009; Widdowson, 2005), calves (Acres, 1977; Foster, 2009), and other mammals (Imagawa et 
al., 1991; Moeser, 2007a).  The primary sequelae of diarrhea include dehydration and metabolic 




2.1.1 Diarrhea in humans 
Diarrhea is a leading cause of morbidity and mortality in developing countries, and while 
worldwide mortality from diarrheal disease has declined over the past half-century, morbidity due 
to diarrhea has remained relatively unchanged (Kosek, 2003; Parashar, Bresee, & Glass, 2003).  
In developing countries, it has been estimated that children under five years of age average three 
diarrheic episodes per year, with diarrhea being responsible for 19.5 – 21% of all deaths in this 
age group (Kosek, 2003).  Estimates are that Americans experience 0.7 diarrheic episodes per 
person, equivalent to a total of 200 million episodes, per year (Herikstad, 2002).  The prevalence 
of diarrheic illness in Canada has been estimated to be 0.99 episodes per person per year, with 
20.4% of people seeking medical attention for diarrheic illness (Scallan et al., 2005).  The 
importance of diarrheic illness is underscored by the fact that Canada’s population is presently 
greater than 30 million. 
Diarrhea and malnutrition interact, particularly in developing countries, in a perpetual 
cycle (Tomkins & Watson, 1989).  Diarrhea causes a decline in nutritional status, more so with 
persistent diarrhea than acute diarrhea, and poor nutritional status can subsequently increase the 
duration of diarrheic episodes (Tomkins & Watson, 1989).  The effects of diarrhea on nutritional 
status can be long-term, and a recent meta-analysis reported a dose-response relationship between 
duration of diarrheal illness and degree of linear growth stunting in children (Checkley, 2008).  
The mechanisms by which diarrhea and diarrhea-associated infections produce these effects 
include reduced intake, reduced nutrient absorption, increased nutritional requirements, and 
increased nutrient losses (Tomkins & Watson, 1989).   
In addition to the human cost of diarrheic illness, diarrhea carries a financial cost to 
sufferers, business, and health care.  In the USA, Herikstad et al. (Herikstad, 2002) reported an 
overall diarrhea prevalence of 11%, with the prevalence being 10% in children less than five 
years of age.  While Herikstad et al. (Herikstad, 2002) did not determine the economic impact of 
diarrheal illness, the annual economic impact of human gastroenteritis in Australia, whose 
population is one-tenth that of the USA, has been estimated to be more than $340 million 
(Hellard, 2003).  Diarrheal illness prevalence in Canada slightly exceeds that of Australia, and 
Canadians seek medical attention at rates comparable to Australians during diarrheal illness 
(Scallan et al., 2005).  Canada’s population in mid-2009 was approximately 50% larger than 
Australia’s population (World population data sheet, 2009), conceivably suggesting that the 
4 
economic burden of human diarrheic illness in Canada exceeds Australia’s estimated $340 
million annual cost.  
 
2.1.2 Diarrhea in other animals 
 Diarrhea is one of the most common reasons that animals present to veterinary clinics 
(Brown, 2008; Marks, 2003).  It is problematic in both small animals, such as dogs (Marks, 2003; 
Yesilbag, 2007) and cats (Zoran, 2008), and large animals, such as horses (Imagawa et al., 1991), 
elk (Keppie, 2005), pigs (Holland, 1990; Moeser, 2007b), and cattle (Foster, 2009; Gow, 2005; 
Holland, 1990; Ott, 1993).  Diarrhea produces significant morbidity and mortality in foals 
(Magdesian, 2005)  and, additionally, is responsible for poor growth in piglets, causing 
substantial economic loss to the swine industry (Moeser, 2007b).  In cattle, particularly neonatal 
calves, diarrhea is one of the most important causes of illness and death, resulting in significant 
economic loss to producers (Foster, 2009).  
 
2.1.2.1 Diarrhea in calves 
The cattle industry is a major agricultural and economic sector in North America.  In 2006, 
Canadian cattle sales totaled $6.5 billion and were the largest source of farm cash receipts (Beef 
Information Centre, 2007).  As of January 1, 2009, the North American cattle inventory was 108 
million head, and the 2008 retail value of the United States beef industry was $76 billion (United 
States Department of Agriculture Economic Research Service, 2009). 
Bovine viral diarrhea virus (BVDV), a common infectious agent in calves (Taylor, 1997), 
causes mucosal disease and is a major animal welfare concern, as it leads to considerable animal 
distress in both young and older cattle (Valle, 2005).  The virus, transmitted via pregnant dams to 
fetuses, results in offspring who are immunotolerant persistent shedders of the virus (Goens, 
2002).  BVDV has been associated with reduced production of milk, fat, and protein by Canadian 
dairy cows (Tiwari et al., 2007) and has been estimated to increase the hazard of culling of 
Canadian dairy cows by 1.86 times (Tiwari et al., 2005).  However, BVDV affects cattle across 
the lifespan and is not specific to the neonatal period.        
Neonatal calf diarrhea, most often of an infectious nature (Foster, 2009) has been 
estimated to be responsible for 49.4 – 57.2 % of preweaned dairy heifer deaths in the USA, 
depending on the season (Ott, 1993).  The United States Department of Agriculture (USDA) has 
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reported scours/diarrhea to be the leading cause of mortality, accounting for 56.5% of all 
preweaned dairy heifer deaths (USDA, 1991-2007).  The USDA also determined digestive 
problems (diarrhea, acidosis, bloat, etc.) to be responsible for 21.2% of the 2.3 million calf deaths 
and 11.1% of the 1.7 million cattle deaths in 2005 (United States Department of Agriculture, 
2007).  The infectious culprits in neonatal calf diarrhea are most often enterotoxigenic E. coli 
(ETEC), Cryptosporidium parvum, coronavirus, and rotavirus (Foster, 2009).   
Enterotoxigenic E. coli tends to cause secretory diarrhea in the first four days of life by 
colonizing the gastrointestinal tract before normal commensal bacteria are firmly established.  
Cryptosporidium parvum and coronavirus infection cause malabsorptive diarrhea secondary to 
villous atrophy, while rotavirus infection gives rise to a combination malabsorptive-secretory 
diarrhea (Foster, 2009).  The parasitic Cryptosporidia species are found on nearly 60 % of 
American dairy farms, and the most pathogenic strain, Cryptosporidium parvum, tends to infect 
younger, and particularly pre-weaned, calves at a much higher rate than older calves, heifers, and 
milking cows (Fayer, 2007).  Coronavirus and rotavirus typically infect calves younger than three 
weeks of age, and most calves demonstrate exposure to these viruses, as evidenced by antibody 
titers (Foster, 2009).  In view of the widespread and detrimental nature of diarrheal illness, an 
improved understanding of the factors associated with calf diarrheic illness will lead to 
improvements in animal welfare and reduce economic loss associated with morbidity and 
mortality of diarrheic calves.    
 
2.2 Metabolic Acidosis 
Metabolic acidosis, which is common in diarrhea, is the accumulation of hydrogen ions in 
the blood caused by the loss of bicarbonate (base) from, or addition of acid to, the blood 
(Ewaschuk, Zello, Naylor, & Brocks, 2002).  Acidosis is a disorder that results in acidemia, 
which is defined as an arterial blood pH below 7.35 (Ayers & Warrington, 2008).    
 
2.2.1 Regulation of pH 
Acids are compounds capable of donating protons (H+), while bases are compounds 
capable of accepting H+ (Morris & Low, 2008a).  Acidity is expressed using a logarithmic scale 
(Morris & Low, 2008a) as pH = -log10[H+]…………………………………………………….(2.1) 
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Normal human blood pH is between 7.38 and 7.42 (Gauthier, 2002) and is determined by the 
ratio of bicarbonate (HCO3-) to carbon dioxide (CO2) in the blood (Ayers & Warrington, 2008).  
The body normally maintains this pH range with a combination of chemical buffering, respiratory, 
and renal mechanisms (Edwards, 2008).   
The Henderson-Hasselbalch equation describes the metabolic and respiratory 









where is the arterial partial pressure of carbon dioxide.  Changes in the body’s acid or base 
production are initially counteracted by buffering systems, including carbonic acid-bicarbonate, 
phosphate, and plasma proteins, but when the changes persist, respiratory and renal mechanisms 
must compensate and correct to restore homeostasis (Clancy, 2007).  Neural respiratory 
mechanisms regulate the blood CO
2CO
Pa
2 level by altering respiration rate, while renal mechanisms 
regulate the blood HCO3- concentration via reabsorption of filtered HCO3-, production of 
titratable acid, production of HCO3-, and excretion of NH4+ (Dubose, 2008).    
Acid excretion is a renal mechanism of regulating pH.  Excretion of the acid load, be it by 
urinary excretion or renal metabolism, by the body can be classed into three categories, namely 
volatile acids (i.e., CO2/H2CO3), organic acids (e.g., lactate, citrate), and inorganic acids (e.g., 
phosphate, sulphate) (Morris & Low, 2008a).  Acidoses are typically divided, based on the type 
of excess acid present, into respiratory acidosis and metabolic acidosis (Kellum, 2005).  
Respiratory acidoses are those that reduce systemic pH by increasing , whereas metabolic 




- without changing 
(Kellum, 2005).  Mixed acidoses, in which both metabolic and respiratory factors 




2.2.2 Anion gap 
Metabolic acidoses can be classified based on the presence or absence of an elevated 
anion gap (Gauthier, 2002).  The anion gap (AG) is defined as the difference between the 
measured cations and measured anions in plasma, and is represented by the following equation 
(Fidkowski & Helstrom, 2009): 
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The normal human AG is 12 ± 2 mEq/L (LeBlond, Brown, & DeGowin, 2009).  Total (i.e., 
measured plus unmeasured) cations must equal total anions in a biological system, and regarding 
AG, this principle dictates that as unmeasured anions increase in body fluids, HCO3- decreases 
and results in elevated AG (Gauthier, 2002).   
The four major causes of elevated AG metabolic acidosis are lactic acidosis, ketoacidosis 
(common in diabetes), renal failure, and drug intoxication from salicylates, methanol, or ethylene 
glycol (Ayers & Warrington, 2008; Morris & Low, 2008b).   The cause of normal AG metabolic 
acidosis is hyperchloremic in nature and commonly related to renal tubular acidosis, renal failure, 
or diarrhea (Ayers & Warrington, 2008; Gauthier, 2002; Morris & Low, 2008b).  However, these 
divisions between elevated AG and normal AG acidoses are not always clear.  For example, 
critically ill patients experiencing increased organic acid accumulation, which should create an 
elevated AG, sometimes present with reduced plasma proteins and phosphate (i.e., unmeasured 
anions), effectively lowering the AG and offsetting any AG elevation caused by organic acid 
accumulation (Fidkowski & Helstrom, 2009). 
 
2.2.3 Metabolic acidosis in diarrheal illness  
A primary consequence of diarrhea, metabolic acidosis is the accumulation of hydrogen 
ions in the blood caused by the loss of bicarbonate from, or addition of acid to, the blood 
(Ewaschuk et al., 2002).  Historically, diarrhea-associated metabolic acidosis has been attributed 
to the L-isomer of lactate which is produced anaerobically by ischemic tissues during critical 
illness, as well as to bicarbonate loss in the feces (Ewaschuk et al., 2002).  However, L-lactate is 
not solely responsible for the acidosis in all cases.  The D-isomer of lactate has been reported as a 
significant contributor to metabolic acidosis in diarrheic calves (Ewaschuk, Naylor, Chirino-
Trejo et al., 2004; Ewaschuk, Naylor, Palmer et al., 2004; Lorenz & Vogt, 2006; Omole et al., 
2001), as well as in humans with short bowel syndrome (Azhar & Beach, 2002; Zhang et al., 
2003).   
Furthermore, elevated AG metabolic acidosis is sometimes not explained by either isomer 
of lactic acid.  Ewaschuk (Ewaschuk, 2004) measured D- and L-lactate in human infants and 
reported a mean anion gap of 23 mmol/L (normal 12 ± 2 mmol/L), with D- and L-lactate 
accounting for a combined mean of 2.1 mmol/L.  It was concluded that other organic acids may 
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contribute to the acidosis, although the contribution of elevated plasma proteins (secondary to 
dehydration) to the anion gap was not evaluated (Ewaschuk, 2004).     
 
2.2.4 Neurological effects of metabolic acidosis 
Metabolic acidosis has been associated with central nervous system effects.  In calves, 
venous pH and bicarbonate values (i.e., metabolic acidosis) have been negatively correlated with 
depression scores (Nakagawa et al., 2007).  Some research has suggested a role for D-lactic acid 
in acidosis-related neurologic disturbance.  Lornez and Vogt (2006) (Lorenz & Vogt, 2006) 
observed associations between D-lactic acid levels and listless demeanor and wobbly posture in 
calves.  Abeysekara et al. (Abeysekara et al., 2007) found strong correlations between serum or 
cerebrospinal fluid (CSF) D-lactic acid levels and neurologic impairment, as measured by 
strength of suck, ability to stand, and palpebral, menace, and tactile reflexes, in acid-infused 
calves.     
Within intensive care settings, metabolic acidosis is common, with acidemia impairing 
cardiovascular function, respiratory function, and neurologic function (Gauthier, 2002).   In 
humans with short bowel syndrome, D-lactic acidosis has been associated with a range of 
neurologic symptoms.  Dahlquist et al. (Dahlquist, Perrault, Callaway, & Jones, 1984) reported 
on two adult patients who had undergone obesity treatment via jejunoileostomy and later 
developed D-lactic acidosis with encephalopathy consisting of confusion, slurred speech, 
unsteadiness, weakness, lethargy, and hostile behavior.  Similar symptoms were observed in a 
22-year-old man with short bowel syndrome and D-lactic acidosis (Uchida et al., 2004).  D-lactic 
acidosis with encephalopathy has also occurred in infants and children with SBS subsequent to 
bowel resection (Gurevitch, 1993), and Zhang et al. (Zhang et al., 2003) reported on a 12-year-
old boy with short bowel syndrome and D-lactic acidosis who exhibited recurring neurologic 
symptoms, including slurred speech, ataxia, and severe lethargy, over a 12-month period. 
 
2.2.4.1 Possible mechanisms of neurological disturbance in metabolic acidosis 
Neurological symptoms associated with D-lactic acidosis have often been attributed to 
acidosis and elevated blood D-lactate concentration, but some reports contradict these hypotheses 
(Petersen, 2005).  Acidemia alone is not a likely cause of neurological symptoms, since 
acidemias from etiologies other than D-lactic acid do not cause neurological disturbance 
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(Abeysekara, Naylor, & Zello, 2006; Petersen, 2005).  This was demonstrated by Abeysekara 
(Abeysekara et al., 2006), who compared the neurological effects of hydrochloric acid (HCl)-
induced and L-lactic acid-induced acidemia with those of D-lactic acid-induced acidemia in 
calves.  That study reported significant inhibitory neurological disturbance from D-lactic 
acidemia, but not from acidemia produced by HCl or L-lactic acid infusion (Abeysekara et al., 
2006).   
One hypothesis regarding the mechanism of neurologic disturbance in D-lactic acidosis is 
that unknown toxic compounds produced along with D-lactate, and not D-lactic acid itself, are 
responsible for the observed signs (Uribarri et al., 1998).  One instance in which a toxin 
precipitates neurologic symptoms is ciguatera poisoning, a seafood-toxin illness characterized by 
diarrhea and neurologic disturbance, with the neurologic disturbance mechanism being related to 
a toxin produced by an ingested microalgae (Wong, 2008).  This hypothesis is supported by 
evidence showing that D-lactate is in fact metabolized and excreted from the body reasonably 
well, which suggests that D-lactate may not be the cause of neurological impairment.   
D-lactate is metabolized in mammals by D-2-hydroxyacid dehydrogenase (Tubbs, 1965), 
and the metabolic rate has been reported to be 75% of an infusion rate of 1.8 - 2.0 mEq/kg/h (Oh 
et al., 1985).  D-lactate is excreted in urine, and its fractional excretion is positively correlated to 
concomitant L-lactate levels (Oh et al., 1985).  Further, serum D-lactic acid greater than 0.5 
mmol/L has been observed in asymptomatic humans with previous jejunoileal bypass surgery, 
although the threshold level required to trigger symptoms is unknown (Thurn, 1985).  In light of 
the observations that humans can be asymptomatic during periods of D-lacatatemia and mammals 
are able to metabolize and excrete D-lactate, it is possible that other compounds are responsible 
for the neurologic manifestations of D-lactic acidosis.   
Alternatively, D-lactate may have an indirect effect on neurologic status through 
interference of vital metabolic processes within the brain.  Up-regulated glycolytic activity has 
been observed in activated neurons and astrocytes, with L-lactate being released and 
subsequently taken up and carried away to the bloodstream by astrocyte networks (Gandhi, 2009).  
It has been proposed that astrocytic L-lactate removal is necessary to maintain the higher 
glycolytic rate of activated brain cells (Gandhi, 2009).  Since D-lactate and L-lactate compete for 
transport into cells via monocarboxylate transporters, D-lactate may produce neurological effects 
as a result of impeded L-lactate removal from brain cells.  Another mechanism involving 
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astrocytes arose from a study on one-day-old chicks, in which D-lactic acid injected into the brain 
was shown to impair memory formation (Gibbs, 2008).  The proposed mechanism for this 
involves astrocytes being vital for this brain function and D-lactate inhibiting pyruvate uptake 
and metabolism in astrocyte mitochondria (Gibbs, 2008).     
 
2.3 Organic acids 
 Organic acids are compounds that contain carbon and are able to donate protons.  These 
compounds are ubiquitous in living, carbon-based systems.  Familiar examples, such as pyruvic 
acid, citric acid, succinic acid, and oxaloacetic acid are found in the energy-producing reactions 
of glycolysis and the tricarboxylic acid cycle and are essential to life.  Humans have employed 
organic acids, primarily monocarboxylic acids and their derivatives, for their beneficial effects as 
antimicrobials in food manufacturing to prevent deterioration and extend shelf life of food 
products (Cherrington et al., 1991, as cited in (Ricke, 2003)).  Organic acids are also a vital part 
of chemical industries.  For instance, lactic acid has served as a building block for biodegradable 
plastic production, citric acid has been employed in environmental remediation, and fumaric acid 
has been used to produce polyesters and other synthetic polymers (Tsao, 1999).  Organic acids, 
including oxalic acid, citric acid, hippuric acid, glucuronic acid, and aconitic acid, are normally 
produced and excreted by humans (Lawson, 1976).   However, some organic acids, when present 
in abnormal concentrations within the body, produce harmful effects.   
 
2.3.1 Detrimental organic acids in biological fluids 
Organic acids have been measured in numerous biological fluids, and their measurement 
is significant within the wide context of health and disease.  Dental health researchers have 
reported organic acids in oral fluid within the context of dental caries (Linke & Moss, 1992).  
Evaluation of exposure to environmental pollutants and of the glutathione antioxidant system can 
be based on urinary organic acid profiles (Lord, 2008).  In medicine, inborn errors of organic acid 
metabolism, many of which cause neurological disease (Marsden, 1992), are screened and 
diagnosed using organic acid analysis of urine (Lehotay, 1995), as well as serum and CSF 
(Hoffmann, 1993).   
Organic acids are present in the CSF and can therefore affect brain function (Hoffmann, 
1993).  Neurological effects associated with organic acidosis include headaches, seizures, 
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intermittent esotropia, and extremity paralysis (Hoffmann, Aramaki, Blum-Hoffmann, Nyhan, & 
Sweetman, 1989).  These organic acids are not necessarily of somatic origin or transported from 
the blood to the CSF, and some organic acids within the CSF are thought to originate from 
cerebral metabolism (Hoffmann, 1993).  In particular, short-chain monocarboxylic acids are 
capable of crossing the blood-brain barrier by facilitated transport; however, the mechanism is 
saturable and, in the case of lactate, stereospecific (Oldendorf, 1973).  This limits the amount of 
organic acids transported from blood to the CSF.  On the other hand, 6-, 8-, and 10-carbon fatty 
acids pass more freely through membranes and cross the blood-brain barrier by diffusion as a 
result of lipid-solubility (Oldendorf, 1973).   
Lactic acidosis is one of the most common and severe forms of acidosis (Gauthier, 2002), 
and up to 3.8% of hospitalized patients suffer from lactic acidosis (Luft, 1983).  The significance 
of this is underscored by the reported 30 – 88% mortality rate associated with lactic acidosis in 
hospitalized patients (Luft, 1983).  In the agriculture sector, lactic acidosis is highly important for 
the cattle industry.  Diarrhea is a major cause of death in neonatal calves (Ott, 1993), and lactic 
acidosis is a primary biochemical abnormality associated with diarrhea, as reviewed by (Grove-
White, 1998; Kaae & de Morais, 2008; Kasari, 1999).  While lactic acid appears to be primarily 
important, acetic acid and pyruvic acid also contribute to diarrheic acidosis in calves (Omole et 
al., 2001) and presumably in human infants (Ewaschuk, 2004).  There may also be other organic 
acids that contribute to the acidosis.  The prevalent and detrimental nature of metabolic acidosis 
in both animals and humans indicates the need to characterize this disorder as thoroughly as 
possible.        
 
2.4 Measurement of organic acids in biological fluids 
2.4.1 High performance liquid chromatography 
HPLC is a form of column chromatography used to identify, quantify, and purify 
molecules of interest (Bird, 1989).  With this technique, a complex liquid mixture of molecules, 
such as a biological fluid, is injected into a continuous stream of liquid mobile phase and carried 
through a hollow, resin-filled column.  Inside the column, individual molecules are separated, 
and subsequently analyzed, from one another based on the molecules’ dissimilar interactions with 
the liquid mobile phase and the stationary phase (resin) (Bird, 1989).  Molecules can be separated 
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based on their solubility in water (normal phase chromatography), solubility in organic solvents 
(reverse phase chromatography), ionic charge, and size (Bird, 1989).  
HPLC column resin must optimally increase the interaction between the solute of interest 
and the resin particles to achieve separation of the solute from other molecules in a complex 
mixture (Bird, 1989).  The use of small resin particles increases the resin surface area with which 
the solute can interact and reduces the solvent volume between resin particles, thereby facilitating 
the interaction (Bird, 1989).  Column resins must be able to withstand the high pressures (1700 – 
20,000 kPa) created as a consequence of reduced resin particle size, and silica is most commonly 
used for this purpose (Lough & Wainer, 1996).  Silica is used either unchanged or altered via 
chemical modification of the silanol groups, depending on the solutes of interest (Lough & 
Wainer, 1996).  The silanol groups within a modified silica-based column can never be 
completely chemically modified, with up to 30% remaining as free silanol, and this can lead to 
irreproducible HPLC results (Lough & Wainer, 1996).  Non-silica-based HPLC column resins, 
including styrene-divinylbenzene copolymer, overcome some of the disadvantages of silica-based 
resins and also provide stability over a wider pH range than silica-based resins (Lough & Wainer, 
1996).  
 
2.4.1.1 High performance liquid chromatography of organic acids 
HPLC has been used to measure organic acids in biological fluids of calves.  In recent 
years, several authors (Abeysekara, 2009; Ewaschuk, 2004; Omole, 1999) have studied lactate 
enantiomers and other organic acids, such as acetate and pyruvate, with HPLC assays of calf 
biological fluids.  Omole et al. (Omole, Brocks, Nappert, Naylor, & Zello, 1999) developed an 
HPLC method for measuring lactic acid enantiomers in calf serum to help determine the origin of 
lactic acidosis in diarrheic calves.  The utility of HPLC was expanded by Ewaschuk et al. 
(Ewaschuk, Naylor, Barabash, & Zello, 2004), who validated HPLC organic acid measurement in 
calf rumen fluid, feces, and urine.  Ewaschuk et al. (Ewaschuk, Naylor, Palmer et al., 2004) 
applied this method to measure organic acids in rumen fluid, feces, serum, and urine from calves 
and discovered that D-lactic acid was over-produced in the colon of diarrheic calves.  Abeysekara 
et al. (Abeysekara et al., 2007) extended the method further by using HPLC to measure organic 
acids in cerebrospinal fluid of acid-infused calves to determine that infused D-lactic acid 
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impaired central nervous system function despite creating a lesser acidemia than other infused 
acids. 
 
2.4.1.2 Biological sample preparation for high performance liquid chromatography analysis 
of organic acids        
Biological fluid samples require preparatory treatment prior to chromatographic analysis 
for organic acids.  Preparatory steps are required to remove interfering substances, concentrate 
analytes, arrest enzymatic processes, and reduce contamination of chromatographic columns 
(Ewaschuk et al., 2002).  Several methods exist for the preparation of biological fluids prior to 
chromatographic analysis.  These include distillation and extraction, dialysis, centrifugation, and 
ultrafiltration (Ewaschuk et al., 2002).   
 Ultrafiltration through a filter with a molecular weight cut off (MWCO) of 5,000, using 
centrifugation at 5,500 x g, is a simple, rapid, accurate, and reliable method that has been used to 
prepare biological fluid samples prior to HPLC.  Omole et al. (Omole et al., 1999) prepared calf 
serum for HPLC analysis of lactic acid using ultrafiltration and reported the technique to be fast 
and simple with excellent recovery of the organic acid being investigated.  Ewaschuk et al. 
(Ewaschuk, Naylor, Barabash et al., 2004) validated the use of this method for preparation of calf 
rumen fluid, feces, and urine for HPLC analysis of organic acids with good results.  Recently, 
Abeysekara et al. (Abeysekara et al., 2007) employed this method to prepare calf cerebrospinal 
fluid prior to HPLC analysis of D- and L-lactic acid. 
 
2.4.2 Mass spectrometry of organic acids 
Gas chromatography and mass spectrometry (GC/MS) is widely used for urinalysis in 
clinical medicine to aid the diagnosis of diseases characterized by metabolic derangements, 
including elevated urinary organic acids (Chace, 2003).  GC/MS sample preparatory steps 
include solvent extraction of organic acids from urine and derivitization using trimethylsilyl or 
tert-butyldimethylsilyl, which is necessary to increase the volatility of intended analytes (Chace, 
2003).  Tandem mass spectrometry (MS/MS) has been described as one of the most important 
advancements in neonatal screening for metabolic disorders in the past half-century (Chace, 
2003).  It has the advantages over GC/MS of not requiring derivitization prior to analysis, having 
the ability to measure multiple analytes from different chemical families (and thus screening for 
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multiple metabolic disorders) in a single analytical run, and facilitating higher throughput, all of 
which have proved important for screening large populations for metabolic disorders (Chace, 
2003).  Although the initial equipment costs are higher for MS/MS compared to GC/MS, the 
running costs are lower (Kawana, 2008).   
MS/MS can be used to help identify biological macromolecules, via comparison of mass 
spectra from an unknown to those of unknown compounds, or by deduction using known 
molecular masses of fragmentable groups as seen on mass spectra of unknown compounds.  For 
example, two fragments on a mass spectrum that differ in m/z by 18 Da or 44 Da can indicate 
loss of a water molecule or a CO2 molecule (Reinnig, 2008).  There are several computer 
programs to assist identification of molecules, as well.  For example, one program (Colby 
College Chemistry, 1998) generates putative molecular formulae based on input information of 
parent peak mass and fragment masses, while another program (Colby College Chemistry, 1997) 




3. MATERIALS AND METHODS 
3.1 Sample collection 
Biological fluids were obtained from previous investigations (Abeysekara, 2009; 
Ewaschuk, 2004; Omole, 1999) and stored at -20°C until the present analysis.  Details describing 
the origin of the samples are presented in Figure 3.1.     
Omole’s (Omole, 1999) research provided serum from diarrheic and healthy calves, 
ranging in age from 1 to 45 days, which were selected from the University of Saskatchewan’s 
WCVM veterinary clinic and Goodale Research Farm, respectively.  The mean serum anion gap 
was 19.7 mM in the diarrheic group and 5.6mM in the healthy group (Omole, 1999).  The mean 
serum D-lactate concentration was 5.1 mM in the diarrheic calves and not quantifiable in the 
healthy calves (Omole, 1999).  Omole (Omole, 1999) also reported an unidentified peak, which 
was higher in the diarrheic group and correlated with the anion gap, on his HPLC chromatograms.  
Ninety percent of the diarrheic calves presented to the clinic in a depressed state (Omole, 1999).  
Venous samples were obtained during the spring of 1997 from the diarrheic (n = 12) and healthy 
(n = 13) calves.  Blood was drawn from the jugular vein and allowed to clot at room temperature 
for 20 to 40 minutes.  Serum was separated by centrifugation and frozen at -20°C until assayed.     
Ewaschuk’s (Ewaschuk, 2004) research provided serum, urine, feces, and rumen fluid 
from healthy and diarrheic calves, less than 35 days old, that were selected from the University of 
Saskatchewan’s Goodale Research Farm and WCVM veterinary clinic, respectively (Ewaschuk, 
2004).  The mean serum anion gap was 28.4 mM in Ewaschuk’s diarrheic calves and 5.6 mM in 
the healthy calves.  Diarrheic calves had significantly higher concentration of D-lactate in serum, 
urine, feces, and rumen fluid (Ewaschuk, 2004). Blood was drawn from the jugular vein of the 
healthy (n = 11) and diarrheic (n = 69) calves, allowed to clot for 20 minutes at room temperature, 
and centrifuged.  Serum was drawn off and stored at -20°C until assayed.  Feces was collected 
from the healthy (n = 11) and diarrheic (n = 14) calves following perineal massage, mixed with 
thiomersal (250 µmol/L) as a bacteriostatic agent, and frozen at -20°C until assayed.  Rumen 
fluid was suctioned via the mouth from the healthy (n = 10) and diarrheic (n = 13) calves with the 
tip and tubing of a human enema kit.  Rumen fluid was mixed with thiomersal (250 µmol/L) as a 
bacteriostatic agent, and frozen at -20°C until assayed.  Urine was collected at admission from 
healthy (n = 10) and diarrheic (n = 14) calves and frozen at -20°C until assayed.   
Abeysekara’s (Abeysekara, 2009) research provided serum and cerebrospinal fluid (CSF) 
from acid-infused calves and saline-infused calves.  The calves were healthy male Holstein 
calves housed in the Dairy Barn, Department of Animal and Poultry Sciences, at the University 
of Saskatchewan (Abeysekara, 2009).  Serum was obtained from HCl-infused calves (n = 16), D-
LA-infused calves (n = 12), L-LA-infused calves (n = 5), and saline-infused calves (n = 6).  CSF 
was obtained from HCl-infused calves (n = 16), D-LA-infused calves (n = 12 ), L-LA-infused 
calves (n = 5), and saline-infused calves (n = 6). 
Ewaschuk’s (Ewaschuk, 2004) research also provided serum from diarrheic piglets (n = 
30) ranging from one to four days old, diarrheic foals (n = 18) aged less than 30 days, and 
diarrheic human infants (n = 22) less than 3 years old.  D-lactate was quantifiable in one foal, not 
detected in any of the piglets, and detected but not quantifiable in one human infant (Ewaschuk, 
2004).  Diarrheic piglets were housed at the Prairie Swine Centre (Saskatoon, Saskatchewan) and 
were chosen based on the presence of diarrhea severe enough to warrant treatment.  The diarrheic 
foals were selected from the University of Saskatchewan’s WCVM large animal teaching 
hospital or from Haygard, Dvidson, McGee and Associates of Lexington, KY.  Diarrheic human 
infants were selected from the Royal University Hospital (Saskatoon, SK) based on the presence 
of diarrhea severe enough to warrant serum electrolyte measurements (Ewaschuk, 2004). 
 
3.2 Experimental design 
 Compound X was measured in biological fluids using HPLC (section 3.4).  The details of 
the analyses, each pertaining to a specific objective (section 1.2), follow in sections 3.2.1 – 3.2.5.  
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Figure 3.1. Experimental design used to characterize Compound X. 
1, Compound X related to Diarrhea 
2, Compound X vs. D-lactate 
3, Compound X vs. neurological disturbance 
4, Compound X in other species 
5, Healthy vs. diarrheic calves 
6, Healthy calves infused with saline, hydrochloric acid, L-lactic acid, or DL-lactic acid 
7, Diarrheic calves 





3.2.1 Compound X related to diarrheal illness 
The relationship between Compound X and diarrheal illness was determined by 
comparing Compound X average peak area ratios (APAR’s) from diarrheic with those of healthy 
calves.  Comparisons were made in serum, urine, feces, and rumen fluid. 
 
3.2.2 Compound X related to D-lactic acidosis 
 The association between Compound X and D-lactic acidosis was determined by 
comparing Compound X APAR’s with D-lactic acid concentrations from diarrheic and healthy 
calves.  Serum, urine, feces, and rumen fluid were analyzed. 
 The correlation between Compound X and D-lactic acidosis was further evaluated by 
comparing Compound X APAR’s from calves infused with saline, hydrochloric acid, L-lactic 
acid, and DL-lactic acid. 
 
3.2.3 Compound X related to acidosis-associated neurological disturbance 
 Amongst diarrheic calves, the relationship between Compound X and neurological 
disturbance was evaluated by comparing the Compound X APAR’s of two categories of diarrheic 
calves – those who presented to the clinic standing (normal neurological status) and those who 
presented in lateral or sternal recumbency (abnormal neurological status).  Information about the 
calves’ presentation status was obtained from their medical records. 
 Abeysekara’s (Abeysekara, 2009) calves that were infused with saline, hydrochloric acid, 
L-lactic acid, or DL-lactic acid were assigned a numerical neurological score.  In these calves, the 
relationship between Compound X and neurological disturbance was evaluated by comparing the 
Compound X APAR’s with the neurological scores that were determined during the experimental 
infusions. 
 
3.2.4 Compound X in other species 
 The presence of Compound X in diarrheic foals, piglets, and human infants, was 
determined by measuring the APAR for these samples.  Compound X levels were compared 
between these groups and calves to determine relative levels. 
 
 
3.2.5 Attempts to identify compound X 
 Techniques employed to attempt to identify Compound X included gas chromatography 
with mass spectrometry (GC/MS), liquid chromatography with tandem mass spectrometry 
(LC/MS/MS), and Fourier-transform mass spectrometry (FTMS).   
 
3.3 Materials and Chemicals 
HPLC grade phosphoric acid (85%) was obtained from EMD Chemicals (Gibbstown, 
New Jersey, USA).  Sterile filtered bovine calf serum was obtained from HyClone (Logan, Utah, 
USA).  Adipic acid (internal standard) was obtained from Sigma (St. Louis, MO, USA).  
Modified polyethersulfone microcentrifugal filtration units (10 K MWCO) were obtained from 
VWR International (Edmonton, AB).  Thirteen millimeter polysulfone syringe filters (0.2 µm) 
were obtained from Whatman (Maidstone, Kent, UK) and 10 mL Luer-Lok™ disposable 
syringes from the National Scientific Company (Rockwood, TN, USA). 
 
3.4 Chromatographic analysis 
Compound X, whose identity was unknown, was measured semi-quantitatively using high 
performance liquid chromatography.  Since the identity of Compound X was unknown, the actual 
concentration in each sample could not be determined.  Instead, an internal standard (7 mM 
adipic acid) was added to each sample prior to HPLC analysis, and the peak area ratio (PAR) of 
Compound X to adipic acid was calculated.  All injections were done in duplicate, which allowed 
calculation of the average peak area ratio (APAR) for each set of duplicate injections.  The 
APAR was used as a semi-quantitative measure of Compound X.    
The Waters HPLC system included a Waters 600 pump, a 486 UV absorbance detector, 
and a 710 Ultra WISP autoinjector (Waters, Mississauga, ON).  Data collection and integration 
were performed using Waters Millennium®32 chromatography manager (Waters, Mississauga, 
ON). 
Chromatographic separation of Compound X and adipic acid (internal standard) was 
achieved with a Shodex RSpak KC-G guard column combined with an ion-exclusion, reversed-
phase 300 x 8.0 mm analytical column (Shodex RSpak KC-8111, Showa Denko K.K., Kawasaki, 
Japan).  Mobile phase, consisting of 0.1% phosphoric acid (0.1% formic acid was used for  
HPLC fraction collection for mass spectrometric analyses) in Milli-Q purified water, was filtered 
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through a 0.45 µm membrane filter and degassed under vacuum to remove contaminants and 
oxygen.  The mobile phase was pumped at 0.7 mL/min for 28 minutes per injection.  The column 
temperature was held constant at 50°C and UV detection was at 205 nm.  The sample injection 
volume was 20 µL for all injections, and all injections were done in duplicate (Omole, 1999).    
The presence of Compound X was designated by a signal to noise ratio greater than or 
equal to 5:1 on the chromatogram. 
 
3.5 HPLC sample preparation 
Samples were prepared by combining 100 µL of the biological fluid with 50 µL of 7 
mmol/L adipic acid (internal standard) and 50 µL of Milli-Q water.  Samples were filtered 
through VWR microcentrifugal filtration units at 14,000 x g for 30 minutes and the filtrate was 
injected into the HPLC system (Ewaschuk, 2004).   
 
3.5.1 Serum samples 
No pre-preparatory steps were required for serum before microcentrifugal filtration.    
 
3.5.2 Urine samples 
Urine was thawed at room temperature and diluted 1 in 5 with 0.1% phosphoric acid prior 
to microcentrifugal filtration (Ewaschuk, 2004). 
 
3.5.3 Fecal samples 
Feces was thawed at 4°C and shaken for 20 minutes on an automatic shaker.  One gram of 
feces was combined with 9 mL of Milli-Q water, homogenized for one minute, and centrifuged at 
17,000 x g for 30 minutes.  The supernatant was passed through a polysulfone syringe filter (0.2 
µm) prior to combining with 50 µL of internal standard and 50 µL of Milli-Q water (J. B. 
Ewaschuk, 2004). 
 
3.5.4 Rumen fluid samples 
Rumen fluid was thawed at 4°C and shaken for 20 minutes on an automatic shaker.  One 
gram of rumen fluid was combined with 9 mL of Milli-Q water, homogenized for one minute, 
and centrifuged at 17,000 x g for 30 minutes.  The supernatant was passed through a polysulfone 
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syringe filter (0.2 µm) prior to combining with 50 µL of internal standard and 50 µL of Milli-Q 
water (Ewaschuk, 2004). 
 
3.5.5 Cerebrospinal fluid samples 
No pre-preparatory steps were required for cerebrospinal fluid prior to microcentrifugal 
filtration. 
 
3.6 Mass spectrometric analysis 
3.6.1 Gas chromatography with mass spectrometry 
 Gas chromatography with mass spectrometry (GC/MS) was performed with a HP 7890 
gas chromatograph interfaced with a HP 5975C mass detector operating in total ion current mode.  
The gas chromatograph was equipped with a HP-5 column with specifications of 0.25 mm ID, 
0.25 µm film thickness, and 30 m length.  The system was controlled with HP MSD ChemStation 
software.   
 A gas chromatogram was obtained for a pooled HPLC urine fraction containing a large 
amount of Compound X.  A mass spectrum was generated for each peak on the gas 
chromatogram.  Peak identification was accomplished by comparing with three silylated organic 
acid libraries. 
 
3.6.2 Liquid chromatography with tandem mass spectrometry 
Liquid chromatography with tandem mass spectrometry (LC/MS/MS) was performed using 
a QSTAR® XL Hybrid LC/MS/MS System, which employs a quadrupole time-of-flight mass 
spectrometer.  The specified resolution of this instrument is 8,000 (Full-width half-height 
maximum, FWHM) (Applied Biosystems). 
Mass spectra were obtained for a pooled HPLC urine fraction collection containing a 
large amount of Compound X (high sample) and a pooled HPLC urine fraction collection 
containing a small amount of Compound X (low sample).  The mass spectra from the high and 
low samples were compared to identify m/z peaks that fit the pattern of high intensity in the 
“high sample” and low intensity in the “low” sample.  The molecular weights corresponding to 
m/z peaks that fit this pattern were searched in the Dictionary of Natural Products (Taylor & 
Francis Group, 2010), a subset of the Chapman & Hall/CRC Chemical Database.  The output 
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results were examined for potentially relevant compounds within the context of diarrheal illness 
and metabolic acidosis. 
Compound X was predicted to be a physiologically-relevant small organic acid or organic 
acid derivative, as it was first observed by Omole (Omole, 1999) in calf serum using an organic 
acid-separating HPLC column with UV detection at 205 nm, which he determined to be the 
absorption maxima for lactic acid.  Additionally, Compound X absorbs light at 205 nm, and all 
compounds with double bonds, including but not limited to carboxylic acids, absorb light in the 
ultraviolet range between 200 and 350 nm (Scott, 2003). 
 
3.6.3 Fourier-transform mass spectrometry 
FTMS was performed using a Bruker Daltonics 7T Apex III mass spectrometer (Bruker 
Daltonics, Billerica, MA, USA).  The ion source was a Bruker Apollo ESI.  
The Compound X peak fractions from 20 injections from a urine sample containing a high 
level of Compound X were collected and pooled using HPLC.  The sample was analyzed using 
Fourier-transform mass spectrometry (FTMS) in positive ESI mode.   
 The accurate masses corresponding to the FTMS m/z ratios were searched in the 
Dictionary of Natural Products (Taylor & Francis Group, 2010), a subset of the Chapman & 
Hall/CRC Chemical Database, using a 10 ppm range.  When matches were obtained in this range, 
the search was repeated using a 5 ppm and then a 2 ppm range to narrow the results.  Compounds 
that matched at this narrow range were deemed as potential candidates for Compound X.     
 
3.7 Mass spectrometry sample preparation 
3.7.1 Gas chromatography with mass spectrometry 
 The Compound X peak fractions from 20 injections from a urine sample containing a high 
level of Compound X were collected and pooled using HPLC.  This was accomplished by 
manually collecting, in a glass vial, the portion of the HPLC effluent that contained Compound X 
from 20 successive injections.  The timing (in seconds after noticing a rise in absorbance on the 
UV detector) of the collection was based on the HPLC mobile phase flow rate (mL/sec) and the 
volume (mL) of the effluent line extending from the UV detector.  This allowed Compound X to 
be collected in isolation from other components in the urine.  
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 Solvent extraction and was performed on the pooled fraction.  The pooled fraction was 
combined with tropic acid (200 µg/mL) as the internal standard.  Methoxyamine (2%) was added 
and the pH was reduced to less than 1 with HCl.  An excess of sodium chloride was added.  Ethyl 
acetate was combined with the mixture, and it was shaken and centrifuged for three minutes.  The 
organic layer was removed and added to anhydrous sodium sulfate and shaken.  The resulting 
organic layer was removed and combined with diethyl ether.  The final organic layer was 
transferred to a test tube and evaporated to dryness with gentle heat under nitrogen. 
 Derivatization was accomplished by adding bistrimethylsilylfluoroacetamide with 1% 
trimethylchlorosilane to the dry tubes containing extracted organic acids and heating at 70°C for 
30 minutes.  One microlitre was injected into the GC/MS system.              
 
3.7.2 Liquid chromatography with tandem mass spectrometry 
 The Compound X peak fractions from 20 injections from a urine sample containing a high 
level of Compound X were collected and pooled (high sample) using HPLC.  This was 
accomplished by manually collecting, in a glass vial, the portion of the HPLC effluent that 
contained Compound X from 20 successive injections.  The timing (in seconds after noticing a 
rise in absorbance on the UV detector) of the collection was based on the HPLC mobile phase 
flow rate (mL/sec) and the volume (mL) of the effluent line extending from the UV detector.  
This allowed Compound X to be collected in isolation from other components in the urine.  
Similarly, the Compound X peak fractions from 20 injections from a urine sample containing a 
low level of Compound X were collected and pooled (low sample) using HPLC.  The high 
sample and low sample were analyzed using LC/MS/MS in negative electrospray ionization (ESI) 
mode.   
 
3.7.3 Fourier-transform mass spectrometry 
The Compound X peak fractions from 20 injections from a urine sample containing a high 
level of Compound X were collected and pooled using HPLC.  The process to obtain this sample 
was identical to that described in section 3.7.1.  The pooled sample was analyzed using Fourier-




3.8 Statistical analysis 
Statistical analyses were performed using SPSS v.16.0 for Microsoft Windows (Chicago, 
IL).  Statistical significance was designated as p < 0.05. 
 
3.8.1 Compound X related to diarrheal illness 
Mann-Whitney U tests were used to determine statistical differences between Compound 
X APAR’s from healthy and diarrheic calf serum, urine, feces, and rumen fluid.  A non-
parametric test was used because the Q-Q plots for these variables showed that the data were not 
normally distributed. 
 
3.8.2 Compound X related to D-lactic acidosis    
Mann-Whitney U tests were used to determine statistical differences between Compound 
X APAR’s amongst the four groups of infused calves (saline, hydrochloric acid, L-lactic acid, 
and DL-lactic acid) in serum and CSF.  Spearman’s rho was used to determine correlations 
between Compound X and D-lactate in diarrheic and healthy calf serum, urine, feces, and rumen 
fluid.  Spearman’s rho was used to determine correlations between Compound X and D-lactate in 
serum and cerebrospinal fluid from the infused calves (all four groups of infused calves were 
combined for this analysis). The non-parametric Mann-Whitney U test was chosen due to small 
sample sizes (5 ≤ n ≤ 15 for infused calves) and because Q-Q plots showed that the Compound X 
APAR data did not fit the normal distribution.   
 
3.8.3 Compound X related to acidosis-associated neurological disturbance 
A Mann-Whitney U test was used to detect a statistical difference between diarrheic 
calves with normal neurological presentation and those with abnormal neurological presentation.  
The non-parametric test was used because of the small sample size (n = 12) of the group that was 
neurologically normal and because the Q-Q plots showed the Compound X APAR data did not fit 
the normal distribution.  
 Spearman’s rho correlation was used to determine correlations in infused calves (all four 
groups of calves were combined for this analysis) between serum Compound X and neurological 
score, as well as between cerebrospinal fluid Compound X and neurological score.  This non-
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parametric correlation test was used due to small sample sizes (4 ≤ n ≤ 14) and data that did not 
fit the normal distribution, as determined by Q-Q plots. 
 
3.8.4 Compound X in other species 
 Mann-Whitney U tests were performed to determine statistical differences between 
Compound X APAR’s amongst diarrheic human infants, diarrheic calves, diarrheic foals, and 
diarrheic piglets.  A non-parametric statistical test was employed because the data were not 
normally distributed, as tested by Q-Q plots.   
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4. RESULTS 
Compound X was present in 411 of 414 (99.3%) samples analyzed.  Compound X was 


























































Figure 4.1. A typical high performance liquid chromatogram of standard calf serum with adipic 
acid added as an internal standard.  Numbers above peaks represent retention times in minutes 

















































































4.1 Compound X related to diarrheal illness 
In healthy calves, the Compound X concentration was greatest in feces, urine, and rumen 
fluid (Figure 4.3).  There were no statistically significant differences between these three 
biological matrices in healthy calves.  The concentration was statistically significantly (p<0.05) 
lower in serum than feces, urine, and rumen fluid.   
In diarrheic calves, the Compound X concentration was greatest in urine, followed by 
feces, serum, and rumen fluid (Figure 4.3).  The difference between each biological fluid was 
statistically significant (p<0.05). 
Both feces and rumen fluid from healthy calves contained a higher concentration of 
Compound X than feces (p<0.05) and rumen fluid (p<0.05) from diarrheic calves, while healthy 
calf serum had a lower Compound X concentration than diarrheic calf  
serum (p<0.05) (Figure 4.3).  There was no statistically significant difference between healthy 
calf urine and diarrheic calf urine. 
Adipic Acid 
(internal standard) 
Figure 4.2. A typical high performance liquid chromatogram of a diarrheic calf serum sample 
with adipic acid added as an internal standard.  Numbers above peaks represent retention times 































Table 4.1. Comparison of Compound X mean average peak area ratios (APAR) in healthy 
nd diarrheic calf biological fluids. a  






































Figure 4.3. Comparison of the median average peak area ratios (numbers directly above bars) 
from biological matrices of healthy and diarrheic calves. Letters above bars indicate statistical 
differences between bars, as determined by Mann-Whitney U tests (any bars with the same 
letter are not different, while any two bars with different letters are significantly different, 




Serum 1.32 ± 0.60, 24 6.35 ± 4.80, 80 <0.05
Urine 44.9 ± 60.3, 10 41.6 ± 46.5, 14 1
Feces 42.7 ± 30.7, 20 11.1 ± 10.1, 29 <0.05
Rumen Fluid 26.1 ± 26.2, 10 4.48 ± 8.60, 20 <0.05
Biological Fluid p-valuea
Healthy
(mean ± SD, n)
Diarrheic
(mean ± SD, n)
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4.2 Compound X related to D-lactic acidosis 
Healthy calves that were experimentally infused with saline, hydrochloric acid (HCl), DL-
lactic acid (DL-LA), or L-lactic acid (L-LA) had relatively low levels of Compound X in serum 
and cerebrospinal fluid (CSF).  The serum Compound X APAR’s from these calves ranged from 
1.45 to 1.87.  These APAR’s were slightly higher than the median APAR (1.2) in healthy calves, 
but lower than the median APAR (4.8) in diarrheic calves (Figures 4.3 and 4.4). 
HCl- and DL-LA-infused calves had higher serum levels of Compound X than those 
infused with saline and L-LA.  There was no statistically significant difference between the HCl- 
and DL-LA-infused calves, nor was there a statistically significant difference between the saline- 
and L-LA-infused calves (Figure 4.4). 
Healthy calves that were experimentally infused with saline, HCl, L-LA, or DL-LA 
showed little variation with regard to the amount of Compound X in CSF.  Compound X was 
statistically significantly higher in the CSF of HCl- and DL-LA-infused calves when compared to 
L-LA-infused calves (Figure 4.4).  However, the concentration of Compound X in CSF of HCl- 
and DL-LA-infused calves was not statistically significantly greater than that of saline-infused 
calves (Figure 4.4).  
The Compound X concentration was higher in serum than CSF from experimentally 
infused calves for each infusate tested.  Comparing serum and CSF across all infusate conditions, 
the Compound X concentration from DL-LA-infused calf CSF was not different from serum 



















 Compound X did not correlate with D-lactate in serum or cerebrospinal fluid from infused 
(all four infusion conditions combined) calves (Table 4.2).  
In diarrheic and healthy calf serum, Compound X correlated with D-lactate concentration 
(Spearman’s rho = 0.289, p = 0.003) when the two groups of calves were considered together 
(Table 4.2).  No significant correlations were observed between Compound X and D-lactate in 
diarrheic or healthy calf serum when these were considered as separate groups (Table 4.2).  In 
rumen fluid, Compound X negatively correlated with D-lactate (Spearman’s rho = -0.389, p = 
0.03) when diarrheic and healthy calves were combined (Table 4.2).  There were no significant 
correlations between Compound X and D-lactate in diarrheic or healthy calf rumen fluid when 
these were considered as separate groups (Table 4.2).  No statistically significant correlations 
were found between Compound X and D-lactate in urine or feces from diarrheic and healthy 











































a,b b 5 
1.101.03 d 
0.830.77 
Figure 4.4. Comparison of the median average peak area ratios from serum and cerebrospinal 
fluid (CSF) of healthy and diarrheic calves. Numbers directly above bars are the median 
APARs.  Letters above bars indicate statistical differences between bars, as determined by 
Mann-Whitney U tests (any bars with the same letter are not different, while any two bars 
with different letters are significantly different, p<0.05).  Whole numbers above bars indicate 








Table 4.2. Correlations between Compound X and D-lactate in calf biological fluids.   
 
Biological Fluid Analyzed n Spearman’s 
rho
p-value
Diarrheic calf serum 69 ns 0.1
Healthy calf serum 24 ns 0.06
All diarrheic & healthy calf serum 93 0.289 0.003
Diarrheic calf urine 14 ns 0.38
Healthy calf urine 10 ns 0.36
All diarrheic & healthy calf urine 24 ns 0.45
Diarrheic calf feces 14 ns 0.23
Healthy calf feces 11 ns 0.14
All diarrheic & healthy calf feces 25 ns 0.09
Diarrheic calf rumen fluid 13 ns 0.16
Healthy calf rumen fluid 10 ns 0.07
All diarrheic & healthy calf rumen fluid 23 -0.389 0.03
Infused calf serum 34 ns 0.14
















 4.3 Compound X related to acidosis-associated neurological disturbance 
 Amongst 51 diarrheic calves, 39 presented in lateral of sternal recumbency and were 
defined in the current study as having abnormal neurological status.  The other 12 calves 
presented in a standing position and were defined as having normal neurological status.  The 
Compound X levels between these two groups were not statistically significantly different (p = 
0.982). 
 Amongst calves infused with saline, hydrochloric acid, L-lactic acid, or DL-lactic acid (all 
four infusion conditions combined), Compound X correlated significantly with the neurological 
score in both serum (Spearman’s rho = 0.399, p = 0.01 ) and CSF (Spearman’s rho = 0.324, p = 
0.043). 
 
4.4 Compound X in other species 
 Compound X was present in diarrheic piglets, foals, and human infants.  Compound X 
was significantly greater in serum from diarrheic human infants than serum from diarrheic calves 
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(p = 0.04), diarrheic foals (p < 0.01), and diarrheic piglets (p < 0.01) (Figure 4.5).  Diarrheic 
piglets had lower serum Compound X levels than all other diarrheic species (p < 0.01 for each 














4.5 Attempts to identify Compound X  
4.5.1 Gas chromatography with mass spectrometry 
 Gas chromatography with mass spectrometry (GC/MS) of a Compound X fraction 
collected from diarrheic calf urine revealed a very large unknown peak, which eluted at 48.1 
minutes near the end of the gas chromatogram.  The mass spectrum for this peak did not match 











n = 22 
 Diar Calf 





























Figure 4.5. Comparison of the Compound X median average peak area ratios from serum of 
various species. Numbers above bars indicate median APAR.  Letters above bars indicate 
statistical differences between bars, as determined by Mann-Whitney U tests (any bars with 
the same letter are not different, while any two bars with different letters are significantly 
different, p<0.05).  Numbers above letters indicate sample size.  Diar, diarrheic; Hlthy, 
healthy. 
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4.5.2 Liquid chromatography with tandem mass spectrometry 
 The LC/MS/MS mass spectra from both the high sample and the low sample showed 
peaks near 146 m/z, 157 m/z, and 337 m/z.  The 146 m/z peak in the high sample had 3-fold the 
intensity of the low sample.  The 157 m/z peak in the high sample had 20-fold the intensity of the 
low sample.  The 337 m/z peak in the high sample was considerably more intense than that in the 
low sample (Figure 4.6). 
A database search for compounds corresponding to the 146 m/z peak returned 173 
matches at the 1000 parts per million (ppm) level of accuracy (Table A.1 in appendix).  Among 
these were several amino acids and amino acid derivatives.  Notably, glutamic acid was among 
these (Table A.1 in appendix). 
A database search for compounds corresponding to the 157 m/z peak returned 112 
matches at the 1000 parts per million (ppm) level of accuracy (Table A.1 in appendix).  Notably, 
butanoic acid anhydride was among these.    
A database search for compounds corresponding to the 337 m/z peak returned 149 
matches at the 50 ppm level of accuracy (Table A.1 in appendix).  None of the matched 
compounds were deemed to be likely candidates for Compound X.   
The mass spectrum from the high sample showed peaks at 315 m/z, 473 m/z, and 517 m/z, 
but these were not present on the mass spectrum from the low sample.  A search of the Chapman 
& Hall Natural Products database returned several matches for compounds corresponding to the 
peaks at 315 m/z, 473 m/z, and 517 m/z (Table A.1 in appendix), though none of these were 




































Figure 4.6. Mass spectra from injection of a)30 µL of calf urine fraction containing a 
all amount of Compound X; b)30 µL of a calf urine fraction containing a large amount 
f Compound X; c)100 µL of a calf urine fraction containing  a small amount of 





4.5.3 Fourier-transform mass spectrometry  
FTMS analysis identified singly-charged molecular ions at m/z 257, 317, 475, 513, 528, 
and 565.   A search of the Chapman & Hall natural products database, using a 10 ppm window, 
yielded a small number of compound matches (Table 4.5).  The database search was completed 
for the same m/z ratio peaks presuming that the ions were sodium adducts (Table 4.6) and 
potassium adducts (Appendix Table A.3). 
Notably, the mass spectrum from FTMS showed monoisotopic peaks at 317 m/z and 475 
m/z.  These m/z’s are similar to peaks observed on the LC/MS/MS mass spectra.  An FTMS peak 
t 513m/z approximately corresponded to a peak at 517m/z on the LC/MS/MS mass spectra. 




A search of the Chapman & Hall Natural P
/z using a 700 ppm accuracy range (Appendix Table A.3).  A search for the 475 m/z 
returned 213 matches at the 250 ppm accuracy range.  A search for the 513 m/z returned 16 
matches at the 700 ppm accuracy range (Appendix Table A.3).  None of the matched compounds
for the FTMS m/z’s were deemed to be likely candidates for Compound X.   
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Table 4.3. Compounds and corresponding molecular formulae identified as putative 
matches for Compound X as identified by FTMS. 
Peak m/za m/z - H+ Low limit 10 ppm
b 
range (molar mass)
High limit 10 ppm 
range (molar mass)
# of library 
matches
257.0300723 256.0227963 256.0202361 256.0253565 2
Compound Name 
Naphthaleneoctolc 
Secobatzelline A; 4-Deimino, 4-oxo 
317.0957864 316.0885104 316.0853495 316.0916713 4
Compound Name 
Cyclodercitine 
Orotidine; 3N-Me, Me ester 
Uridine-5-acetic acid; Me ester 
475.1369619 474.1296859 474.1249446 474.1344272 5
Compound Name 
1,5-Anhydrofructose, 9CI; D-form, Tribenzoylc 
513.084279 512.077003 512.0718822 512.0821238 0
528.0473004 527.0400244 527.034754 527.0452948 0
565.2863106 564.2790346 564.2733918 564.2846774 4
Compound Name 
 Aristophyll A; 3,4-Didehydro 
 Cholestane-3,21-diol, 9CI; (3a,5a)-form, Disulfated 
 Cholestane-3,21-diol, 9CI; (3ß,5a)-form, Disulfated 
 Pemptoporphyrin; Di-Me ester 
2,4,5-Trihydroxy-2-(hydroxymethyl)pentanoic acid; (2R,4S)-form, 
1,4-Lactone, tribenzoylc 
Arginine, INN, USAN; (S)-form, Mono(2-mercaptoethanesulfonate)c 
1,6-Anhydromannose; ß-D-Pyranose-form, 2,3,4-Tribenzoylc 
15-Chloro-1,4-epoxy-5,8,9-trihydroxy-11(13)-germacren-12,6-olid-
14-oic acid; (1ß,4ß,5ß,6a,8ß,9a,10ßH)-form, 8-(2-Hydroxymethyl-2-
butenoyl), Me esterd 





















am/z = mass to charge ratio of molecular ion fragments identified by the mass spectrometer 
bppm = parts per million 
calso matched at 5ppm, but not at 2 ppm 
dalso matched at 5 ppm and 2 ppm 
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Table 4.4. Compounds and corresponding molecular formulae identified as putative 
matches for Compound X as identified by FTMS, assuming molecular ions were sodium 
adducts. 
Peak m/za m/z - Na+
Low limit 10 ppmb 
range (molar 
mass)






257.0300723 234.0408423 234.0385019 234.0431827 0
317.0957864 294.1065564 294.1036153 294.1094975 3
Compound Name 
 Distichonic acid Ac
 Distichonic acid A; 2'-Deoxy, 3-hydroxyc 
 Distichonic acid A; 2'-Epimerc 
475.1369619 452.1477319 452.1432104 452.1522534 9
Compound Name 
Aiphanolc 
Artonin E; 4'''-Hydroxyc 





513.084279 490.095049 490.090148 490.09995 0
528.0473004 505.0580704 505.0530198 505.063121 0
565.2863106 542.2970806 542.2916576 542.3025036 0
9,10-Dihydro-3,9,10-trihydroxy-8,8-dimethyl-2-phenyl-
4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one; (9R*,10R*)-
form, 3-Me ether, 9,10-di-Acc 
 9,10-Dihydro-5,9,10-trihydroxy-8,8-dimethyl-2-phenyl-
4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one; (9R*,10R*)-















am/z = mass to charge ratio of molecular ion fragments identified by the mass spectrometer 
bppm = parts per million 





Table 4.5. Chapman & Hall database-searched mass ranges and number of putative 







Low end of 
searched range 
(molar mass)






LC/MS/MSc 146.073 1000 146.9332 147.2274 173
LC/MS/MS 157.0697 1000 157.9189 158.2351 112
LC/MS/MS 315.1263 500 315.9755 316.2916 110
LC/MS/MS 337.1211 50 338.1115 338.1453 149
LC/MS/MS 473.2008 100 474.1607 474.2555 71
LC/MS/MS 517.161 1000 517.6501 518.6864 214
FTMSd 317.0958 700 315.8672 316.3098 130
FTMS 475.137 250 474.0112 474.2482 213
FTMS 513.0843 700 511.7185 512.4355 16  
am/z = mass to charge ratio of molecular ion fragments identified by the mass spectrometer 
bppm = parts per million 
cLC/MS/MS = liquid chromatography with tandem mass spectrometry 





5.1 Characterization of Compound X 
5.1.1 Compound X in diarrheal illness 
Compound X was present in higher concentrations in serum from diarrheic calves than 
serum from healthy calves.  The elevated Compound X in diarrheic calf serum may have arisen 
from increased absorption through the intestinal epithelium due to gastrointestinal bacterial 
production, epithelial barrier dysfunction, or in combination.  Additional possible contributors to 
the increased serum Compound X include enhanced normal intestinal absorption, reduced renal 
clearance, and decreased metabolism of Compound X during diarrheal illness.  Carbohydrate 
malabsorption during diarrheal illness can lead to proliferation of certain bacteria, namely 
Lactobacillus spp., with consequent production of short-chain fatty acids and D-lactate 
(Ewaschuk, Naylor, Palmer et al., 2004).  The elevated serum Compound X level in diarrheic 
calves matched the pattern for D-lactate observed by Ewaschuk (Ewaschuk, 2004).  Conceivably, 
these bacteria may simultaneously produce other organic acids, one of which could be Compound 
X.   
A mild positive correlation (Spearman’s rho 0.289, p = 0.003) was observed between D-
lactate and Compound X in diarrheic and healthy calf serum (Table 4.2).   This relationship was 
not observed in calves that were infused with saline, HCl, L-lactic acid, or DL-lactic acid (Table 
4.2).  Furthermore, serum Compound X levels in acid-infused calves were very low, even in 
those that received the DL-lactic acid infusion (Figure 4.4).  This suggests that some aspect of 
diarrheal illness, possibly the infectious agent, is involved in Compound X production or 
permeation through the intestinal wall.  A limitation of the current study was that the role of 
hemoconcentration, due to dehydration, was not evaluated as a contributor to the increased serum 
Compound X levels in diarrheic illness.        
Intestinal bacterial production of Compound X does not in itself explain the Compound X 
levels in biological fluids, since healthy calf feces contained large quantities of Compound X 
with little apparent permeation or absorption into the bloodstream (Figure 4.3).  Intestinal 
permeability may be a significant contributory factor to the elevated Compound X levels in 
diarrheic calf serum compared to healthy calf serum.  Ewaschuk (Ewaschuk, 2004) observed 
increased D-lactate absorption from the intestinal tract in diarrheic calves, indicating that small, 
microbial-produced molecules can be absorbed during diarrheal illness.  Intestinal permeability 
has been reported to increase during infection with Cryptosporidium parvum, rotavirus, and 
enteroaggregative E. coli (Kukuruzovic, 2002), as well as Shigella and enteropathogenic E. coli 
(Johansen, 1989).  At least two of these, Cryptosporidium parvum and rotavirus, are within the 
four most significant causes of calf diarrhea (Foster, 2009), and, as such, could have accounted 
for a significant portion of the diarrheic calf cases.  Unfortunately, the cause of the diarrhea was 
not determined in the studies from which the samples were obtained. 
Compound X was relatively high in healthy calf feces compared to diarrheic feces and 
other biological fluids (Figure 4.3).  The relatively low Compound X in diarrheic feces may, at 
least in part, be explained by a dilution effect in which abnormally large amounts of water are 
drawn into the intestinal lumen to produce diarrhea.  However, this is opposite to the pattern 
observed by Ewaschuk (Ewaschuk, 2004), who reported increased fecal D-lactate during 
diarrheal illness.  The large amount of Compound X in healthy feces suggests that it is a normal 
component of feces, such as an unabsorbed dietary component, a compound that is normally 
excreted in bile, or a bacterial metabolite.   For instance, Compound X could be a di- or tripeptide, 
as oligopeptides have been reported to be present in digesta flowing at the ileum in calves 
(Montagne L, 2003).  Oligopeptides have also been observed in calf plasma (Koeln, 1993); 
however they are present in only very small (micromolar) quantities in urine, owing to efficient 
renal reabsorption (Daniel, 2003).  Since urinary Compound X levels were high in the current 
study, the likelihood of Compound X being an oligopeptide is very small.   
The plausibility of Compound X originating from bile warrants consideration, since bile 
contains numerous organic compounds, including bile acids, phospholipids, cholesterol, bilirubin, 
proteins, peptides, and glutathione (Esteller, 2008).  Many exogenous and endogenous 
compounds undergo enterohepatic circulation, and numerous metabolites are formed as these 
flow through the intestinal lumen, enterocytes, blood, hepatocytes, and biliary system (Esteller, 
2008).  The possibility remains that Compound X is one of these bile components or biliary 
component metabolites.   
An inverse relationship (Spearman’s rho = -0.682, p < 0.0001) (also see Figure 4.3) was 
observed between fecal Compound X and serum Compound X in healthy and diarrheic 
(combined) calves.  Although fecal dilution of Compound X during diarrheal illness probably 
contributed to this relationship, it may also suggest that Compound X is an abundant, normal 
intestinal floral metabolite that is normally kept within the lumen by a healthy gut epithelium and 
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translocated across the epithelium during diarrheic illness.  This hypothesis is backed by reports 
that intestinal permeability increases during infectious diarrhea (Isolauri, 1989; Zuckerman, 
1993). 
 
5.1.2 Compound X in D-lactic acidosis 
 Compound X was arguably related to diarrheic D-lactic acidosis more than D-lactic 
acidosis per se, as evidenced by differences between infused and diarrheic calves.  The serum 
Compound X levels in DL-lactic acid-infused calves (median APAR = 1.86) were similar in 
magnitude to those of healthy calves (median APAR = 1.2), while the Compound X in diarrheic 
calves (median APAR = 4.8) was significantly greater than that of healthy calves.  Additionally, 
the serum Compound X was significantly (p<0.0001) greater in diarrheic calves compared to DL-
lactic acid-infused calves.   
These relationships imply that Compound X is related to some aspect of the diarrheal 
illness, such as bacterial metabolism in the intestinal lumen.  However, this is difficult to assess 
because no relationship was found between Compound X and D-lactate (produced by microbes) 
in feces and because Compound X was abundant in healthy calf feces and lower in diarrheic 
feces, which is opposite to the pattern observed by Ewaschuk (Ewaschuk, Naylor, Palmer et al., 
2004) for fecal D-lactate in calves.  Overall, comparisons with Ewaschuk’s (Ewaschuk, 2004) 
data showed Compound X and D-lactate in healthy vs. diarrheic calves to have a similar pattern 
only for serum, while the feces and rumen fluid showed opposite patterns.  The pattern for urine 
was also dissimilar, with Ewaschuk (Ewaschuk, 2004) reporting significantly increased D-lactate 
in diarrheic calves, while no significant difference was observed for urinary Compound X. 
        
5.1.3 Compound X and neurological disturbance 
 Neurological disturbance associated with D-lactic acidosis, particularly after infusion of 
DL-lactic acid, in calves has been reported (Abeysekara, 2009), with the mechanism being 
related to D-lactate and not acidemia per se (Abeysekara, 2009).  A low-moderate correlation 
(Spearman’s rho = 0.399, p = 0.01) was found between serum Compound X and neurological 
disturbance score in DL-lactic acid-infused calves, but no correlation was observed between 
Compound X and D-lactate in serum or CSF from these calves.  These findings imply that 
Compound X has some role in the neurological symptoms, but because they arose from analysis 
42 
of acid-infused calves that had only slightly elevated serum Compound X, the practical 
implications are uncertain.    
Unfortunately, the data from diarrheic calves showed relationships that were opposite to 
those from acid-infused calves with regard to neurological disturbance and D-lactate.  
Specifically, serum Compound X and D-lactate were mildly correlated, while Compound X 
showed no correlation with neurologic disturbance in diarrheic calves.  The major limitation of 
this analysis in diarrheic calves was the broad working definition of neurologic disturbance.  An 
objectively-assigned neurological score for diarrheic calves would have improved the robustness 
of the analysis.  
In order for Compound X to affect the nervous system, it would have to be present in the 
brain and cerebrospinal fluid.  Abeysekara (Abeysekara, 2009) reported increased cerebrospinal 
fluid D-lactate levels that corresponded to neurological symptoms in DL-lactic acid-infused 
calves.  Compound X was observed in cerebrospinal fluid from these calves, but the levels were 
not significantly different between DL-lactic acid-infused calves, saline-infused calves, and HCl-
infused calves.  These levels were also physiologically low compared to those of diarrheic calf 
serum.  Nonetheless, a low-moderate positive correlation (Spearman’s rho = 0.324, p < 0.05) 
existed between cerebrospinal fluid Compound X and neurological score, suggesting a possible 
link between the two.    
 
5.1.4 Compound X in monogastric species 
Compound X was present in serum from diarrheic piglets, foals, and human infants and 
the levels were significantly different from one another (Figure 4.5).  Compound X was lowest in 
diarrheic piglet serum and highest in human infant serum.  The differences could be in part due to 
the age differences between species.  The diarrheic piglets were one to four days old, the 
diarrheic foals were less than 30 days old, the diarrheic calves were less than 45 days old, and the 
diarrheic human infants were less than three years old.   Also, age- and species-specific 
susceptibilities to certain infectious causes of diarrhea may have differentially impacted the 
intestinal luminal environment.  For example, the major causes of piglet diarrhea have been 
reported to be ETEC and rotavirus (Lecce, 1986), while foal diarrhea is commonly caused by 
Clostridium perfringens, Clostridium difficile, Salmonella typhimurium, and rotavirus 
(Magdesian, 2005).  Calf diarrhea, on the other hand, is most often caused by enterotoxigenic 
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ETEC, Cryptosporidium parvum, coronavirus, and rotavirus (Foster, 2009).  Differences in 
animal husbandry, specifically the clean piglet housing conditions and piglet treatment with 
antibiotics, could also affect Compound X by altering the intestinal flora.  It is unknown if or 
how these factors affected Compound X, but it is not possible to rule out their influence.     
 Ewaschuk (Ewaschuk, 2004) reported elevated anion gap in diarrheic human infant serum 
with low (1-3 mmol/L) levels of L-LA and non-detectable levels of D-LA.  It was suggested that 
another organic acid may be responsible for the elevated anion gap (Ewaschuk, 2004).  If 
Compound X is an organic acid, it could help explain the elevated anion gap in diarrheic human 
infants.  Indeed, Compound X was high in diarrheic human infant serum and was significantly 
higher than serum from diarrheic calves, foals, and piglets (Figure 4.5). 
 
5.2 Efforts toward identifying Compound X  
Compound X was hypothesized to be an organic acid, since it was first observed during 
HPLC using an organic acid-separating column and since it correlated with the anion gap (Omole, 
1999).  Compound X was elevated in serum from calves with diarrheal illness, a time during 
which many calves are neurologically depressed, raising the possibility that Compound X is a 
neurotoxin that contributes to neurological symptoms.  Data from acid-infusion trials 
(Abeysekara, 2009) indicated that the neurologic disturbance was most pronounced during DL-
lactic acid infusion.  Intriguingly, the Compound X concentration was highest, albeit non-
significantly, in CSF during DL-lactic acid infusion compared to other acid infusions, weakly 
supporting the hypothesis that Compound X contributes to neurological symptoms.  However, 
lack of a clear relationship between Compound X and neurological dysfunction makes it unlikely 
that Compound X is a neurotoxin.   
 
5.2.1 HPLC retention times for selected molecules  
One way to identify an unknown compound, such as Compound X, is to check the 
retention times (RT) of possible compounds against that of Compound X using HPLC.  A major 
limitation of this method is that the number of possible compounds could be very large, and the 
time and financial costs are prohibitive.  Also, HPLC has poor specificity in that many 
compounds have similar RT’s (Dalluge et al., 2002).  This implies that Compound X could 
actually be a mixture of compounds that elute from the HPLC machine simultaneously.  Thus, 
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even if a putative compound had a RT similar to Compound X, the identity of Compound X 
would need to be verified using more specific techniques.   
Despite the limitations of this approach, the RT’s of a small number of possible 
compounds were tested against Compound X.  Although the data relating Compound X to D-
lactic acidosis and neurologic symptoms was contradictory, there is a small possibility that 
Compound X depresses the central nervous system (CNS).  The possibility that Compound X 
was an inhibitory neurotransmitter, GABA, was explored.  HPLC analysis of CSF spiked with 
GABA failed to detect the compound using the described conditions (Figure 5.1).  This indicates 
that Compound X is not likely GABA. 
One of the putative matches arising from further LC/MS/MS was the amino acid 
neurotransmitter glutamic acid.  Glutamic acid is the most abundant excitatory neurotransmitter 
in the mammalian CNS (Garattini, 2000).  It is also the precursor for GABA, an inhibitory 
neurotransmitter.  HPLC analysis of cerebrospinal fluid spiked with glutamic acid failed to detect 
the compound using the described conditions (Figure 5.2).  This indicates that Compound X is 
not likely glutamic acid.  Further evidence against Compound X being glutamic acid comes from 
the very high levels observed in healthy calf feces.  Enterocytes have been reported to readily 
absorb and subsequently metabolize or sequester a large portion of the glutamate presented to the 
small intestine (Blachier, Boutry, Bos, & Tomé, 2009).  On the contrary, significant amounts of 
protein and peptides from exogenous and endogenous sources have been observed in the colon, 
and these must be metabolized by bacteria, since there is little to no transfer of amino acids from 






































































































Figure 5.1. HPLC chromatograms showing a) healthy calf CSF and b) healthy calf CSF 
spiked with 50 mM gamma-amino butyric acid (GABA).  GABA was not detected using the 




































































































Figure 5.2. HPLC chromatogram showing a) diarrheic calf urine and b) 
diarrheic calf urine spiked with 25 mM glutamic acid.  Glutamic acid had a 
retention time of 18.8 minutes, compared to Compound X’s retention time 





5.2.2 Limitations of gas chromatography for identifying Compound X  
 Gas chromatography (GC) of a typical urine sample showed a small unknown peak at 
48.05 minutes, which closely matched the retention time (48.18 minutes) for the very large peak 
observed from the Compound X fraction.  Unfortunately this peak was not identified with the 
database searches used. 
 The Compound X fraction was collected using HPLC, which implies that the fraction may 
have contained several different compounds that elute simultaneously from the HPLC column.  
Therefore, although the observed gas chromatograph peak was assumed to be Compound X, the 
possibility exists that Compound X may not have produced a peak and that the observed peak 
was another component of the fraction.   
Many compounds can go undetected by GC, so derivatization (using trimethylsilylation) 
is used to reduce polarity and increase volatility of the compound of interest (Regis Technologies, 
2000).  Trimethylsilylation derivatizes alcohol, phenol, carboxyl, amine, and amide groups 
(Regis Technologies, 2000).  Therefore, Compound X would have to lack these functional groups 
to avoid derivatization, which is possible but unlikely.  On the other hand, Compound X may be a 
complex molecule containing several functional groups.  In this case, the addition of numerous 
trimethylsilyl groups could cause either the Compound X molecule to become too large to pass 
through the GC column or the corresponding m/z ratio to exceed the mass range of the mass 
spectrometer detector (Halket, Waterman, Przyborowska, Patel, Fraser, & Bramley, 2004).  As a 
result of these limitations, other techniques are required to identify Compound X.  
 
5.2.3 Limitations of mass spectrometry for identifying Compound X 
MS/MS and Fourier transform mass spectrometry FTMS did not provide a definitive 
identity of Compound X.  Several factors may have contributed to this.  One factor is that 
Compound X may be a mixture of compounds rather than a single compound.  This is a 
limitation of the primary technique, HPLC, which is not necessarily specific enough to separate 
all of the individual components of a biological sample.  Since fractions were collected and 
pooled using HPLC prior to MS/MS and FTMS, there may have been several compounds 
entering the mass spectrometers, which complicates the analysis.  If this is the case, it would help 
explain the fact that several m/z peaks appeared on the spectrum from FTMS. 
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Another potential reason for Compound X not being identified by mass spectrometry is 
that Compound X may not have efficiently ionized under the conditions used.  Ionization is a 
fundamentally essential step in mass spectrometric analysis, since the mass analyzer, by design, 
separates ions according to their mass to charge ratio (Van Bramer, 1998).   Without ionization, a 
molecule will not be detected by the mass spectrometer’s detector.  When liquid chromatography 
precedes mass spectrometry, the likelihood is great that several compounds co-elute and therefore 
enter the mass spectrometer simultaneously.  As the solution stream enters the mass spectrometer, 
the compound of interest may co-precipitate out of solution with non-volatile components, or it 
may be non-volatile itself and remain in the liquid portion of the stream and collect on the 
interface plate of the mass spectrometer (King, 2000).  In either case, the molecule will fail to be 
ionized.    
A final limitation of the FTMS was that the lowest observed m/z ratio was 257, 
corresponding to a molecular weight of 256 u.  This is higher than many common organic acids 
in biological systems.  For instance, the molar masses of larger common organic acids such as 
uric acid and citric acid are 168 and 192 g/mol, respectively.  It may be beneficial in the future to 
explore m/z ratios in the 90 – 200 range using FTMS to determine whether or not there are any 
putative matches for Compound X in this range.  
 
5.2.4 Future efforts toward identifying Compound X 
Compound X was present in healthy, sick, and acid-infused animals.  Further clues as to 
its origin could be obtained from HPLC analysis to search for Compound X in the milk replacer 
fed to calves or in the acid and saline infusates used in Abeysekara’s (Abeysekara, 2009) studies. 
Importantly, Compound X may be a collection of compounds that elute around the same 
time using the HPLC conditions described in section 3.4.  Employment of a technique, such as 
ultra performance liquid chromatography (UPLC), could resolve the individual peaks that 
comprise the Compound X peak obtained with HPLC.  UPLC systems use columns with smaller 
packing particle size, which increases the efficiency and resolving power of the system (Swartz, 
2005).     
Further study of Compound X using mass spectrometry may be warranted, particularly if 
the Compound X peak can be further resolved using UPLC.  FTMS is advantageous over MS/MS 
with respect to resolution, precision, and accuracy (Zhang, McCombie, Guenat, & Knochenmuss, 
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2005).  Since the lowest observed m/z from FTMS analysis was 257 u and many organic acids 
have masses well below this, future FTMS analysis should focus on a lower (e.g., 50 – 250) m/z 
ratio range.  
Future efforts toward identifying Compound X may do well to make use of nuclear 
magnetic resonance (NMR) spectrometry.  A major strength of NMR is that it provides 
information about functional groups within molecules (Mitchell, 2007).  This would be useful in 
that carboxylic acid groups or amino groups could be identified to provide clues to the identity of 
Compound X.  Previously, the sample requirements for NMR analysis introduced challenges, as 
samples were required to be isolated, purified, and of relatively large volume (Chary, 2008.).  
However, NMR has been refined into a highly sensitive technique, and it is now common to 
couple HPLC to NMR spectrometry (Mitchell, 2007).  Although costly deuterated solvents are 
normally used for NMR, these can be kept to a minimum by using techniques designed to 
suppress confounding solvent signals (Mitchell, 2007).  As such, NMR appears to be a 
reasonable next step for determining the identity of Compound X.  
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6. CONCLUSIONS 
 Compound X was determined to be ubiquitous in the biological fluids studied, implying 
that it is a normal biological compound.  Fecal Compound X levels were high in healthy calves, 
suggesting that Compound X is produced by intestinal bacteria.  The elevated serum Compound 
X levels in diarrheic calves may have been caused by absorption of Compound X from the 
intestinal lumen into the bloodstream.  As serum Compound X increases in diarrheal illness, it 
may partly explain the neurological signs observed in diarrheic, D-lactic acidotic calves.   
 Compound X positively correlated with D-lactate in clinical cases and positively 
correlated with neurological score in experimentally infused calves, insinuating a potential role 
for Compound X in the neurological disturbance.  Additionally, Compound X may be pertinent to 
human infants, since it was significantly elevated in serum from diarrheic infants in whom 
increased anion gap could not be explained by L- or D-lactate.  
 In light of the aforementioned findings, Compound X is worthy of further study to 
determine its identity.  HPLC with mass spectrometry was unsuccessful in achieving this, but 
other biochemical techniques, such as NMR, may prove to be more effective in this regard.  Also, 
techniques to separate the probable several components of the isolated Compound X HPLC peak 
may be required prior to further attempts to identify Compound X.  Since identification of an 
unknown compound is not a trivial task, this might best be accomplished by seeking partnership 
with an institution or company that specializes in biochemical techniques used for molecular 
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Table A.1. Putative matches for Compound X from the Chapman & Hall database 
based on m/z ratios obtained from LC/MS/MS analysis of pooled Compound X 





Names of Putative Compounds Chemical Formula 
146.073 1000   
   Actinidine   C10H13N  
   Actinidine; (R)-form   C10H13N  
   Actinidine; (S)-form   C10H13N  
   Actinidine; (±)-form   C10H13N  
   Albizziine   C4H9N3O3  
   Albizziine; (R)-form   C4H9N3O3  
   Albizziine; (S)-form   C4H9N3O3  
   Albizziine; (±)-form   C4H9N3O3  
   2-Amino-3-hydroxybutanoic acid; (2R,3S)-form, N-
Formyl  
 C5H9NO4  
   2-Amino-3-hydroxybutanoic acid; (2S,3R)-form, N-
Formyl  
 C5H9NO4  
   2-Amino-4-hydroxybutanoic acid; (S)-form, Et ether   C6H13NO3  
   2-Amino-4-hydroxy-3,3-dimethylbutanoic acid   C6H13NO3  
   2-Amino-4-hydroxy-3,3-dimethylbutanoic acid; (±)-form   C6H13NO3  
   2-Amino-5-hydroxyhexanoic acid   C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid   C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid; (2S,3R)-
form  
 C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid; (2S,3S)-
form  
 C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid; (2RS,3RS)-
form  
 C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid; (2RS,3SR)-
form  
 C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid; (2R,3R)-
form  
 C6H13NO3  
   2-Amino-3-hydroxy-4-methylpentanoic acid; (2R,3S)-
form  
 C6H13NO3  
   2-Amino-4-hydroxy-3-methylpentanoic acid   C6H13NO3  
   2-Amino-4-hydroxy-3-methylpentanoic acid; (2R,3R,4R)-
form  
 C6H13NO3  
   2-Amino-4-hydroxy-3-methylpentanoic acid; (2S,3R,4S)-
form  
 C6H13NO3  
   2-Amino-4-hydroxy-3-methylpentanoic acid; (2R,3R,4S)-
form  
 C6H13NO3  
   2-Amino-4-hydroxy-3-methylpentanoic acid; (2S,3R,4R)-
form  
 C6H13NO3  
   2-Amino-4-hydroxy-3-methylpentanoic acid; (2S,3S,4R)-
form  







Names of Putative Compounds Chemical Formula 
146.073 1000  2-Amino-4-hydroxy-4-methylpentanoic acid   C6H13NO3  
(continued)   2-Amino-4-hydroxy-4-methylpentanoic acid; (S)-form   C6H13NO3  
   2-Amino-4-hydroxy-4-methylpentanoic acid; (±)-form   C6H13NO3  
   2-Amino-5-hydroxy-4-oxopentanoic acid   C5H9NO4  
   2-Amino-5-hydroxy-4-oxopentanoic acid; (S)-form   C5H9NO4  
   2-Amino-5-hydroxy-4-oxopentanoic acid; (±)-form   C5H9NO4  
   2-Amino-3-methylbutanedioic acid   C5H9NO4  
   2-Amino-3-methylbutanedioic acid; (2R,3R)-form   C5H9NO4  
   2-Amino-3-methylbutanedioic acid; (2S,3S)-form   C5H9NO4  
   2-Amino-3-methylbutanedioic acid; (2RS,3RS)-form   C5H9NO4  
   2-Amino-3-methylbutanedioic acid; (2RS,3SR)-form   C5H9NO4  
   2-Amino-3-methylbutanedioic acid; (2S,3R)-form   C5H9NO4  
   2-Amino-3-methylbutanedioic acid; (2S,3S)-form, N-
Hydroxy  
 C5H9NO4  
   3-Aminopentanedioic acid, 9CI   C5H9NO4  
   1-(2-Aminophenyl)-2-propen-1-one   C9H9NO  
   3-Aminopropanal, 9CI; Di-Et acetal   C7H17NO2  
   3-Amino-2,3,6-trideoxy-arabino-hexose   C6H13NO3  
   3-Amino-2,3,6-trideoxy-arabino-hexose; D-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-arabino-hexose; a-D-Pyranose-
form  
 C6H13NO3  
   3-Amino-2,3,6-trideoxy-arabino-hexose; ß-D-Pyranose-
form  
 C6H13NO3  
   3-Amino-2,3,6-trideoxy-arabino-hexose; L-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-arabino-hexose; a-L-Pyranose-
form  
 C6H13NO3  
   3-Amino-2,3,6-trideoxy-lyxo-hexose   C6H13NO3  
   3-Amino-2,3,6-trideoxy-lyxo-hexose; D-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-lyxo-hexose; a-D-Pyranose-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-lyxo-hexose; L-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-lyxo-hexose; a-L-Pyranose-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-lyxo-hexose; DL-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-ribo-hexose   C6H13NO3  
   3-Amino-2,3,6-trideoxy-ribo-hexose; L-form   C6H13NO3  
   3-Amino-2,3,6-trideoxy-ribo-hexose; a-L-form   C6H13NO3  
   4-Amino-2,4,6-trideoxy-arabino-hexose   C6H13NO3  
   4-Amino-2,4,6-trideoxy-arabino-hexose; L-form   C6H13NO3  
   4-Amino-2,4,6-trideoxy-arabino-hexose; a-L-Pyranose-
form  
 C6H13NO3  
   4-Amino-2,4,6-trideoxy-arabino-hexose; ß-L-Pyranose-
form  
 C6H13NO3  
   4-Amino-2,4,6-trideoxy-arabino-hexose; ß-DL-Pyranose-
form  
 C6H13NO3  
   Aspartic acid, USAN, INN; (S)-form, 1-Hydrazide   C4H9N3O3  
   Aspartic acid, USAN, INN; (R)-form, 1-Me ester   C5H9NO4  
   Aspartic acid, USAN, INN; (S)-form, 1-Me ester   C5H9NO4  
   Aspartic acid, USAN, INN; (S)-form, 4-Me ester   C5H9NO4  
   Aspartic acid, USAN, INN; (±)-form, 4-Me ester   C5H9NO4  
   Aspartic acid, USAN, INN; (R)-form, N-Me   C5H9NO4  






Names of Putative Compounds Chemical Formula 
146.073 1000  Aspartic acid, USAN, INN; (±)-form, N-Me   C5H9NO4  
(continued)   Benzoic acid, USAN, 9CI; Azide   C7H5N3O  
  N-(Carboxymethyl)alanine, 9CI   C5H9NO4  
  N-(Carboxymethyl)alanine, 9CI; (S)-form   C5H9NO4  
   3-(Carboxymethylamino)propanoic acid   C5H9NO4  
   Coelobillardierine; (±)-form, Ketone   C9H9NO  
   Coelobillardierine; 7,8-Didehydro   C9H9NO  
   Coelobillardierine; Ketone   C9H9NO  
   Cysteine, INN; (R)-form, S-Vinyl   C5H9NO2S  
   Diethanolamine; N-Isopropyl   C7H17NO2  
   Diethanolamine; N-Propyl   C7H17NO2  
   3,4-Dihydro-1(2H)-isoquinolinone, 9CI   C9H9NO  
   3,4-Dihydro-1(2H)-isoquinolinone, 9CI; NH-form   C9H9NO  
   2,3-Dihydro-4(1H)-quinolinone, 9CI   C9H9NO  
   3,4-Dihydroxybutanoic acid; (S)-form, Ethylamide   C6H13NO3  
   2,4-Dihydroxy-3,3-dimethylbutanoic acid, 9CI; (R)-form, 
Amide  
 C6H13NO3  
   2,4-Dihydroxy-3,3-dimethylbutanoic acid, 9CI; (S)-form, 
Amide  
 C6H13NO3  
   2,4-Dihydroxy-3,3-dimethylbutanoic acid, 9CI; (±)-form, 
Amide  
 C6H13NO3  
   3,4-Dihydroxy-2-(1-hydroxyethyl)pyrrolidine   C6H13NO3  
   3,4-Dihydroxy-2-(1-hydroxyethyl)pyrrolidine; 
(1'R,2R,3R,4S)-form  
 C6H13NO3  
   3,4-Dihydroxy-2-(hydroxymethyl)-5-methylpyrrolidine   C6H13NO3  
   3,4-Dihydroxy-2-(hydroxymethyl)-5-methylpyrrolidine; 
(2R,3R,4R,5R)-form  
 C6H13NO3  
   3,4-Dihydroxy-2-(hydroxymethyl)-5-methylpyrrolidine; 
(2S,3R,4S,5R)-form  
 C6H13NO3  
   3,4-Dihydroxy-2-(hydroxymethyl)-5-methylpyrrolidine; 
(2S,3S,4S,5R)-form  
 C6H13NO3  
   3,4-Dihydroxy-2-(hydroxymethyl)-5-methylpyrrolidine; 
(2R,3R,4S,5R)-form  
 C6H13NO3  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid   C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2R,3S,4R)-
form  
 C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2S,3R,4R)-
form  
 C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2S,3S,4S)-
form  
 C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2S,3S,4R)-
form  
 C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2S,3R,4S)-
form  
 C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2R,3R,4R)-
form  
 C5H9NO4  
   3,4-Dihydroxy-2-pyrrolidinecarboxylic acid; (2?,3?,4?)-
form  
 C5H9NO4  






Names of Putative Compounds Chemical Formula 
146.073 1000  Glutamic acid   C5H9NO4  
(continued)   Glutamic acid; (R)-form   C5H9NO4  
   Glutamic acid; (S)-form   C5H9NO4  
   Glutamic acid; (±)-form   C5H9NO4  
   Glyoxylic acid, 8CI; Di-Et acetal, amide   C6H13NO3  
   Glyoxylic acid, 8CI; Thiosemicarbazone   C3H5N3O2S  
   2-Hydroxybenzoic acid, 9CI; Et ether, nitrile   C9H9NO  
   3-Hydroxybenzoic acid, 9CI; Et ether, nitrile   C9H9NO  
   4-Hydroxybenzoic acid, 8CI, 9CI; Et ether, nitrile   C9H9NO  
   4-Hydroxy-3,5-dimethylbenzoic acid; Nitrile   C9H9NO  
  N-Hydroxyglycine, 9CI; tert-Butyl ester   C6H13NO3  
  N-Hydroxyleucine, 9CI   C6H13NO3  
  N-Hydroxyleucine, 9CI; (R)-form   C6H13NO3  
  N-Hydroxyleucine, 9CI; (S)-form   C6H13NO3  
  N-Hydroxyleucine, 9CI; (±)-form   C6H13NO3  
   2-Hydroxy-3-methyl-1H-indole   C9H9NO  
   2-Hydroxy-3-methyl-1H-indole; (±)-form   C9H9NO  
   2-Hydroxy-3-methyl-1H-indole; (?)-form   C9H9NO  
   5-Hydroxy-3-methyl-1H-indole   C9H9NO  
   2-(Hydroxymethyl)-3,4-piperidinediol, 9CI   C6H13NO3  
   2-(Hydroxymethyl)-3,4-piperidinediol, 9CI; (2R,3R,4R)-
form  
 C6H13NO3  
   2-(Hydroxymethyl)-3,4-piperidinediol, 9CI; (2R,3R,4S)-
form  
 C6H13NO3  
   2-(Hydroxymethyl)-3,4-piperidinediol, 9CI; (2R,3S,4S)-
form  
 C6H13NO3  
   6-(Hydroxymethyl)-3,4-piperidinediol, 9CI   C6H13NO3  
   6-(Hydroxymethyl)-3,4-piperidinediol, 9CI; (2S,4R,5R)-
form  
 C6H13NO3  
   6-(Hydroxymethyl)-3,4-piperidinediol, 9CI; (2S,4R,5S)-
form  
 C6H13NO3  
   6-(Hydroxymethyl)-3,4-piperidinediol, 9CI; (2S,4S,5R)-
form  
 C6H13NO3  
   8-Hydroxy-2,4,6-octatriynoic acid; Amide   C8H5NO2  
   2-Hydroxyphenylacetic acid; Me ether, nitrile   C9H9NO  
   3-Hydroxyphenylacetic acid; Me ether, nitrile   C9H9NO  
   4-Hydroxyphenylacetic acid; Me ether, nitrile   C9H9NO  
   2-Hydroxy-2-phenylacetonitrile; (±)-form, Me ether   C9H9NO  
   2-Hydroxy-3-phenylpropanoic acid; (±)-form, Nitrile   C9H9NO  
   3-(2-Hydroxyphenyl)propanoic acid; Nitrile   C9H9NO  
   3-Hydroxy-3-phenylpropanoic acid; (S)-form, Nitrile   C9H9NO  
   3-(4-Hydroxyphenyl)propanoic acid; Nitrile   C9H9NO  
   1H-Indole-2,3-dione, 9CI   C8H5NO2  
   1H-Indole-3-methanol   C9H9NO  
   1H-Indole-7-methanol, 9CI   C9H9NO  
   3H-Indol-3-one, 8CI, 9CI; 1-Oxide   C8H5NO2  
   1-Isothiocyanato-3-(methylthio)propane, 9CI   C5H9NS2  
   Malic acid, 8CI; (S)-form, 1-Amide, 4-Me ester   C5H9NO4  
   Malic acid, 8CI; (R)-form, 4-Amide, 1-Me ester   C5H9NO4  
   Malic acid, 8CI; (S)-form, 4-Amide, 1-Me ester   C5H9NO4  






Names of Putative Compounds Chemical Formula 
146.073 1000  3,4-Methylenedioxybenzoic acid; Nitrile   C8H5NO2  
(continued)   2-Methyl-3,4,5-piperidinetriol, 9CI   C6H13NO3  
   2-Methyl-3,4,5-piperidinetriol, 9CI; (2R,3R,4R,5S)-form   C6H13NO3  
   3-(Methylthio)-2-propenoic acid, 9CI; (Z)-form, 
Methylamide, S-oxide  
 C5H9NO2S  
   3-(Methylthio)-2-propenoic acid, 9CI; (E)-form, 
Methylamide, S-oxide  
 C5H9NO2S  
   3-Nitropropanoic acid, 9CI; Et ester   C5H9NO4  
   3-Nitro-1-propanol, 8CI, 9CI; Ac   C5H9NO4  
   Oxobutanedioic acid, 9CI; Oxo-form, Oxime   C4H5NO5  
   2-Phenyl-2-propenal; Oxime   C9H9NO  
   3-Phenyl-2-propenal, 9CI; (E)-form, E-Oxime   C9H9NO  
   3-Phenyl-2-propenal, 9CI; (E)-form, Z-Oxime   C9H9NO  
   3-Phenyl-2-propenoic acid, 9CI; (E)-form, Amide   C9H9NO  
   Phthalimide, 8CI   C8H5NO2  
   3,4,5-Piperidinetriol, 9CI; [(±)-(3a,4a,5ß)]-form, N-Me   C6H13NO3  
   3,4,5-Piperidinetriol, 9CI; [3S-(3a,4a,5ß)]-form, N-Me   C6H13NO3  
   2-Propenoic acid, 9CI; Anilide   C9H9NO  
   Serine; (±)-form, N-Ac   C5H9NO4  
   Serine; (S)-form, N-Ac   C5H9NO4  
   Serine; (S)-form, O-Ac   C5H9NO4  
   Serine; (±)-form, O-Ac   C5H9NO4  
   5,6,7,8-Tetrahydro-4-methylquinoline   C10H13N  
   3-Thiomorpholinecarboxylic acid, 9CI   C5H9NO2S  
   3-Thiomorpholinecarboxylic acid, 9CI; (R)-form   C5H9NO2S  
   3-Thiomorpholinecarboxylic acid, 9CI; (±)-form   C5H9NO2S  
157.07 1000   
   Allantoin, USAN, BAN   C4H6N4O3  
   Allantoin, USAN, BAN; (R)-form   C4H6N4O3  
   Allantoin, USAN, BAN; (S)-form   C4H6N4O3  
   Allantoin, USAN, BAN; (±)-form   C4H6N4O3  
   2-Amino-4-methylenepentanedioic acid; (S)-form, ?-
Amide  
 C6H10N2O3  
   2-(Aminomethyl)-4-thiazolecarboxylic acid, 9CI   C5H6N2O2S  
   2,3-Butanedione; Semicarbazone-oxime   C5H10N4O2  
   Butanoic acid, 9CI; Anhydride   C8H14O3  
   Cephalosporolide D   C8H14O3  
   1,2-Cyclohexanediol, 9CI; (1S,2S)-form, Mono-Ac   C8H14O3  
   2-Decene-4,6,8-triynoic acid   C10H6O2  
   2-Decene-4,6,8-triynoic acid; (E)-form   C10H6O2  
   2-Decene-4,6,8-triynoic acid; (Z)-form   C10H6O2  
   1-Decene-4,6,8-triyn-3-one; 1?,2?-Epoxide   C10H6O2  
   2,3-Dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one; 
(S)-form, Me ether  
 C7H10O4  
   Dihydro-3-hydroxy-3-(1-hydroxyethyl)-4-methyl-2(3H)-
furanone, 9CI; (1'S,3R,4R)-form, 1'-Ketone  
 C7H10O4  
   4,5-Dihydroxy-3-(1-hydroxyethyl)-2-cyclopenten-1-one   C7H10O4  
   4,5-Dihydroxy-3-(1-hydroxyethyl)-2-cyclopenten-1-one; 
(1'R,4R,5S)-form  
 C7H10O4  
   4,5-Dihydroxy-4-(1-hydroxyethyl)-2-cyclopenten-1-one, 
9CI  






Names of Putative Compounds Chemical Formula 
157.07 1000  3,5-Dihydroxy-2-hydroxymethyl-4H-pyran-4-one, 9CI   C6H6O5  
(continued)   2,4-Dimethylquinazoline, 9CI   C10H10N2  
   4,6-Dioxoheptanoic acid, 9CI   C7H10O4  
   4,5-Dioxopentanoic acid; Et ester   C7H10O4  
   2-Ethyl-3-methyl-2-butenedioic acid, 9CI   C7H10O4  
   2-Ethyl-3-methyl-2-butenedioic acid, 9CI; (E)-form   C7H10O4  
   2-Ethyl-3-methyl-2-butenedioic acid, 9CI; (Z)-form   C7H10O4  
   6-Ethyl-1-methyl-2,7,8-trioxabicyclo[3.2.1]octane   C8H14O3  
   5-Fluoro-2,4-dihydroxypyrimidine; 1,3-Di-Me   C6H7FN2O2  
   5-Fluoro-2,4-dihydroxypyrimidine; 1-Et   C6H7FN2O2  
   Heptanedioic acid, 9CI; Diamide   C7H14N2O2  
   5-(2,4-Hexadiynylidene)-2(5H)-furanone   C10H6O2  
   5-(2,4-Hexadiynylidene)-2(5H)-furanone; (E)-form   C10H6O2  
   5-(2,4-Hexadiynylidene)-2(5H)-furanone; (Z)-form   C10H6O2  
   Hexahydro-3a,6(4H)-benzofurandiol, 9CI   C8H14O3  
   Hexahydro-3a,6(4H)-benzofurandiol, 9CI; 
(3aR*,6R*,7aS*)-form  
 C8H14O3  
   Hexahydro-3a,6(4H)-benzofurandiol, 9CI; 
(3aR*,6S*,7aS*)-form  
 C8H14O3  
   3-Hydroxy-2-butanone, 8CI, 9CI; (±)-form, Butanoyl   C8H14O3  
   10-Hydroxy-8-decene-2,4,6-triynal   C10H6O2  
   10-Hydroxy-8-decene-2,4,6-triynal; (E)-form   C10H6O2  
   3-(1-Hydroxyethyl)-2,5-piperazinedione, 9CI   C6H10N2O3  
   3-(1-Hydroxyethyl)-2,5-piperazinedione, 9CI; (1'R,3S)-
form  
 C6H10N2O3  
   3-(1-Hydroxyethyl)-2,5-piperazinedione, 9CI; (1'?,3?)-
form  
 C6H10N2O3  
   1-Hydroxy-3-hexanone, 9CI; Ac   C8H14O3  
   6-Hydroxy-3-hexanone, 9CI; Ac   C8H14O3  
   4-Hydroxy-4-(2-hydroxyethyl)cyclohexanone, 9CI   C8H14O3  
   4-Hydroxy-3-methyl-2-butenoic acid, 9CI; (E)-form, Ac   C7H10O4  
   4-Hydroxy-2-methylenebutanoic acid; Ac   C7H10O4  
   5-Hydroxy-4-methyl-2-heptenoic acid   C8H14O3  
   5-Hydroxy-4-methyl-2-heptenoic acid; (2E,4S,5R)-form   C8H14O3  
   5-Hydroxy-4-methyl-2-heptenoic acid; (2E,4S,5S)-form   C8H14O3  
   3-Hydroxy-5-octenoic acid   C8H14O3  
   3-Hydroxy-5-octenoic acid; (3R,5Z)-form   C8H14O3  
   3-Hydroxy-5-octenoic acid; (3S,5E)-form   C8H14O3  
   3-Hydroxy-5-octenoic acid; (±)-(E)-form   C8H14O3  
   6-Hydroxy-7-octenoic acid   C8H14O3  
   6-Hydroxy-7-octenoic acid; (R)-form   C8H14O3  
   3-Hydroxypropanal, 9CI; Tetrahydropyranyl ether   C8H14O3  
   Ibotenic acid   C5H6N2O4  
   Ibotenic acid; (±)-form   C5H6N2O4  
   Imidazole, 9CI, 8CI; N-Benzyl   C10H10N2  
   1H-Indole-3-carboxylic acid; N-Hydroxy, nitrile   C9H6N2O  
   Isoquinoline, 9CI, 8CI; N-Et   C11H12N  
   2-Methyl-2-butenedioic acid, 9CI; (E)-form, Di-Me ester   C7H10O4  
   2-Methyl-2-butenedioic acid, 9CI; (Z)-form, Di-Me ester   C7H10O4  
   2-Methyl-2-butene-1,4-diol; (E)-form, 4-Me ether, 1-Ac   C8H14O3  






Names of Putative Compounds Chemical Formula 
157.07 1000  Methylenebutanedioic acid, 9CI; Di-Me ester   C7H10O4  
(continued)   Methylenebutanedioic acid, 9CI; 4-Mono-Et ester   C7H10O4  
   2-Methylene-4-oxopentanedioic acid   C6H6O5  
   5-Methyl-2,3-hexanedione, 9CI; Dioxime   C7H14N2O2  
   2-Methylpropanoic acid, 9CI; Anhydride   C8H14O3  
   2-Methyl-2-propenoic acid, 9CI; 2-Ethoxyethyl ester   C8H14O3  
   1-Methyl-4(1H)-quinolinone, 9CI; Imine   C10H10N2  
   Muscazone   C5H6N2O4  
   Muscazone; (±)-form   C5H6N2O4  
   2-Nonene-4,6,8-triynoic acid, 9CI; (E)-form, Me ester   C10H6O2  
   2-Oxohexanoic acid, 9CI; Et ester   C8H14O3  
   2-Oxo-4-methylenepentanedioic acid   C6H6O5  
   2-Oxooctanoic acid, 9CI   C8H14O3  
   4-Oxopentanoic acid, 9CI; Isopropyl ester   C8H14O3  
   4-Oxopentanoic acid, 9CI; Propyl ester   C8H14O3  
   3-Oxopropanoic acid, 9CI; (E)-Enol-form, Et ester, Ac   C7H10O4  
   5-Phenyl-2,4-pentadienal, 9CI   C11H10O  
   5-Phenyl-2,4-pentadienal, 9CI; (E,E)-form   C11H10O  
   5-Phenyl-2,4-pentadienal, 9CI; (2Z,4E)-form   C11H10O  
   1,2,3-Propanetricarboxylic acid, 9CI, 8CI; 1,2-Anhydride   C6H6O5  
   3-(2-Pyrrolyl)pyridine; N-Me   C10H10N2  
   Pyruvic acid, 8CI; 3-Methylbutyl ester   C8H14O3  
   Rengyoxide   C8H14O3  
   Terrestric acid   C4H6N4O3  
   Tetrahydro-2,5-furandicarboxylic acid; (2RS,5SR)-form, 
Diamide  
 C6H10N2O3  
   Tetrahydro-2-furanmethanol, 9CI; (±)-form, Propanoyl   C8H14O3  
   1,4,5,6-Tetrahydro-5-hydroxy-2-methyl-4(6)-
pyrimidinecarboxylic acid  
 C6H10N2O3  
   Tetrahydro-6-methyl-2H-pyran-2-acetic acid   C8H14O3  
   Tetrahydro-6-methyl-2H-pyran-2-acetic acid; (2S,6S)-
form  
 C8H14O3  
   Tetrahydro-6-methyl-2H-pyran-2-acetic acid; (2RS,6RS)-
form  
 C8H14O3  
   Tetrahydro-6-methyl-2H-pyran-2-acetic acid; (2RS,6SR)-
form  
 C8H14O3  
   2,3,4-Trihydroxybutanoic acid, 9CI; (2R,3R)-form, 1,4-
Lactone, 2,3-isopropylidene  
 C7H10O4  
   2,3,4-Trihydroxybutanoic acid, 9CI; (2S,3S)-form, 
Lactone, 2,3-O-isopropylidene  
 C7H10O4  
   4,5,6-Trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-one; 
(4R*,5S*,6R*)-form, 1'-Deoxy  
 C7H10O4  
   2,5,6-Trihydroxy-3-methyl-2-cyclohexen-1-one   C7H10O4  
   2,5,6-Trihydroxy-3-methyl-2-cyclohexen-1-one; (5R,6R)-
form  
 C7H10O4  
   3,4,5-Trihydroxy-5-methyl-2-cyclohexen-1-one   C7H10O4  
   3,4,5-Trihydroxy-5-methyl-2-cyclohexen-1-one; 
(4R*,5S*)-form  
 C7H10O4  
   3,4,5-Trihydroxy-5-methyl-2-cyclohexen-1-one; (4R,5R)-
form  






Names of Putative Compounds Chemical Formula 
   3,4,6-Trihydroxy-2-methyl-2-cyclohexen-1-one   C7H10O4  
   3,4,6-Trihydroxy-2-methyl-2-cyclohexen-1-one; (4R,6R)-
form  
 C7H10O4  
   4,5,6-Trihydroxy-2-methyl-2-cyclohexen-1-one   C7H10O4  
   4,5,6-Trihydroxy-2-methyl-2-cyclohexen-1-one; 
(4R,5R,6S)-form  
 C7H10O4  
   4,5,6-Trihydroxy-2-methyl-2-cyclohexen-1-one; 
(4R,5R,6R)-form  
 C7H10O4  
   Valine; (±)-form, N-Ac, amide   C7H14N2O2  
   Zymonic acid   C6H6O5  
337.121 50   
   Acremonin A; (+)-form, 6-O-ß-D-Glucopyranoside   C17H22O7  
   Alangimaridine; (R)-form, 14?-Hydroxy, 13,13a-
didehydro, 14,15-dihydro  
 C19H18N2O4  
   Alangimaridine; (R)-form, 14?-Hydroxy, 13,13a-
didehydro, 14,15-dihydro, O-de-Me, O2-Me  
 C19H18N2O4  
   Alpinumisoflavone; 3,4-Dihydro   C20H18O5  
   3-Amino-3-pyrrolidinecarboxylic acid, 9CI; (S)-form, 
N,N'-Dibenzoyl  
 C19H18N2O4  
   Anislactone A; 7-Epimer, 7-Ac   C17H22O7  
   Antibiotic C 15462; Antibiotic C 15462V   C20H18O5  
   Antibiotic MK 3018   C20H18O5  
   Antibiotic Sch 58450   C20H18O5  
   Apiocarpin   C20H18O5  
   Aplysinopsin; Di-Ac   C18H18N4O3  
   Bakuchalcone; 2-Hydroxy, 3''-deoxy, 3'',4''-didehydro   C20H18O5  
   17(15?16),18(4?3)-Bisabeo-12,16-epoxy-11-hydroxy-
3,5,8,11,13-abietapentaen-7-one; 1-Oxo, 14-hydroxy, 
15,16-didehydro  
 C20H18O5  
   Buceracidin B   C20H18O5  
   Capitellataquinone B; 3',8-Dideoxy   C20H18O5  
   Carpachromene; 2,3-Dihydro   C20H18O5  
   Carpachromene; 3'',4''-Dihydro   C20H18O5  
   Carrabiose; a-Pyranose-form, Me glycoside   C13H22O10  
   Carrabiose; ß-Pyranose-form, Me glycoside   C13H22O10  
   Caseadinium(1+)   C20H20NO4  
   Citflavanone   C20H18O5  
   Citflavanone; (S)-form   C20H18O5  
   Citflavanone; (?)-form   C20H18O5  
   Citflavanone; (±)-form   C20H18O5  
   Cladosporol A; Deepoxy   C20H18O5  
   Corylin; 3',4'-Dihydro, 3'-hydroxy   C20H18O5  
   Curcumin; Demethoxy   C20H18O5  
   Cyclocalopin A; 7-Ac   C17H22O7  
   Cyclokievitone; 5-Deoxy   C20H18O5  
   Daleformis   C20H18O5  
   Decaspirone F   C20H18O5  
   Decaspirone F; 6,7-Dihydro, 4-ketone   C20H18O5  
   5-Deoxy-3-C-hydroxymethyllyxose, 9CI; a-L-Furanose-
form, Benzyl glycoside, 2,3'-di-O-Ac  






Names of Putative Compounds Chemical Formula 
337.121 50  2,4-Diamino-2,4,6-trideoxy-3-(a-D-
galactopyranuronosyl)-D-galactose  
 C12H22N2O9  
(continued)   2,4-Diamino-2,4,6-trideoxy-3-(a-D-
galactopyranuronosyl)-D-galactose; a-Pyranose-form  
 C12H22N2O9  
   2,6-Diamino-2,3,6-trideoxy-ribo-hexose; a-D-Pyranose-
form, Me glycoside, N,N'-di-Ac, 4-mesyl  
 C12H22N2O7S 
   1,2:3,4-Diepoxy-8,10-dihydroxy-12,6-guaianolide; 
(1ß,2ß,3ß,4ß,6a,8a,10a,11a)-form, 8-Ac  
 C17H22O7  
   1,2:3,4-Diepoxy-8,10-dihydroxy-11(13)-guaien-12,6-
olide; (1ß,2ß,3ß,4ß,5a,6a,8a,10a)-form, 11ß,13-Dihydro, 
8-Ac  
 C17H22O7  
   7,8-Dihydro-5,7-dihydroxy-2,2-dimethyl-8-phenyl-
2H,6H-benzo[1,2-b:5,4-b']dipyran-6-one  
 C20H18O5  
   7,8-Dihydro-5,7-dihydroxy-2,2-dimethyl-8-phenyl-
2H,6H-benzo[1,2-b:5,4-b']dipyran-6-one; (2R*,3R*)-form  
 C20H18O5  
   3,4-Dihydro-2-methyl-2H-pyran-3,4-diol; (2S,3R,4S)-
form, 3,4-Dibenzoyl  
 C20H18O5  
   5,7-Dihydroxy-8-(3-hydroxy-3-methylbutyl)-2-methyl-
4H-1-benzopyran-4-one; 1',2'-Dihydroxy, 5,7-di-Me ether  
 C17H22O7  
   4,7-Dihydroxy-5-[2-(4-hydroxyphenyl)ethenyl]-3-methyl-
2H-1-benzopyran-2-one; (E)-form, 4,7-Di-Me ether  
 C20H18O5  
   5,7-Dihydroxy-8-(3-methyl-1-oxobutyl)-4-phenyl-2H-1-
benzopyran-2-one  
 C20H18O5  
   2,10-Dihydroxy-3-oxo-1,11(13)-eremophiladien-12-oic 
acid; 10ß-form, 10-Hydroperoxide, 2-Ac  
 C17H22O7  
   2-(3,4-Dihydroxyphenyl)-2,3-dihydro-3-methyl-7-(2-
propenyl)-4,5-benzofurandiol; (7R*,8R*)-form, 3',4':4,5-
Bis(methylene) ether  
 C20H18O5  
   5,7-Dihydroxy-8-prenylflavanone; (S)-form, 4''-Oxo   C20H18O5  
   2-(2,4-Dihydroxy-5-prenylphenyl)-5,6-
dihydroxybenzofuran; 5,6-Methylene ether  
 C20H18O5  
   4-[(Di-1H-indol-3-yl)methyl]phenol, 9CI   C23H18N2O  
   2,2-Dimethyl-2H-1-benzopyran-7-ol, 9CI; O-ß-D-
Glucopyranoside  
 C17H22O7  
   8-(1,1-Dimethyl-2-propenyl)-3,5,7-trihydroxyflavone   C20H18O5  
   6-(1,1-Dimethyl-2-propenyl)-4',5,7-trihydroxyisoflavone   C20H18O5  
   8-(1,1-Dimethyl-2-propenyl)-4',5,7-trihydroxyisoflavone   C20H18O5  
   Dugesin A   C20H18O5  
   15,16-Epoxy-1,3,7,13(16),14-clerodapentaene-
17,12:18,19-diolide  
 C20H18O5  
   4,5-Epoxy-8,13-dihydroxy-1-oxo-7(11)-germacren-12,6-
olide; (4a,5ß,6a,8a,10a)-form, 13-Ac  
 C17H22O7  
   7,8-Epoxy-9,17-dihydroxy-13,14,15,16-tetranor-
12,17:19,6-labdanediolide; (6ß,7a,8a,9a,17a)-form, 17-Me 
ether  
 C17H22O7  
   1,4-Epoxy-1,8,13-trihydroxy-5,7(11)-germacradien-12,6-
olide; (1a,4ß,5E,8a,10ßH)-form, 13-Ac  
 C17H22O7  






Names of Putative Compounds Chemical Formula 
337.121 50  Ezomontanin; 11ß,13-Dihydro   C17H22O7  
(continued)   Glyasperin F; 5-Deoxy   C20H18O5  
   Glyceollin I   C20H18O5  
   Glyceollin II   C20H18O5  
   Glyceollin III   C20H18O5  
   Glyceollin III; 13-Epimer   C20H18O5  
   Glyinflanin B   C20H18O5  
   Hatomarubigin C   C20H18O5  
   2-Hydroxy-1,5,8,10(20),13-icetexapentaene-3,7,11,12-
tetrone  
 C20H18O5  
   5-Hydroxy-7-methoxy-8-(3-oxo-1-butenyl)flavanone   C20H18O5  
   5-Hydroxy-7-methoxy-8-(3-oxo-1-butenyl)flavanone; 
(S,E)-form  
 C20H18O5  
   1-Hydroxy-2-(4-methyl-3-pentenyl)anthraquinone; 3,4-
Dihydroxy  
 C20H18O5  
   4'-Hydroxyongokein; (1'RS,2S,4'SR)-form, 4'-Ketone, di-
Me acetal  
 C17H22O7  
   6a-Hydroxyphaseollin   C20H18O5  
   1a-Hydroxyphaseollone   C20H18O5  
   6-Hydroxy-5(10)-pinguisen-11,6-olide-12,15-dioic acid; 
(6aOH)-form, Di-Me ester  
 C17H22O7  
   Iduronic acid; ß-L-Furanose-form, 1,2-Isopropylidene, 3-
benzyl, Me ester  
 C17H22O7  
   Isobavachromene; 2''-Hydroxy   C20H18O5  
   Isobavachromene; 3''-Hydroxy   C20H18O5  
   Licoisoflavone B; 2,3-Dihydro, 5-deoxy   C20H18O5  
   Mallotus A   C20H18O5  
   Moracin G; 4'-Methoxy   C20H18O5  
   Murragleinin   C17H22O7  
   Neoraufurane   C20H18O5  
   Otobain; (-)-form, 8-Epimer, 7-oxo   C20H18O5  
   Otobain; (-)-form, 7-Oxo   C20H18O5  
   Ovigerine; (±)-form, N,N-Di-Me   C20H20NO4  
   Oxazinine 1; O-De(cyanoethyl)   C19H18N2O4  
   Palmarumycin CP3; 6,7-Dihydro, 5ß-alcohol   C20H18O5  
   Palmatine; O10-De-Me   C20H20NO4  
   Palmatine; O2-De-Me   C20H20NO4  
   Palmatine; O3-De-Me   C20H20NO4  
   Palmatine; O9-De-Me   C20H20NO4  
   Pinnatal   C20H18O5  
   Pinnatal; 9-Deoxy, 8-hydroxy   C20H18O5  
   Prehalenaquinone; Hydroquinone   C20H18O5  
   Pseudopalmatine; O2-De-Me   C20H20NO4  
   Pseudopalmatine; O3-De-Me   C20H20NO4  
   Psorolactone B   C20H18O5  
   Reframidine; (-)-form, N-Me   C20H20NO4  
   Reframidine; (±)-form, N-Me   C20H20NO4  
   Rhyacophilin; 7,8-Didehydro   C20H18O5  
   Rubiginone A1   C20H18O5  
   3,7,8,15-Scirpenetetrol; 8-Ketone, 15-Ac   C17H22O7  






Names of Putative Compounds Chemical Formula 
337.121 50  Stylopine, 9CI; (S)-form, N-Me (cis-)   C20H20NO4  
(continued)   Stylopine, 9CI; (S)-form, N-Me (trans-)   C20H20NO4  
   Tanshinonic acid; Me ester   C20H18O5  
   Terphenyllin   C20H18O5  
   3',4,4',5-Tetrahydroxy-2,7'-cyclolignan-7-one; 
(7'R,8R,8'S)-form, 3',4':4,5-Bis(methylene) ether  
 C20H18O5  
   3',4,4',5-Tetrahydroxy-2,7'-cyclolignan-7-one; 
(7'R,8S,8'R)-form, 3',4':4,5-Bis(methylene) ether  
 C20H18O5  
   3',4,4',5-Tetrahydroxy-2,7'-cyclolignan-7-one; 
(7'R,8S,8'S)-form, 3',4':4,5-Bis(methylene) ether  
 C20H18O5  
   1,3,4,8-Tetrahydroxy-9,11(13)-guaiadien-12,6-olide; 
(1a,3a,4ß,5a,6a,8a)-form, 8-Ac  
 C17H22O7  
   2,8,9,10-Tetrahydroxy-3,11(13)-guaiadien-12,6-olide; 
(1a,2ß,5a,6a,8a,9a,10a)-form, 9-Ac  
 C17H22O7  
   3,4,8,10-Tetrahydroxy-1,11(13)-guaiadien-12,6-olide; 
(3a,4a,5a,6a,8a,10ß)-form, 8-Ac  
 C17H22O7  
   3,4,8,10-Tetrahydroxy-1,11(13)-guaiadien-12,6-olide; 
(3ß,4a,5a,6a,8a,10ß)-form, 8-Ac  
 C17H22O7  
   3,8,9,10-Tetrahydroxy-4,11(13)-guaiadien-12,6-olide; 
(1a,3a,6a,8a,9a,10a)-form, 8-Ac  
 C17H22O7  
   Tetrangomycin; (?)-form, 1?-Alcohol, O8-Me   C20H18O5  
   Tetrangomycin; (?)-form, Stereoisomer (?), 1?-alcohol, 
O8-Me  
 C20H18O5  
   Teuvincenone E; 15,16-Didehydro   C20H18O5  
   1,3,8-Trihydroxy-4,10(14),11(13)-germacratrien-12,6-
olide; (1ß,3ß,4E,6a,8ß)-form, 1-Hydroperoxide, 3-Ac  
 C17H22O7  
   1,8,15-Trihydroxy-4,10(14),11(13)-germacratrien-12,6-
olide; (1ß,4E,6a,8a)-form, 1-Hydroperoxide, 15-Ac  
 C17H22O7  
   4,9,10-Trihydroxy-2,11(13)-guaiadien-12,6-olide; 
(4a,6a,9a,10a)-form, 4-Hydroperoxide, 9-Ac  
 C17H22O7  
   1,3,8-Trihydroxy-6-methylanthraquinone, 8CI; 3-O-(3-
Methyl-2-butenyl)  
 C20H18O5  
   1,3,8-Trihydroxy-6-methyl-2-(3-methyl-2-
butenyl)anthraquinone  
 C20H18O5  
   8,9,13-Trihydroxy-1-oxo-4,7(11)-germacradien-12,6-
olide; (4E,6a,8a,9ß,10ß)-form, 13-Ac  
 C17H22O7  
   9,11,13-Trihydroxy-4-oxo-2-pseudoguaien-12,8-olide; 
(1a,5ß,8a,9ß,10a,11ß)-form, 9-Ac  
 C17H22O7  
   3',4',6-Trihydroxy-5-prenylaurone   C20H18O5  
   3',4',6-Trihydroxy-7-prenylaurone   C20H18O5  
   3',4',7-Trihydroxy-6-prenylflavone   C20H18O5  
   3',4',7-Trihydroxy-8-prenylflavone   C20H18O5  
   3,5,7-Trihydroxy-6-prenylflavone   C20H18O5  
   4',5,7-Trihydroxy-3'-prenylflavone   C20H18O5  
   4',5,7-Trihydroxy-6-prenylflavone   C20H18O5  
   4',5,7-Trihydroxy-8-prenylflavone   C20H18O5  
   2',4',7-Trihydroxy-3'-prenylisoflavone   C20H18O5  
   3',4',7-Trihydroxy-5'-prenylisoflavone   C20H18O5  






Names of Putative Compounds Chemical Formula 
337.121 50  3',4',7-Trihydroxy-8-prenylisoflavone   C20H18O5  
(continued)   4',5,7-Trihydroxy-3'-prenylisoflavone   C20H18O5  
   4',5,7-Trihydroxy-6-prenylisoflavone   C20H18O5  
   4',5,7-Trihydroxy-8-prenylisoflavone   C20H18O5  
   3,8,9-Trihydroxy-7-prenylpterocarpene   C20H18O5  
   3,7,15-Trihydroxy-8-scirpenone; (3a,7a)-form, 3-Ac   C17H22O7  
   Tryptophan, 9CI, USAN, 8CI; (R)-form, Na-
Benzyloxycarbonyl  
 C19H18N2O4  
   Tuberosin   C20H18O5  
   Tuberosin; (+)-form   C20H18O5  
   Tuberosin; (-)-form   C20H18O5  
   Vismiaguianin A   C20H18O5  
   Vitrofolal B; 3-Deoxy   C20H18O5  
315.126 500   
   2-Acetyl-1,3,6,8-tetrahydroxyanthraquinone; 1'R-Alcohol   C16H12O7  
   2-Amino-3-(3-bromo-4-hydroxyphenyl)propanoic acid; 
(S)-form, 4-Me ether, N,N,N-tri-Me, betaine  
 C13H18BrNO3 
   1,5-Anhydroglucitol, 9CI, 8CI; D-form, 2-O-(3,4,5-
Trihydroxybenzoyl)  
 C13H16O9  
   1,5-Anhydroglucitol, 9CI, 8CI; D-form, 6-O-(3,4,5-
Trihydroxybenzoyl)  
 C13H16O9  
   Boxazomycin A   C14H12N4O5  
   6-Bromo-1,2,3,4-tetrahydro-7,8-dihydroxy-3-
isoquinolinecarboxylic acid; (S)-form, 7-Me ether, Me 
ester  
 C12H14BrNO4 
   8-Bromo-1,2,3,4-tetrahydro-6,7-dihydroxy-3-
isoquinolinecarboxylic acid; (S)-form, 7-Me ether, Me 
ester  
 C12H14BrNO4 
   Coccineone D   C16H12O7  
   Crombeone   C16H12O7  
   1,1-Dibromo-2-heptanol; (±)-form, Ac   C9H16Br2O2  
   2',5'-Dihydroxyacetophenone, 8CI; Bis(2,2,2-
trifluoroethyl) ether  
 C12H10F6O3  
   2,3-Dihydroxybenzoic acid, 9CI; 3-O-ß-D-
Glucopyranoside  
 C13H16O9  
   2,5-Dihydroxybenzoic acid, 9CI; 2-O-ß-D-
Glucopyranoside  
 C13H16O9  
   2,5-Dihydroxybenzoic acid, 9CI; 5-O-ß-D-
Glucopyranoside  
 C13H16O9  
   3,4-Dihydroxybenzoic acid; 3-O-ß-D-Glucopyranoside   C13H16O9  
   3,4-Dihydroxybenzoic acid; 4-O-ß-D-Glucopyranoside   C13H16O9  
   3-(3,4-Dihydroxybenzylidene)-5,6,7-trihydroxy-4-
chromanone  
 C16H12O7  
   3-(3,4-Dihydroxybenzylidene)-5,6,7-trihydroxy-4-
chromanone; (Z)-form  
 C16H12O7  
   3-(3,4-Dihydroxybenzylidene)-5,7,8-trihydroxy-4-
chromanone  






Names of Putative Compounds Chemical Formula 
315.126 500  3-(3,4-Dihydroxybenzylidene)-5,7,8-trihydroxy-4-
chromanone; (Z)-form  
 C16H12O7  
(continued)   1,9-Dihydroxy-3-hydroxymethyl-10-
methoxydibenz[b,e]oxepin-6,11-dione  
 C16H12O7  
   2,8-Dihydroxy-6-hydroxymethylxanthone-1-carboxylic 
acid; Me ester  
 C16H12O7  
   2,8-Dihydroxy-6-hydroxymethylxanthone-1-carboxylic 
acid; 8-Me ether  
 C16H12O7  
   2-(3,4-Dihydroxyphenyl)-4,6-dihydroxy-3-
benzofurancarboxylic acid; Me ester  
 C16H12O7  
   1-(2,4-Dihydroxyphenyl)-2-(2,4,5-
trihydroxyphenyl)ethanedione; 4,5-Methylene, 4'-Me ether  
 C16H12O7  
   Ellagic acid, INN; 3-Me ether   C15H8O8  
   1,2-Epoxy-8-hydroxy-6-(hydroxymethyl)-1-
methoxycarbonylxanthone  
 C16H12O7  
   Fusidienol   C16H12O7  
   Laughine   C11H18BrN5O 
   Lindbladiapyrone   C16H12O7  
   Orotidine; 3N-Me, Me ester   C12H16N2O8  
   Pannaric acid   C16H12O7  
   1,2,3,5,8-Pentahydroxyanthraquinone; 1,3-Di-Me ether   C16H12O7  
   1,2,3,7,8-Pentahydroxyanthraquinone; 2,3-Di-Me ether   C16H12O7  
   3',4,4',5',6-Pentahydroxyaurone; 4-Me ether   C16H12O7  
   1,2,3,8,9-Pentahydroxycoumestan   C15H8O8  
   2',3',5,6,7-Pentahydroxyflavanone; (S)-form, 6,7-
Methylene ether  
 C16H12O7  
   2',3,4',5,7-Pentahydroxyflavone; 2'-Me ether   C16H12O7  
   2',3,4',5,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   2',3,4',5,7-Pentahydroxyflavone; 5-Me ether   C16H12O7  
   2',3',4',6,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   2',3,5,7,8-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   2',4',5,6,7-Pentahydroxyflavone; 6-Me ether   C16H12O7  
   2',5,6',7,8-Pentahydroxyflavone; 8-Me ether   C16H12O7  
   3,3',4',6,7-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,3',4',6,7-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   3,3',4',7,8-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,3',4',7,8-Pentahydroxyflavone; 3'-Me ether   C16H12O7  
   3,3',4',7,8-Pentahydroxyflavone; 8-Me ether   C16H12O7  
   3',4',5,5',7-Pentahydroxyflavone; 3'-Me ether   C16H12O7  
   3',4',5,5',7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3,4',5,6,7-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,4',5,6,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyflavone; 5-Me ether   C16H12O7  
   3,4',5,6,7-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   3,4',5,7,8-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,4',5,7,8-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3,4',5,7,8-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   3',4',5,7,8-Pentahydroxyflavone; 8-Me ether   C16H12O7  






Names of Putative Compounds Chemical Formula 
315.126 500  4',5,6,7,8-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
(continued)   4',5,6,7,8-Pentahydroxyflavone; 6-Me ether   C16H12O7  
   2',4',5,5',7-Pentahydroxyisoflavone; 5'-Me ether   C16H12O7  
   3',4',5,5',7-Pentahydroxyisoflavone; 4'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyisoflavone; 3'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyisoflavone; 6-Me ether   C16H12O7  
   3',4',5,7,8-Pentahydroxyisoflavone; 8-Me ether   C16H12O7  
   4',5,6,7,8-Pentahydroxyisoflavone; 8-Me ether   C16H12O7  
   1,2,3,4,5-Pentahydroxy-7-methylanthraquinone; 2-Me 
ether  
 C16H12O7  
   1,2,3,7,8-Pentahydroxy-6-methylanthraquinone; 1-Me 
ether  
 C16H12O7  
   1,2,3,7,8-Pentahydroxy-6-methylanthraquinone; 2-Me 
ether  
 C16H12O7  
   1,3,4,5,7-Pentahydroxy-2-methylanthraquinone; 7-Me 
ether  
 C16H12O7  
   1,3,5,6,8-Pentahydroxy-2-methylanthraquinone; 6-Me 
ether  
 C16H12O7  
   1,3,5,7,8-Pentahydroxy-2-methylanthraquinone; 7-Me 
ether  
 C16H12O7  
   3',4,4',5',6-Pentahydroxy-5-methylaurone   C16H12O7  
   3,3',4',5,7-Pentahydroxy-6-methylflavone   C16H12O7  
   3,3',4',5,7-Pentahydroxy-8-methylflavone   C16H12O7  
   3,4',5,6,7-Pentahydroxy-8-methylflavone   C16H12O7  
   3',4',5,6,7-Pentahydroxy-8-methylflavone   C16H12O7  
   3,4',5,7,8-Pentahydroxy-6-methylflavone   C16H12O7  
   3',4',5,5',7-Pentahydroxy-6-methylisoflavone   C16H12O7  
   3,6a,7,8,9-Pentahydroxypterocarpan; 8,9-Methylene ether   C16H12O7  
  proto-Quercitol; L-form, 1-O-(3,4,5-Trihydroxybenzoyl)   C13H16O9  
  scyllo-Quercitol, 9CI, 8CI; 2-O-(3,4,5-Trihydroxybenzoyl)   C13H16O9  
   1,3,5,6-Tetrahydroxy-2-hydroxymethylanthraquinone; 6-
Me ether  
 C16H12O7  
   3',4',5,7-Tetrahydroxy-3-hydroxymethylflavone   C16H12O7  
   3,3',4',5-Tetrahydroxy-7-methoxyflavone   C16H12O7  
   3,3',4',7-Tetrahydroxy-5-methoxyflavone   C16H12O7  
   3,3',5,7-Tetrahydroxy-4'-methoxyflavone   C16H12O7  
   3',4',5,6-Tetrahydroxy-7-methoxyflavone   C16H12O7  
   3,4',5,7-Tetrahydroxy-3'-methoxyflavone   C16H12O7  
   3',4',5,7-Tetrahydroxy-3-methoxyflavone   C16H12O7  
   3,4',5,7-Tetrahydroxy-6-methoxyflavone   C16H12O7  
   3',4',5,7-Tetrahydroxy-6-methoxyflavone   C16H12O7  
   3,4',5,7-Tetrahydroxy-8-methoxyflavone   C16H12O7  
   3,4',6,7-Tetrahydroxy-5-methoxyflavone   C16H12O7  
   3',5,7,8-Tetrahydroxy-4'-methoxyflavone   C16H12O7  
   4',5,6,7-Tetrahydroxy-3'-methoxyflavone   C16H12O7  
   4',5,7,8-Tetrahydroxy-3'-methoxyflavone   C16H12O7  
   4,9,11,12a-Tetrahydroxyrotenoid   C16H12O7  
   3,4,5-Trihydroxybenzaldehyde, 9CI; 4-O-ß-D-
Glucopyranoside  






Names of Putative Compounds Chemical Formula 
315.126 500  3,4,5-Trihydroxybenzoic acid; a-L-Rhamnopyranosyl 
ester  
 C13H16O9  
(continued)   2,5,7-Trihydroxy-4H-1-benzopyran-4-one; 2-O-(3-
Hydroxy-4-methoxyphenyl)  
 C16H12O7  
   5,6,7-Trihydroxy-2-(4-hydroxyphenoxy)-4H-1-
benzopyran-4-one; 6-Me ether  
 C16H12O7  
   5,7,10-Trihydroxy-3-methyl-1H-naphtho[2,3-c]pyran-
1,6,9-trione; 5,7-Di-Me ether  
 C16H12O7  
   2,5,8-Trihydroxy-6-methylxanthone-1-carboxylic acid; 8-
Me ether  
 C16H12O7  
   2,3,7-Trihydroxy-1,6-phenazinedicarboxylic acid, 9CI   C14H8N2O7  
   Uridine-5-acetic acid; Me ester   C12H16N2O8  
   Verrucarin G   C15H12N2O6  
473.201 100   
   Acremolactone A   C26H34O8  
   Agrimophol   C26H34O8  
   Amoorastatin; O3-De-Ac   C26H34O8  
   Austalide B   C26H34O8  
   Clausenolide; 1-Me ether   C26H34O8  
   Cryptochlorophaeic acid; O-De-Me, 4,4'-di-Me ether   C26H34O8  
   Cryptochlorophaeic acid; 4-Me ether   C26H34O8  
   Cryptochlorophaeic acid; 4'-Me ether   C26H34O8  
   14,15:19,29-Diepoxy-1,3,7,29-tetrahydroxy-11-
meliacanone  
 C26H34O8  
   14,15:19,29-Diepoxy-1,3,7,29-tetrahydroxy-11-
meliacanone; (1a,3a,7a,14ß,15ß,29R)-form  
 C26H34O8  
   7,8:17,18-Diepoxy-1(19),6(20),10(17),13-xenicatetraene-
11,12,18-triol; Tri-Ac  
 C26H34O8  
   4,8-Dihydroxy-2,10(14),11(13)-guaiatrien-12,6-olide; 
(1a,4a,5a,6a,8ß)-form, 8-O-[4-Hydroxy-2-(2-
hydroxymethyl-2E-butenoyloxy)methyl-2E-butenoyl]  
 C25H30O9  
   Epiphorellic acid 1   C26H34O8  
   15,16-Epoxy-1,2-dihydroxy-3,13(16),14-clerodatrien-
17,12-olid-18-oic acid; (ent-1ß,2ß,12ßH)-form, Di-Ac, Me 
ester  
 C25H30O9  
   10,14-Epoxy-2,8-dihydroxy-3,11(13)-guaiadien-12,6-
olide; (1a,2ß,5a,6a,8ß,10a)-form, 8-[2-(2-Hydroxymethyl-
2E-butenoyloxymethyl)-2E-butenoyl]  
 C25H30O9  
   19,29-Epoxy-1,3,7,12,29-pentahydroxy-14-meliacen-11-
one  
 C26H34O8  
   19,29-Epoxy-1,3,7,12,29-pentahydroxy-14-meliacen-11-
one; (1a,3a,7a,12a,29R)-form  
 C26H34O8  
   14,15-Epoxy-3,5,16,19-tetrahydroxybufa-20,22-dienolide; 
(3ß,5ß,14ß,15ß,16ß)-form, 16-Ac  
 C26H34O8  
   19,29-Epoxy-1,3,7,29-tetrahydroxymeliacane-11,15-dione   C26H34O8  
   19,29-Epoxy-1,3,7,29-tetrahydroxymeliacane-11,15-
dione; (1a,3a,7a,29R)-form  







Names of Putative Compounds Chemical Formula 
473.201 100  8,17-Epoxy-2,9,12-trihydroxy-5,13-briaradien-18,7-olide; 
(2ß,5Z,7a,8a,9ß,12a,17a)-form, 12-Ketone, 2-butanoyl, 9-
Ac  
 C26H34O8  
(continued)   3',4,4',5,5',9,9'-Heptahydroxy-2,7'-cyclolignan; 
(7'S,8R,8'R)-form, 3',5,5'-Tri-Me ether, 9,9'-di-Ac  
 C25H30O9  
   3,3',4,4',5,9,9'-Heptahydroxylignan; (8R,8'R)-form, 3',4'-
Methylene, 3,5-di-Me ether, 9,9'-di-Ac  
 C25H30O9  
   1,3,5,11,14,19-Hexahydroxybufa-20,22-dienolide; 
(1ß,3ß,5ß,11a,14ß)-form, 1,3,5-Orthoacetate  
 C26H34O8  
   3',4,4',5,9,9'-Hexahydroxy-2,7'-cyclolignan; (7'S,8R,8'R)-
form, 3',5-Di-Me ether, 9-O-(5-hydroxy-4-oxopentanoyl)  
 C25H30O9  
   3',4,4',5,9,9'-Hexahydroxy-2,7'-cyclolignan; (7'S,8R,8'R)-
form, 3',5-Di-Me ether, 9'-O-(5-hydroxy-4-oxopentanoyl)  
 C25H30O9  
   3,3',4,4',9,9'-Hexahydroxylignan; (8R,8'R)-form, 3,3',4,4'-
Tetra-Me ether, 9,9'-di-Ac  
 C26H34O8  
   8-Hydroxy-1(10),3,11(13)-guaiatrien-12,6-olide; 
(5a,6a,8ß)-form, [4-Hydroxy-2-(4-hydroxy-2-
hydroxymethyl-2E-butenoyloxymethyl)-2E-butenoyl]  
 C25H30O9  
   8-Hydroxy-3,10(14),11(13)-guaiatrien-12,6-olide; 
(1a,5a,6a,8ß)-form, 8-[4-Hydroxy-2-(4-hydroxy-2-
hydroxymethyl-2-butenoyloxymethyl)-2-butenoyl](E,E-)  
 C25H30O9  
   Isocryptochlorophaeic acid; 4-Me ether   C26H34O8  
   4-Isopropylbenzyl alcohol; O-[ß-D-Glucopyranosyl-
(1?2)-ß-D-galactopyranoside]  
 C22H34O11  
   2-Isopropyl-5-methyl-1,4-benzenediol; 5-O-[a-L-
Rhamnopyranosyl-(1?2)-ß-D-glucopyranoside]  
 C22H34O11  
   2-Isopropyl-5-methylphenol; O-[ß-D-Glucopyranosyl-
(1?2)-ß-D-glucopyranoside]  
 C22H34O11  
   5-Isopropyl-2-methylphenol; O-[ß-D-Glucopyranosyl-
(1?2)-ß-D-glucopyranoside]  
 C22H34O11  
   Kadsulignan A; 6ß-Acetoxy   C25H30O9  
   Kopsaporine; 12-Methoxy, 14,15-dihydro, 15a-hydroxy   C24H30N2O8  
   Ligulaverin C; 6-Deacyl, 6-angeloyl   C26H34O8  
   Loxodinol   C25H30O9  
   Maximowicziol A; 11-Ketone, 4-O-ß-D-glucopyranoside   C25H30O9  
   Munronin F   C25H30O9  
   Murrafoline B   C32H30N2O2  
   Murrafoline B; (±)-form   C32H30N2O2  
   Murrafoline D   C32H30N2O2  
   Murrafoline D; (±)-form   C32H30N2O2  
   Murrafoline G   C32H30N2O2  
   Murrafoline G; (±)-form   C32H30N2O2  
   Murrastifoline D; 3'-Deoxy   C32H30N2O2  
   1,3,5,14,19-Pentahydroxybufa-20,22-dienolide; 
(1ß,3ß,5ß,14ß)-form, 19-Aldehyde, 3-Ac  
 C26H34O8  
   3,6,8,12,14-Pentahydroxybufa-4,20,22-trienolide; 
(3ß,6ß,12ß,14ß)-form, 6-Ac  
 C26H34O8  
   1,3,7,11,12-Pentahydroxy-14-meliacen-28-oic acid; 
(1a,3a,7a,11ß,12a)-form, 7-Ketone  
 C26H34O8  
78 




Names of Putative Compounds Chemical Formula 
473.201 100  Picrasin A   C26H34O8  
(continued)   Podophyllic acid; (7R,7'R,8R,8'R)-form, N-
Ethylhydrazide  
 C24H30N2O8  
   Robustaol A   C25H30O9  
   Saroaspidin C   C26H34O8  
   4,15-Scirpenediol; 4ß-form, Dibenzoyl   C29H30O6  
   13(16),14-Spongiadiene-2,3,17,19-tetrol; 3a-form, 2-
Ketone, tri-Ac  
 C26H34O8  
   Terretonin D   C26H34O8  
   2,4,6,8,10,12-Tetradecahexaenedioic acid; (all-E)-form, 
1-L-Aspartic acid, 14-L-isoleucine diamide  
 C24H30N2O8  
   1,4,6,9-Tetrahydroxydihydro-ß-agarofuran; (1a,4ß,6ß,9ß)-
form, 1-Benzoyl, 6,9-di-Ac  
 C26H34O8  
   1,6,8,9-Tetrahydroxydihydro-ß-agarofuran; (1a,6ß,8a,9a)-
form, 9-Benzoyl, 1,6-di-Ac  
 C26H34O8  
   3,5,11,14-Tetrahydroxy-12-oxobufa-20,22-dienolide; 
(3ß,5ß,11a,14ß)-form, 3-Ac  
 C26H34O8  
   3,5,12,14-Tetrahydroxy-11-oxobufa-20,22-dienolide; 
(3ß,5ß,12ß,14ß)-form, 3-Ac  
 C26H34O8  
   2,3,14-Trihydroxy-5,8(17),11-briaratrien-18,7-olide; 
(2ß,3a,5Z,7a,14a)-form, Tri-Ac  
 C26H34O8  
   6,10,14-Trihydroxy-3,7,11,15(17)-cembratetraen-16,2-
olide; (1S,2S,3E,6S,7E,10S,11E,14S)-form, Tri-Ac  
 C26H34O8  
   5,6,8-Trihydroxy-28-norisotoonafolin   C25H30O9  
   5,6,8-Trihydroxy-28-norisotoonafolin; (5a,6ß,8a)-form   C25H30O9  
   2,11,12-Trihydroxy-6,7-seco-8,11,13-abietatriene-6,7-dial 
11,6-hemiacetal; 2a-form, Tri-Ac(6a-)  
 C26H34O8  
   Trillenogenin; 1-Ketone   C26H34O8  
   14(17)-Vouacapene-1,5,6,7-tetrol; (1a,5a,6a,7ß)-form, 
1,6,7-Tri-Ac  
 C26H34O8  
   Xenione   C26H34O8  
   Xenione; Stereoisomer   C26H34O8  
    
517.161 1000   
   (2-Acetamido-2-deoxy-a-D-glucopyranos-1-yl)(methyl 2-
acetamido-2-deoxy-a-D-glucopyranosid-6-yl) phosphate  
 C17H31N2O14P 
   Acylsucroses; 3'-O-(4-Hydroxy-3-methoxy-E-cinnamoyl)   C22H30O14  
   Acylsucroses; 6-O-(4-Hydroxy-3-methoxy-E-cinnamoyl)   C22H30O14  
   Ajmaline, BAN, JAN; N-Propyl, hydrogen tartrate   C27H38N2O8  
  Alangium Alkaloid AL64; Mono-Ac   C31H39N3O4  
   Allaric acid; D-form, 1,4-Lactone, 2,3,5-tribenzoyl, 6-Me 
ester  
 C28H22O10  
   Aloin, BAN; (10R)-form, 7-Hydroxy, 4',6'-di-Ac   C25H26O12  
   Aloin, BAN; (10S)-form, 7-Hydroxy, 4',6'-di-Ac   C25H26O12  
   Ambruticin VS 5; N,N-Di-Me, N-oxide   C30H47NO6  
   Antibiotic GKK 1032A2; 2'-Me ether   C33H43NO4  
   Antibiotic TAN 1532B; 13-Me ether   C30H30O8  
79 




Names of Putative Compounds Chemical Formula 
517.161 1000  Austalide H; 13-Ac   C28H38O9  
(continued)   Batrachotoxinin A; O20-(3-Hydroxypentanoyl)   C29H43NO7  
   Bisnubenolide   C30H30O8  
   Cedrodorin; 9a-Hydroxy   C27H34O10  
   Chlorodesmin   C28H38O9  
   Colletotrichin A; 3-O-Formyl   C29H42O8  
   Colletotrichin A; 3''-O-Formyl   C29H42O8  
   Cosmosiin; 6''-O-Malonyl   C24H22O13  
   Cyclo(alanylalanylvalyltyrosylglycylglycyl)   C24H34N6O7  
   8-Daucene-2,4,6,10-tetrol; (2a,4ß,6a,10a)-form, 6-O-(3,4-
Dimethoxybenzoyl), 2,10-di-Ac  
 C28H38O9  
   Deacetylasperuloside; 10-O-(4-Hydroxy-E-cinnamoyl)   C25H26O12  
   Deacetylasperuloside; 10-O-a-L-Rhamnopyranoside   C22H30O14  
   Dehydrobruceolide; 15-O-(3-Methyl-2-butenoyl)   C26H30O11  
   ß-D-Galactopyranosyl-(1?6)-ß-D-galactopyranosyl-(1?6)-
D-galactose, 9CI; ß-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Galactopyranosyl-(1?3)-[a-D-galactopyranosyl-
(1?6)]-D-glucose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Galactopyranosyl-(1?4)-ß-D-galactopyranosyl-(1?4)-
D-glucose, 9CI; ß-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Galactopyranosyl-(1?2)-[ß-D-glucopyranosyl-(1?3)]-
D-glucose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Galactopyranosyl-(1?3)-[ß-D-glucopyranuronosyl-
(1?2)]-D-mannose, 9CI  
 C18H30O17  
   a-D-Galactopyranosyl-(1?3)-[ß-D-glucopyranuronosyl-
(1?2)]-D-mannose, 9CI; a-Pyranose-form  
 C18H30O17  
   a-D-Galactopyranosyl-(1?3)-[a-D-mannopyranosyl-
(1?6)]-D-mannose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   ß-D-Glucopyranosyl-(1?3)-a-D-galactopyranuronosyl-
(1?3)-D-mannose, 9CI  
 C18H30O17  
   ß-D-Glucopyranosyl-(1?2)-[ß-D-glucopyranosyl-(1?6)]-
D-glucose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Glucopyranosyl-(1?3)-a-D-glucopyranosyl-(1?3)-D-
glucose, 8CI; ß-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Glucopyranosyl-(1?3)-a-D-glucopyranosyl-(1?4)-D-
glucose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   ß-D-Glucopyranosyl-(1?3)-[ß-D-glucopyranosyl-(1?6)]-
D-glucose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   ß-D-Glucopyranosyl-(1?3)-[ß-D-glucopyranosyl-(1?6)]-
D-glucose, 9CI; ß-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Glucopyranosyl-(1?4)-a-D-glucopyranosyl-(1?3)-D-
glucose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Glucopyranosyl-(1?4)-[a-D-glucopyranosyl-(1?6)]-
D-glucose, 9CI; ß-Pyranose-form, Me glycoside  
 C19H34O16  
   a-D-Glucopyranosyl-(1?2)-a-D-glucopyranuronosyl-
(1?3)-D-mannose, 9CI  







Names of Putative Compounds Chemical Formula 
517.161 1000  a-D-Glucopyranosyl-(1?6)-[a-D-mannopyranosyl-(1?3)]-
D-mannose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
(continued)   ß-D-Glucopyranuronosyl-(1?6)-ß-D-galactopyranosyl-
(1?6)-D-galactose, 9CI  
 C18H30O17  
   ß-D-Glucopyranuronosyl-(1?4)-ß-D-glucopyranosyl-
(1?4)-D-glucose  
 C18H30O17  
   a-D-Mannopyranosyl-(1?4)-ß-D-glucopyranuronosyl-
(1?2)-D-mannose, 9CI  
 C18H30O17  
   a-D-Mannopyranosyl-(1?2)-[a-D-mannopyranosyl-(1?4)]-
D-mannose, 9CI; a-Pyranose-form, Me glycoside  
 C19H34O16  
   ß-D-Mannopyranuronosyl-(1?4)-ß-D-glucopyranosyl-
(1?4)-D-galactose, 8CI  
 C18H30O17  
   6-O-ß-D-Xylopyranosyl-D-galactose, 9CI; a-Pyranose-
form, 1,2:3,4-Di-O-isopropylidene, tri-Ac  
 C23H34O13  
   3,4-Di-O-caffeoylquinic acid; 7'',8''-Dihydro   C25H26O12  





   Didethiodi(methylthio)acetylapoaranotin   C24H26N2O7S2 
   2,3:6,7-Diepoxy-1,5,12,16,27-pentahydroxywith-24-
enolide; (1a,2a,3a,5a,6a,7a,12a,16ß,22R)-form, 16-Ketone  
 C28H38O9  
   4,18:7,20-Diepoxy-15,19,20-trihydroxy-6-oxo-11-
cleroden-16,15-olide; (ent-4ß,5ß,7ß,11E,15?, 20R)-form, 
Tri-Ac  
 C26H30O11  
   3-[9,10-Dihydro-3,4,7,9-tetrahydroxy-10-
(hydroxymethyl)-2-phenanthrenyl]-2-propenal; 3,7-Di-Me 
ether, 4-O-ß-D-glucopyranoside  
 C26H30O11  
   4,5-Dihydroxyanthraquinone-2-carboxylic acid; 5-O-(6-
O-Oxalyl-ß-D-glucopyranoside)  
 C23H18O14  
   3,14-Dihydroxycarda-4,20(22)-dienolide; (3ß,14ß)-form, 
3-O-a-L-Rhamnopyranoside  
 C29H42O8  
   3,14-Dihydroxycard-20(22)-enolide; (3ß,5a,14ß,17a)-
form, 3-O-(4-Amino-2,4,6-trideoxy-3-O-methyl-ß-D-ribo-
hexopyranoside)  
 C30H47NO6  
   3,14-Dihydroxycard-20(22)-enolide; (3ß,5a,14ß,17a)-
form, 3-O-(4-Amino-2,4,6-trideoxy-3-O-methyl-a-L-
arabino-hexopyranoside)  
 C30H47NO6  
   5,7-Dihydroxy-4',6-dimethoxyflavone; 7-O-(6-O-Acetyl-
ß-D-glucopyranoside)  
 C25H26O12  
   1,2-Dihydroxy-3,11(13)-eudesmadien-12,8-olid-14-oic 
acid; (1a,2ß,8ß)-form, Di-Ac, 4,5-dimethyl-3-oxo-2-heptyl 
ester  
 C28H38O9  











Names of Putative Compounds Chemical Formula 




 C27H34O10  
(continued)   3,5-Dihydroxy-6,7-megastigmadien-9-one; (3S,5R,7Rax)-
form, 3-O-[ß-D-Apiofuranosyl-(1?6)-ß-D-
glucopyranoside]  
 C24H38O12  
   6,9-Dihydroxy-4,7-megastigmadien-3-one; (6S,7E,9R)-
form, 9-O-[ß-D-Apiofuranosyl-(1?2)-ß-D-
glucopyranoside]  
 C24H38O12  
   6,9-Dihydroxy-4,7-megastigmadien-3-one; (6S,7E,9R)-
form, 9-O-[ß-D-Apiofuranosyl-(1?6)-ß-D-
glucopyranoside]  
 C24H38O12  
   6,9-Dihydroxy-4,7-megastigmadien-3-one; (6?,7E,9?)-
form, 9-O-[ß-D-Apiofuranosyl-(1?6)-ß-D-
glucopyranoside]  
 C24H38O12  
   6,9-Dihydroxy-4,7-megastigmadien-3-one; (6S,7E,9R)-
form, 9-O-[ß-D-Xylopyranosyl-(1?6)-ß-D-
glucopyranoside]  
 C24H38O12  
   6,9-Dihydroxy-4,7-megastigmadien-3-one; (6S,7E,9R)-
form, 9-O-[a-L-Arabinopyranosyl-(1?6)-ß-D-
glucopyranoside]  
 C24H38O12  
   7,18-Dihydroxy-4-methylaconit-8(15)-en-14-one; 5ß-
form, O7-Me, N-Et, 18-O-(2-acetamidobenzoyl)  
 C31H38N2O5  
   19,22-Dihydroxy-24-nor-2,3-seco-4,12-ursadiene-2,3,28-
trioic acid  
 C29H42O8  
   19,22-Dihydroxy-24-nor-2,3-seco-4,12-ursadiene-2,3,28-
trioic acid; (4Z,19a,22a)-form  
 C29H42O8  
   3,14-Dihydroxy-19-oxocarda-4,20(22)-dienolide; 
(3ß,14ß)-form, 3-O-ß-D-Xylopyranoside  
 C28H38O9  
   3,14-Dihydroxy-19-oxocard-20(22)-enolide; (3ß,5a,14ß)-
form, 3-O-(2,6-Dideoxy-D-ribo-hexopyranoside)  
 C29H42O8  
   3,14-Dihydroxy-19-oxocard-20(22)-enolide; 
(3ß,5a,14ß,17a)-form, 3-O-(2,6-Dideoxy-D-ribo-
hexopyranoside)  
 C29H42O8  
   3,14-Dihydroxy-19-oxocard-20(22)-enolide; (3ß,5ß,14ß)-
form, 3-O-(2,6-Dideoxy-D-ribo-hexopyranoside)  
 C29H42O8  
   3,14-Dihydroxy-19-oxocard-20(22)-enolide; (3ß,5a,14ß)-
form, 3-O-(2,6-Dideoxy-D-xylo-hexopyranoside)  
 C29H42O8  
   3,14-Dihydroxy-19-oxocard-20(22)-enolide; (3a,5a,14ß)-
form, 3-O-(2,6-Dideoxy-D-xylo-hexopyranoside)  
 C29H42O8  
   3,14-Dihydroxy-19-oxocard-20(22)-enolide; 
(3a,5a,14ß,17a)-form, 3-O-(2,6-Dideoxy-D-xylo-
hexopyranoside)  







Names of Putative Compounds Chemical Formula 
517.161 1000  3-(3,4-Dihydroxyphenyl)-2-propen-1-ol; (E)-form, 1,3'-
Di-Me ether, 4'-O-[3,4-dihydroxy-E-cinnamoyl-(?6)-ß-D-
glucopyranoside]  
 C26H30O11  
(continued)   Echitamidine; (-)-form, Nb-Oxide, 19-O-ß-D-
glucopyranoside  
 C26H34N2O9  
   4,7'-Epoxy-3,8'-bilign-7-ene-3',4',5,9,9'-pentol; (7'R,8'S)-
form, 9-Aldehyde, 3',5-di-Me ether, 4'-O-ß-D-
glucopyranoside  
 C26H30O11  
   4,7'-Epoxy-3,8'-bilign-7-ene-3',4',5,9,9'-pentol; (7'S,8'R)-
form, 9-Aldehyde, 3',5-di-Me ether, 4'-O-ß-D-
glucopyranoside  
 C26H30O11  
   4,7'-Epoxy-3,8'-bilign-7-ene-3',4',5,9,9'-pentol; (7'R,8'S)-
form, 9-Aldehyde, 3',5-di-Me ether, 9'-O-ß-D-
glucopyranoside  
 C26H30O11  
   4,7'-Epoxy-3,8'-bilign-7-ene-3',4',5,9,9'-pentol; (7'S,8'R)-
form, 9-Aldehyde, 3',5-di-Me ether, 9'-O-ß-D-
glucopyranoside  
 C26H30O11  
   18,19-Epoxy-12,14-clerodadiene-2,6,18,19-tetrol; (ent-
2ß,5a,6a,8a,12E,18a,19a)-form, 2-Tigloyl, 18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,12,14-clerodatriene-2,6,7,18,19-pentol; 
(2a,5a,6a,7ß,8a,12Z,18a,19a)-form, 2-Ketone, 7-butanoyl, 
18,19-di-Ac  
 C28H38O9  
   18,19-Epoxy-3,12,14-clerodatriene-2,6,18,19-tetrol; (ent-
2ß,5a,6a,8a,12E,18a,19a)-form, 6-Me ether, 2-O-(2-
methylpropanoyl), 18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,12,14-clerodatriene-2,6,18,19-tetrol; 
(2ß,5a,6a,8a,12E,18a,19a)-form, 2-O-(2-Methylbutanoyl), 
18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,12,14-clerodatriene-2,6,18,19-tetrol; (ent-
2ß,5a,6a,8a,12E,18a,19a)-form, 2-O-(2-Methylbutanoyl), 
18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,12,14-clerodatriene-2,6,18,19-tetrol; 
(2a,5a,6a,8a,12E,18a,19a)-form, 2-O-(2-Methylbutanoyl), 
18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,12,14-clerodatriene-2,6,18,19-tetrol; (ent-
2a,5a,6a,8a,12E,18a,19a)-form, 6-O-(2-Methylbutanoyl), 
18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,12,14-clerodatriene-2,7,18,19-tetrol; 
(2a,5a,7ß,8a,12Z,18a,19a)-form, 2-Me ether, 7-butanoyl, 
18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,13(16),14-clerodatriene-2,6,18,19-tetrol; 
(2a,5a,6a,8ßH,18a,19ß)-form, 6-Me ether, 2-(2-
methylpropanoyl), 18,19-di-Ac  
 C29H42O8  
   18,19-Epoxy-3,13(16),14-clerodatriene-2,6,18,19-tetrol; 
(2a,5a,6a,8ßH,18a,19ß)-form, 2-(2-Methylbutanoyl), 
18,19-di-Ac  







Names of Putative Compounds Chemical Formula 
517.161 1000  18,19-Epoxy-3,13(16),14-clerodatriene-2,6,18,19-tetrol; 
(ent-2a,5a,6a,8ßH,18a,19ß)-form, 2-(2-Methylbutanoyl), 
18,19-di-Ac  
 C29H42O8  
(continued)   18,19-Epoxy-3,13(16),14-clerodatriene-2,6,18,19-tetrol; 
(ent-2ß,5a,6a,8ßH,18a,19a)-form, 2-(2-Methylbutanoyl), 
18,19-di-Ac  
 C29H42O8  
   11,12-Epoxy-2,3,14-trihydroxy-5,8(17)-briaradien-18,7-
olide; (2ß,3a,7a,11ß,12ß,14a)-form, 2-Butanoyl, 3,14-di-
Ac  
 C28H38O9  
   11,12-Epoxy-2,4,14-trihydroxy-5,8(17)-briaradien-18,7-
olide; 2-Butanoyl, 4,14-di-Ac  
 C28H38O9  
   16,24-Epoxy-21,24,25-trihydroxy-17-cheilanthen-19,25-
olide; (24a,25?)-form, 21,24-Di-Ac  
 C29H42O8  
   5,6-Epoxy-3,4,28-trihydroxy-1-oxowith-24-enolid-19-oic 
acid  
 C28H38O9  
   5,6-Epoxy-3,4,28-trihydroxy-1-oxowith-24-enolid-19-oic 
acid; (3ß,4ß,5ß,6ß)-form  
 C28H38O9  
   17,18-Epoxy-1(19),6,10(17),13-xenicatetraene-
8,11,12,18-tetrol; (6E,8a,11R,12R,18ß)-form, Tetra-Ac  
 C28H38O9  
   Euchretin C; 9-Me ether   C31H34O7  
   Fibleucin; 4-O-ß-D-Glucopyranoside   C26H30O11  
   Fumadensine   C30H34N2O6  
   Galactinol; 6'-O-a-D-Galactopyranosyl, 4-Me   C19H34O16  
   Galactotriose; ß-Pyranose-form, Me glycoside   C19H34O16  
   Gentiopicroside; 3'-ß-D-Glucopyranosyl   C22H30O14  
   Gentiopicroside; 4'-ß-D-Glucopyranosyl   C22H30O14  
   Gentiopicroside; 6'-ß-D-Glucopyranosyl   C22H30O14  
   8-Glucopyranosyl-4',5,7-trihydroxyisoflavone; 6''-O-
Malonyl  
 C24H22O13  
   Gomphoside   C29H42O8  
   Gomphotin   C29H42O8  
   Gossypol   C30H30O8  
   Gossypol; (+)-form   C30H30O8  
   Gossypol; (-)-form   C30H30O8  
   Gossypol; (±)-form   C30H30O8  
   Guan-fu base E   C29H43NO7  
   Haperforin D   C27H34O10  
   2,3',4,4',5',6-Hexahydroxydiphenyl ether; Hexa-Ac   C24H22O13  
   2,3,14,20,22,28-Hexahydroxy-6-oxostigmast-7-en-26-oic 
acid; (2ß,3ß,5ß,14a,20R,22R,24S,25S,28R)-form, 26?28-
Lactone, 22-ketone  
 C29H42O8  
   9-Hydroxy-4-megastigmen-3-one; (6R,9R)-form, O-[a-L-
Rhamnopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C25H42O11  
   1-Hydroxy-5-methoxy-6-methyl-2(1H)-pyridinone, 9CI; 
Fe complex (3:1)  
 C21H24FeN3O9 
   3-Hydroxy-9-methoxypterocarpan; (-)-form, 3-O-(6-O-
Malonyl-ß-D-glucopyranoside)  
 C25H26O12  







Names of Putative Compounds Chemical Formula 
517.161 1000 chiro-Inositol, 9CI, 8CI; D-form, 4-Me, 2-O-[a-D-
galactopyranosyl-(1?6)-a-D-galactopyranoside]  
 C19H34O16  
(continued)  myo-Inositol, 8CI, 9CI; 2-O-[a-D-Mannopyranosyl-(1?4)-
a-D-glucuronopyranoside]  
 C18H30O17  
   Ipobscurine B   C29H30N2O7  
   Ixoside; 6'-(E-Cinnamoyl)   C25H26O12  
   Jioglutoside B   C23H34O13  
   16-Kaurene-3,6,7,11,15-pentol; (ent-3a,6ß,7a,11a,15a)-
form, 11-Ketone, tetra-Ac  
 C28H38O9  
   16-Kaurene-3,6,7,11,15-pentol; (ent-3a,6ß,7a,11a,15a)-
form, 15-Ketone, tetra-Ac  
 C28H38O9  
   16-Kaurene-3,6,7,11,15-pentol; (ent-3a,6ß,7a,11a,15a)-
form, 6-Ketone, tetra-Ac  
 C28H38O9  
   Khayanolide B   C27H34O10  
   Lebstatin; 17-Demethoxy   C28H42N2O7  
   2-O-a-L-Fucopyranosyl-D-galactose; ß-Pyranose-form, 
1,6-Anhydro, penta-Ac  
 C22H30O14  
   Lotusine A   C30H38N4O4  
   Maculalactone E; 3a,3aa-Epoxide   C34H30O5  
   Mallotus B   C30H30O8  
   5,7-Megastigmadiene-3,4,9-triol; (3?,4?,7E)-form, 9-
Ketone, 4-O-[ß-D-apiofuranosyl-(1??)-ß-D-
glucopyranoside]  
 C24H38O12  
   5-Megastigmene-3,9-diol; (3ß,9R)-form, 9-Ketone, 3-O-
[a-L-rhamnopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C25H42O11  
   Mitiphylline; N-De-Me   C30H47NO6  
   Myricanol; 11-Deoxy, 9-oxo, 5-O-ß-D-glucopyranoside   C27H34O10  
   Myricanol; Ketone, 5-O-ß-D-glucopyranoside   C27H34O10  
   1,4,5-Naphthalenetriol, 9CI; 4-O-[4-Hydroxy-3,5-
dimethoxybenzoyl-(?6)-ß-D-glucopyranoside]  
 C25H26O12  
   3,3',4,4',5,5',9,9'-Octahydroxy-7,7'-epoxylignan; 
(7R,7'S,8R,8'R)-form, 3',4'-Methylene, 3,5,5'-tri-Me ether, 
9,9'-di-Ac  
 C26H30O11  
   3,3',4,4',5,5',9,9'-Octahydroxylignan; (8S,8'S)-form, 3,4-
Methylene, 3',4',5,5'-tetra-Me ether, 9,9'-di-Ac  
 C27H34O10  
   Opuntial   C28H38O9  
   Paspalitrem A; ?1'-Isomer, 3'-hydroxy   C32H39NO5  
   1,1,2,6,6-Pentabromo-1,4-octadien-3-one   C8H7Br5O  
   1,1,2,6,6-Pentabromo-1,4-octadien-3-one; (E)-form   C8H7Br5O  
   3,4',5,7,8-Pentahydroxyflavone; 8-O-(2,3-Di-O-acetyl-ß-
D-xylopyranoside)  
 C24H22O13  
   2,3,14,21,22-Pentahydroxy-6-oxoergosta-7,24(28)-dien-
29,25-olide  
 C29H42O8  
   2,3,14,21,22-Pentahydroxy-6-oxoergosta-7,24(28)-dien-
29,25-olide; (2ß,3ß,5ß,14a,20R,22R)-form  
 C29H42O8  
   2,3,14,20,25-Pentahydroxy-6-oxostigmasta-7,24(28)-
dien-29,22-olide  
 C29H42O8  
   2,3,14,20,25-Pentahydroxy-6-oxostigmasta-7,24(28)-
dien-29,22-olide; (2ß,3ß,5ß,14a,20R,22R)-form  
 C29H42O8  
85 




Names of Putative Compounds Chemical Formula 
517.161 1000  2,3,14,20,28-Pentahydroxy-6-oxostigmasta-7,24-dien-
26,22-olide  
 C29H42O8  
(continued)   2,3,14,20,28-Pentahydroxy-6-oxostigmasta-7,24-dien-
26,22-olide; (2ß,3ß,5ß,14a,20R,22R,28?)-form  
 C29H42O8  
   Petrosaspongiolide G; 16,21-Di-Ac   C29H42O8  
   Petrosaspongiolide G; 17,24,25-Triepimer, 16,21-di-Ac   C29H42O8  
   Phellamuretin; 3-O-ß-D-Glucopyranoside   C26H30O11  
   Pinillidine   C28H22O10  
   Piperitol; (+)-form, O-ß-D-Glucopyranoside   C26H30O11  
   Polybromohydroxydiphenyl ethers; 2,2',4,4'-Tetrabromo-
6,6'-dihydroxydiphenyl ether  
 C12H6Br4O3  
   Polybromohydroxydiphenyl ethers; 2,3',4,5'-Tetrabromo-
2',6-dihydroxydiphenyl ether  
 C12H6Br4O3  
   Polybromohydroxydiphenyl ethers; 3,3',5,6'-Tetrabromo-
2,2'-dihydroxydiphenyl ether  
 C12H6Br4O3  
   Polybromohydroxydiphenyl ethers; 3,5,5',6-Tetrabromo-
2,2'-dihydroxydiphenyl ether  
 C12H6Br4O3  
   5-(1-Propenyl)-1,2,3-benzenetriol, 9CI; (E)-form, 1,3-Di-
Me ether, 2-O-[ß-D-glucopyranosyl-(1?6)-ß-D-
glucopyranoside]  
 C23H34O13  
   5-(2-Propenyl)-1,2,3-benzenetriol; 1,3-Di-Me ether, 2-O-
[ß-D-glucopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C23H34O13  
   Purealidin H; O4-(3-Aminopropyl)   
C17H22Br2N6O
3  
   Quercetin 3-glycosides; Monosaccharides, 3-O-(3,5-Di-
O-acetyl-a-L-arabinofuranoside)  
 C24H22O13  
   Rubratoxin A; 25-Ketone   C26H30O11  
   Rutaevinexic acid   C26H30O11  
   Sarcotrine A; N-Dealkyl, N-(2-phenylethyl)   C33H43NO4  
   Sarcotrine A; 17-Epimer, N-dealkyl, N-(2-phenylethyl)   C33H43NO4  
   Sativanine B   C30H38N4O4  
   Scandenin; Di-Ac   C30H30O8  
   Scytonine   C31H22N2O6  
   Segetalin G   C25H38N6O6  
   Sirodesmin A; Trisulfide homologue   C20H26N2O8S3 
   Sirodesmin A; Trisulfide homologue, 1-epimer   C20H26N2O8S3 
   13(16),14-Spongiadiene-2,3,17,19-tetrol; (2ß,3ß)-form, 
Tetra-Ac  
 C28H38O9  
   Swertiabisxanthone I   C26H14O12  
   4(20),11-Taxadiene-2,5,10,14-tetrol; (2a,5a,10ß,14ß)-
form, 14-Propanoyl, 2,5,10-tri-Ac  
 C29H42O8  
   Terpendole C; 6,7-Didehydro   C32H39NO5  
   Terragine A   C26H38N4O7  
   1,4,9,20-Tetraacetoxy-1,3(20),6,10,14-phytapentaen-19-al   C28H38O9  
   2,3,11,15-Tetrahydroxy-16-kauren-6-one; (ent-
2a,3a,11a,15a)-form, Tetra-Ac  







Names of Putative Compounds Chemical Formula 
517.161 1000  2,3,6,11-Tetrahydroxy-16-kauren-15-one; (ent-
2a,3a,6ß,11ß)-form, Tetra-Ac  
 C28H38O9  
(continued)   4,14,17,20-Tetrahydroxy-1-oxowitha-2,5,24-trienolide; 
(4ß,14a,17ßOH,20S,22R)-form, 28-Hydroxy, 5ß,6ß-
epoxide  
 C28H38O9  
   5,6,14,15-Tetrahydroxy-1-oxowitha-2,16,24-trienolide; 
(5a,6ß,14a,15a,22R)-form, 25-Hydroxy, 16,17-epoxide  
 C28H38O9  
   3,4',5,7-Tetrahydroxy-3'-prenylflavanone; (2R,3R)-form, 
7-O-ß-D-Glucopyranoside  
 C26H30O11  
   3,4',5,7-Tetrahydroxy-8-prenylflavanone; (2R,3R)-form, 
7-O-ß-D-Glucopyranoside  
 C26H30O11  
   2,5,9,10-Tetrahydroxy-4(20),11-taxadien-13-one; 
(2a,5a,9a,10ß)-form, Tetra-Ac  
 C28H38O9  
   Thevetiogenin; 3-O-a-L-Rhamnopyranoside   C29H42O8  
   5,7,8-Trihydroxy-2H-1-benzopyran-2-one, 9CI; 5-O-[ß-
D-Glucopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C21H26O15  
   5,7,8-Trihydroxy-2H-1-benzopyran-2-one, 9CI; 5,7-Di-O-
ß-D-glucopyranoside  
 C21H26O15  
   4',5,7-Trihydroxyflavone; 7-O-(2-ß-D-
Glucuronopyranosyloxypropanoyl)  
 C24H22O13  
   4',5,7-Trihydroxyflavone; 5-O-(6-O-Malonyl-ß-D-
glucopyranoside)  
 C24H22O13  
   5,6,7-Trihydroxyflavone; 7-O-(6-O-Malonyl-ß-D-
glucopyranoside)  
 C24H22O13  
   4',5,7-Trihydroxyisoflavone; 7-O-(6-O-Malonyl-D-
glucopyranoside)  
 C24H22O13  
   1,2,8-Trihydroxy-3-methylanthraquinone; 2-O-(6-O-
Malonyl-ß-D-glucopyranoside)  
 C24H22O13  
   4',5,7-Trihydroxy-8-prenylflavanone; (S)-form, 4''-
Hydroxy(E-), 7-O-ß-D-glucopyranoside  
 C26H30O11  
   4',5,7-Trihydroxy-8-prenylisoflavone; 2'',3''-Dihydro, 3''-
hydroxy, 7-O-ß-D-glucopyranoside  
 C26H30O11  
   3,7,12-Trihydroxy-25,26,27-trinor-11,15-dioxolanost-8-
en-24-oic acid; (3ß,7ß,12ß)-form, 12-Ac  
 C29H42O8  
   Trioxacarcin A, 9CI; Aglycone   C25H26O12  
   Tryptoquialanine A   C27H26N4O7  
   Ustilaginoidin A; (R)-form, 2?,2'?,3,3'-Tetrahydro   C28H22O10  
   Ustilaginoidin A; (S)-form, 2?,2'?,3,3'-Tetrahydro   C28H22O10  
   Venturamide B   C22H26N6O5S2 
   Veprisonic acid   C27H34O10  
   Veprisonic acid; 21-Ketone(lactone), 23?-alcohol   C27H34O10  
   Verrucarin A; 16-Hydroxy   C27H34O10  
   Verrucarin A; 8-Hydroxy   C27H34O10  




Table A.2. Putative matches for Compound X from the Chapman & Hall database based on 
m/z ratios obtained from FTMS analysis of pooled Compound X fractions from HPLC of 
calf urine.  
Peak m/z Searched 
Range 
(ppm) 
Names of Putative Compounds Chemical Formula
317.0958 700   
   2-Acetyl-1,3,6,8-tetrahydroxyanthraquinone; 1'R-Alcohol   C16H12O7  
   2-Amino-3-(3-bromo-4-hydroxyphenyl)propanoic acid; 
(S)-form, 4-Me ether, N,N,N-tri-Me, betaine  
 C13H18BrNO3  
   1,5-Anhydroglucitol, 9CI, 8CI; D-form, 2-O-(3,4,5-
Trihydroxybenzoyl)  
 C13H16O9  
   1,5-Anhydroglucitol, 9CI, 8CI; D-form, 6-O-(3,4,5-
Trihydroxybenzoyl)  
 C13H16O9  
   Aquilegiolide; 4,5-Dihydro, O-ß-D-glucopyranoside   C14H20O8  
   Aquilegiolide; 6-Epimer, 4,5-dihydro, O-ß-D-
glucopyranoside  
 C14H20O8  
   Aquilegiolide; 7a-Epimer, 4,5-dihydro, O-ß-D-
glucopyranoside  
 C14H20O8  
   1,2,3-Benzenetriol, 9CI; 1,3-Di-Me ether, 2-O-ß-D-
glucopyranoside  
 C14H20O8  
   1,2,4-Benzenetriol, 8CI, 9CI; 1,2-Di-Me ether, 4-O-ß-D-
glucopyranoside  
 C14H20O8  
   1,3,5-Benzenetriol, 9CI; Di-Me ether, O-ß-
glucopyranoside  
 C14H20O8  
   Boxazomycin A   C14H12N4O5  
   6-Bromo-1,2,3,4-tetrahydro-7,8-dihydroxy-3-
isoquinolinecarboxylic acid; (S)-form, 7-Me ether, Me 
ester  
 C12H14BrNO4  
   8-Bromo-1,2,3,4-tetrahydro-6,7-dihydroxy-3-
isoquinolinecarboxylic acid; (S)-form, 7-Me ether, Me 
ester  
 C12H14BrNO4  
   Coccineone D   C16H12O7  
   Crombeone   C16H12O7  
   1,2,3,4-Cyclohexanetetrol, 9CI; (1RS,2RS,3RS,4RS)-
form, Tetra-Ac  
 C14H20O8  
   1,2,4,5-Cyclohexanetetrol, 9CI; (1S,2S,4S,5S)-form, 
Tetra-Ac  
 C14H20O8  
   1,1-Dibromo-2-heptanol; (±)-form, Ac   C9H16Br2O2  
   2',5'-Dihydroxyacetophenone, 8CI; Bis(2,2,2-
trifluoroethyl) ether  
 C12H10F6O3  
   2,3-Dihydroxybenzoic acid, 9CI; 3-O-ß-D-
Glucopyranoside  
 C13H16O9  
   2,5-Dihydroxybenzoic acid, 9CI; 2-O-ß-D-
Glucopyranoside  
 C13H16O9  
   2,5-Dihydroxybenzoic acid, 9CI; 5-O-ß-D-
Glucopyranoside  
 C13H16O9  
   3,4-Dihydroxybenzoic acid; 3-O-ß-D-Glucopyranoside   C13H16O9  
   3,4-Dihydroxybenzoic acid; 4-O-ß-D-Glucopyranoside   C13H16O9  
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Names of Putative Compounds Chemical Formula
317.0958 700  3,4-Dihydroxybenzyl alcohol, 8CI; 3-Me ether, 4-O-ß-D-
glucopyranoside  
 C14H20O8  
(continued)   3-(3,4-Dihydroxybenzylidene)-5,6,7-trihydroxy-4-
chromanone  
 C16H12O7  
   3-(3,4-Dihydroxybenzylidene)-5,6,7-trihydroxy-4-
chromanone; (Z)-form  
 C16H12O7  
   3-(3,4-Dihydroxybenzylidene)-5,7,8-trihydroxy-4-
chromanone  
 C16H12O7  
   3-(3,4-Dihydroxybenzylidene)-5,7,8-trihydroxy-4-
chromanone; (Z)-form  
 C16H12O7  
   1,9-Dihydroxy-3-hydroxymethyl-10-
methoxydibenz[b,e]oxepin-6,11-dione  
 C16H12O7  
   2,8-Dihydroxy-6-hydroxymethylxanthone-1-carboxylic 
acid; Me ester  
 C16H12O7  
   2,8-Dihydroxy-6-hydroxymethylxanthone-1-carboxylic 
acid; 8-Me ether  
 C16H12O7  
   2-(3,4-Dihydroxyphenyl)-4,6-dihydroxy-3-
benzofurancarboxylic acid; Me ester  
 C16H12O7  
   2-(3,4-Dihydroxyphenyl)ethanol; 3'-O-ß-D-
Galactopyranoside  
 C14H20O8  
   2-(3,4-Dihydroxyphenyl)ethanol; 3'-O-ß-D-
Glucopyranoside  
 C14H20O8  
   2-(3,4-Dihydroxyphenyl)ethanol; 4'-O-ß-D-
Glucopyranoside  
 C14H20O8  
   2-(3,5-Dihydroxyphenyl)ethanol; 3'-O-ß-D-
Glucopyranoside  
 C14H20O8  
   1-(2,4-Dihydroxyphenyl)-2-(2,4,5-
trihydroxyphenyl)ethanedione; 4,5-Methylene, 4'-Me ether  
 C16H12O7  
   Ellagic acid, INN; 3-Me ether   C15H8O8  
   1,2-Epoxy-8-hydroxy-6-(hydroxymethyl)-1-
methoxycarbonylxanthone  
 C16H12O7  
   Fusidienol   C16H12O7  
  altro-2-Heptulose, 8CI, 9CI; ß-D-Pyranose-form, 2,7-
Anhydro, 4,5-O-isopropylidene, 1,3-di-Ac  
 C14H20O8  
   4-Hydroxy-4-(2-hydroxyethyl)-2,5-cyclohexadien-1-one; 
2'-O-ß-D-Glucopyranoside  
 C14H20O8  
   4-Hydroxy-2-isopropylidene-5-methyl-3(2H)-furanone; 
O-ß-D-Glucopyranoside  
 C14H20O8  
   Hydroxytyrosol 1-glycosides; 1-O-ß-D-Allopyranoside   C14H20O8  
   Hydroxytyrosol 1-glycosides; 1-O-ß-D-Glucopyranoside   C14H20O8  
   Laughine   C11H18BrN5O  
   Lindbladiapyrone   C16H12O7  
   2-Methyl-1,3,5-benzenetriol; 1-Me ether, 5-O-ß-D-
glucopyranoside  
 C14H20O8  
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Names of Putative Compounds Chemical Formula
317.0958 700  Orotidine; 3N-Me, Me ester   C12H16N2O8  
(continued)   Pannaric acid   C16H12O7  
   1,2,3,5,8-Pentahydroxyanthraquinone; 1,3-Di-Me ether   C16H12O7  
   1,2,3,7,8-Pentahydroxyanthraquinone; 2,3-Di-Me ether   C16H12O7  
   3',4,4',5',6-Pentahydroxyaurone; 4-Me ether   C16H12O7  
   1,2,3,8,9-Pentahydroxycoumestan   C15H8O8  
   2',3',5,6,7-Pentahydroxyflavanone; (S)-form, 6,7-
Methylene ether  
 C16H12O7  
   2',3,4',5,7-Pentahydroxyflavone; 2'-Me ether   C16H12O7  
   2',3,4',5,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   2',3,4',5,7-Pentahydroxyflavone; 5-Me ether   C16H12O7  
   2',3',4',6,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   2',3,5,7,8-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   2',4',5,6,7-Pentahydroxyflavone; 6-Me ether   C16H12O7  
   2',5,6',7,8-Pentahydroxyflavone; 8-Me ether   C16H12O7  
   3,3',4',6,7-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,3',4',6,7-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   3,3',4',7,8-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,3',4',7,8-Pentahydroxyflavone; 3'-Me ether   C16H12O7  
   3,3',4',7,8-Pentahydroxyflavone; 8-Me ether   C16H12O7  
   3',4',5,5',7-Pentahydroxyflavone; 3'-Me ether   C16H12O7  
   3',4',5,5',7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3,4',5,6,7-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,4',5,6,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyflavone; 5-Me ether   C16H12O7  
   3,4',5,6,7-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   3,4',5,7,8-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   3,4',5,7,8-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   3,4',5,7,8-Pentahydroxyflavone; 7-Me ether   C16H12O7  
   3',4',5,7,8-Pentahydroxyflavone; 8-Me ether   C16H12O7  
   3,5,6,7,8-Pentahydroxyflavone; 3-Me ether   C16H12O7  
   4',5,6,7,8-Pentahydroxyflavone; 4'-Me ether   C16H12O7  
   4',5,6,7,8-Pentahydroxyflavone; 6-Me ether   C16H12O7  
   2',4',5,5',7-Pentahydroxyisoflavone; 5'-Me ether   C16H12O7  
   3',4',5,5',7-Pentahydroxyisoflavone; 4'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyisoflavone; 3'-Me ether   C16H12O7  
   3',4',5,6,7-Pentahydroxyisoflavone; 6-Me ether   C16H12O7  
   3',4',5,7,8-Pentahydroxyisoflavone; 8-Me ether   C16H12O7  
   4',5,6,7,8-Pentahydroxyisoflavone; 8-Me ether   C16H12O7  
   1,2,3,4,5-Pentahydroxy-7-methylanthraquinone; 2-Me 
ether  
 C16H12O7  
   1,2,3,7,8-Pentahydroxy-6-methylanthraquinone; 1-Me 
ether  
 C16H12O7  
   1,2,3,7,8-Pentahydroxy-6-methylanthraquinone; 2-Me 
ether  
 C16H12O7  
   1,3,4,5,7-Pentahydroxy-2-methylanthraquinone; 7-Me 
ether  







Names of Putative Compounds Chemical Formula
317.0958 700  1,3,5,6,8-Pentahydroxy-2-methylanthraquinone; 6-Me 
ether  
 C16H12O7  
(continued)   1,3,5,7,8-Pentahydroxy-2-methylanthraquinone; 7-Me 
ether  
 C16H12O7  
   3',4,4',5',6-Pentahydroxy-5-methylaurone   C16H12O7  
   3,3',4',5,7-Pentahydroxy-6-methylflavone   C16H12O7  
   3,3',4',5,7-Pentahydroxy-8-methylflavone   C16H12O7  
   3,4',5,6,7-Pentahydroxy-8-methylflavone   C16H12O7  
   3',4',5,6,7-Pentahydroxy-8-methylflavone   C16H12O7  
   3,4',5,7,8-Pentahydroxy-6-methylflavone   C16H12O7  
   3',4',5,5',7-Pentahydroxy-6-methylisoflavone   C16H12O7  
   3,6a,7,8,9-Pentahydroxypterocarpan; 8,9-Methylene ether   C16H12O7  
  proto-Quercitol; L-form, 1-O-(3,4,5-Trihydroxybenzoyl)   C13H16O9  
  scyllo-Quercitol, 9CI, 8CI; 2-O-(3,4,5-Trihydroxybenzoyl)   C13H16O9  
   3,3a,7,7a-Tetrahydro-6-hydroxy-2(6H)-benzofuranone; 
(3aS,6R,7aR)-form, O-ß-D-Glucopyranoside  
 C14H20O8  
   1,3,5,6-Tetrahydroxy-2-hydroxymethylanthraquinone; 6-
Me ether  
 C16H12O7  
   3',4',5,7-Tetrahydroxy-3-hydroxymethylflavone   C16H12O7  
   3,3',4',5-Tetrahydroxy-7-methoxyflavone   C16H12O7  
   3,3',4',7-Tetrahydroxy-5-methoxyflavone   C16H12O7  
   3,3',5,7-Tetrahydroxy-4'-methoxyflavone   C16H12O7  
   3',4',5,6-Tetrahydroxy-7-methoxyflavone   C16H12O7  
   3,4',5,7-Tetrahydroxy-3'-methoxyflavone   C16H12O7  
   3',4',5,7-Tetrahydroxy-3-methoxyflavone   C16H12O7  
   3,4',5,7-Tetrahydroxy-6-methoxyflavone   C16H12O7  
   3',4',5,7-Tetrahydroxy-6-methoxyflavone   C16H12O7  
   3,4',5,7-Tetrahydroxy-8-methoxyflavone   C16H12O7  
   3,4',6,7-Tetrahydroxy-5-methoxyflavone   C16H12O7  
   3',5,7,8-Tetrahydroxy-4'-methoxyflavone   C16H12O7  
   4',5,6,7-Tetrahydroxy-3'-methoxyflavone   C16H12O7  
   4',5,7,8-Tetrahydroxy-3'-methoxyflavone   C16H12O7  
   4,9,11,12a-Tetrahydroxyrotenoid   C16H12O7  
   3,4,5-Trihydroxybenzaldehyde, 9CI; 4-O-ß-D-
Glucopyranoside  
 C13H16O9  
   3,4,5-Trihydroxybenzoic acid; a-L-Rhamnopyranosyl 
ester  
 C13H16O9  
   2,5,7-Trihydroxy-4H-1-benzopyran-4-one; 2-O-(3-
Hydroxy-4-methoxyphenyl)  
 C16H12O7  
   5,6,7-Trihydroxy-2-(4-hydroxyphenoxy)-4H-1-
benzopyran-4-one; 6-Me ether  
 C16H12O7  
   5,7,10-Trihydroxy-3-methyl-1H-naphtho[2,3-c]pyran-
1,6,9-trione; 5,7-Di-Me ether  
 C16H12O7  
   2,5,8-Trihydroxy-6-methylxanthone-1-carboxylic acid; 8-
Me ether  
 C16H12O7  
   2,3,7-Trihydroxy-1,6-phenazinedicarboxylic acid, 9CI   C14H8N2O7  
   Uridine-5-acetic acid; Me ester   C12H16N2O8  
   Verrucarin G   C15H12N2O6  
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Names of Putative Compounds Chemical Formula
475.137 250   
   2-Acetyl-1,6,8-trihydroxy-3-methylanthraquinone, 8CI; 8-
O-ß-D-Glucoside  
 C23H22O11  
   Acremolactone A   C26H34O8  
   Agrimophol   C26H34O8  
   Amoorastatin; O3-De-Ac   C26H34O8  
   1,5-Anhydrofructose, 9CI; D-form, Tribenzoyl   C27H22O8  
   1,6-Anhydromannose; ß-D-Pyranose-form, 2,3,4-
Tribenzoyl  
 C27H22O8  
   Apigenin 7-glycosides; 7-O-ß-D-Glucuronopyranoside, Et 
ester  
 C23H22O11  
   Austalide B   C26H34O8  
   Bacillisporin B   C26H18O9  
   Bergenin; 11-O-(E-4-Hydroxycinnamoyl)   C23H22O11  
   Bipinnatin B   C24H26O10  
   Bisinaiquinone   C30H18O6  
   Chicoric acid   C22H18O12  
   Chicoric acid; (2R,3R)-form   C22H18O12  
   Chicoric acid; (2S,3S)-form   C22H18O12  
   Chicoric acid; (2RS,3RS)-form   C22H18O12  
   Chicoric acid; (2RS,3SR)-form   C22H18O12  
   15-Chloro-1,4-epoxy-5,8,9-trihydroxy-11(13)-germacren-
12,6-olid-14-oic acid; (1ß,4ß,5ß,6a,8ß,9a,10ßH)-form, 8-
(2-Hydroxymethyl-2-butenoyl), Me ester  
 C21H27ClO10  
   Clausenolide; 1-Me ether   C26H34O8  
   Cosmosiin; 2''-Ac   C23H22O11  
   Cosmosiin; 3''-Ac   C23H22O11  
   Cosmosiin; 4''-Ac   C23H22O11  
   Cosmosiin; 6''-Ac   C23H22O11  
   Cryptochlorophaeic acid; O-De-Me, 4,4'-di-Me ether   C26H34O8  
   Cryptochlorophaeic acid; 4-Me ether   C26H34O8  
   Cryptochlorophaeic acid; 4'-Me ether   C26H34O8  
   Curcapitoside   C23H22O11  
   1-[5-ß-D-Glucopyranosyl-4',5'-dihydro-3',4,4',6-
tetrahydroxy-5'-(hydroxymethyl)spiro[benzofuran-
2(3H),2'(3'H)-furan]-7-yl]ethanone, 9CI  
 C20H26O13  
   Deacyltaiwanschirin; 10-Ac   C24H26O10  
   4-N-Demethyl-4-N-ethyloxytetracycline   C23H26N2O9  
   1-Deoxy-ß-D-fructopyranosyl-(1?2)-[1-deoxy-ß-D-
fructopyranosyl-(1?3)]-L-arabinose  
 C17H30O15  
   1-Deoxy-ß-D-fructopyranosyl-(1?2)-[1-deoxy-ß-D-
fructopyranosyl-(1?3)]-L-arabinose; a-Furanose-form  
 C17H30O15  
   6-Deoxymannonic acid, 9CI, 8CI; L-form, 1,5-Lactone, 
tribenzoyl  
 C27H22O8  
   Derrisin; 11,12a-Dihydroxy, 4'-Me ether   C24H26O10  
   a-D-Arabinofuranosyl-(1?2)-a-D-mannopyranosyl-(1?2)-
D-glucose, 9CI  







Names of Putative Compounds Chemical Formula
475.137 250  a-D-Arabinofuranosyl-(1?2)-a-D-mannopyranosyl-(1?2)-
D-glucose, 9CI; a-Pyranose-form  
 C17H30O15  
(continued)   ß-D-Arabinopyranosyl-(1?2)-a-D-mannopyranosyl-(1?2)-
D-glucose  
 C17H30O15  
   ß-D-Arabinopyranosyl-(1?2)-a-D-mannopyranosyl-(1?2)-
D-glucose; a-Pyranose-form  
 C17H30O15  
  D-Galactopyranosyl-(1?3)-D-galactopyranosyl-(1?3)-L-
arabinose, 9CI  
 C17H30O15  
   ß-D-Galactopyranosyl-(1?6)-ß-D-galactopyranosyl-(1?3)-
L-arabinose, 8CI  
 C17H30O15  
   ß-D-Glucopyranosyl-(1?2)-[ß-D-apiofuranosyl(1?6)]-D-
glucose  
 C17H30O15  
   ß-D-Glucopyranosyl-(1?2)-[ß-D-apiofuranosyl(1?6)]-D-
glucose; ß-D-Pyranose-form  
 C17H30O15  
   ß-D-Glucopyranosyl-(1?3)-ß-D-glucopyranosyl-(1?2)-D-
xylose, 9CI  
 C17H30O15  
   ß-D-Glucopyranosyl-(1?3)-ß-D-glucopyranosyl-(1?2)-D-
xylose, 9CI; Pyranose-form  
 C17H30O15  
   ß-D-Glucopyranosyl-(1?2)-[ß-D-glucopyranosyl-(1?4)]-
L-arabinose, 8CI  
 C17H30O15  
   a-D-Xylopyranosyl-(1?6)-ß-D-glucopyranosyl-(1?4)-D-
glucose, 9CI  
 C17H30O15  
   ß-D-Xylopyranosyl-(1?6)-ß-D-glucopyranosyl-(1?4)-D-
glucose, 9CI  
 C17H30O15  
   3,6:7,8-Diepoxy-13-hydroxy-18-oxo-3,5,11,15-
cembratetraen-20,10-olide; (1R,7S,8S,10S,13R)-form, 17-
Acetoxy, 11a,12a-epoxide, 13-Ac  
 C24H26O10  
   14,15:19,29-Diepoxy-1,3,7,29-tetrahydroxy-11-
meliacanone  
 C26H34O8  
   14,15:19,29-Diepoxy-1,3,7,29-tetrahydroxy-11-
meliacanone; (1a,3a,7a,14ß,15ß,29R)-form  
 C26H34O8  
   7,8:17,18-Diepoxy-1(19),6(20),10(17),13-xenicatetraene-
11,12,18-triol; Tri-Ac  
 C26H34O8  
   Dihydro-3-(hydroxymethyl)-4-[bis(3,4,5-
trihydroxyphenyl)methyl]-2(3H)furanone; (8R*,8'R*)-
form, 3,4-Methylene, 3',5,5'-tri-Me ether, 7-Ac  
 C24H26O10  
   3',4'-Dihydroxyacetophenone, 8CI; 3'-Me ether, 4'-O-[a-
L-rhamnopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C21H30O12  
   3',4'-Dihydroxyacetophenone, 8CI; 3'-Me ether, 4'-O-[4-
hydroxy-E-cinnamoyl-(?6)-ß-D-glucopyranoside]  
 C24H26O10  
   6,7-Dihydroxy-2H-1-benzopyran-2-one, 9CI; 7-O-[4-
Hydroxyphenylacetyl-(?6)-ß-D-glucopyranoside]  
 C23H22O11  
   1-(3,4-Dihydroxybenzoyl)-3,6,7-naphthalenetriol; 3-O-ß-
D-Glucopyranoside  
 C23H22O11  
   6-O-(3,4-Dihydroxycinnamoyl)glucose; ß-D-Pyranose-
form, 2,3,4-Trihydroxy-3-methylbutyl glycoside, 3'-Me 
ether  
 C21H30O12  
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Names of Putative Compounds Chemical Formula
475.137 250  4,8-Dihydroxy-2,10(14),11(13)-guaiatrien-12,6-olide; 
(1a,4a,5a,6a,8ß)-form, 8-O-[4-Hydroxy-2-(2-
hydroxymethyl-2E-butenoyloxy)methyl-2E-butenoyl]  
 C25H30O9  
(continued)   5,7-Dihydroxy-1(3H)-isobenzofuranone, 9CI; 5-Me ether, 
7-O-[ß-D-xylopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C20H26O13  
   4,13-Dihydroxylupanine; (4?,13?)-form, O13-(3,4,5-
Trimethoxybenzoyl)  
 C25H34N2O7  
   5,7-Dihydroxy-4'-methoxyflavone, 8CI; 7-O-ß-D-
Glucuronopyranoside, Me ester  
 C23H22O11  
   4',5-Dihydroxy-6,7-methylenedioxyisoflavone; 5-Me 
ether, 4'-O-ß-D-glucopyranoside  
 C23H22O11  
   2,3-Dihydroxy-2-(2-methylpropyl)butanedioic acid; 
(2R,3S)-form, 1-(4-ß-D-Glucopyranosyloxybenzyl) ester  
 C21H30O12  
   2,3-Dihydroxy-2-(2-methylpropyl)butanedioic acid; 
(2R,3S)-form, 4-(4-ß-D-Glucopyranosyloxybenzyl) ester  
 C21H30O12  
   1-(3,4-Dihydroxyphenyl)-1-propanone, 9CI; 3-Me ether, 
4-O-[ß-D-apiofuranosyl-(1?6)-ß-D-glucopyranoside]  
 C21H30O12  
   3-(3,4-Dihydroxyphenyl)-2-propenoic acid, 9CI; (E)-
form, [ß-D-Apiofuranosyl-(1?6)-ß-D-glucopyranosyl] 
ester  
 C20H26O13  
   3-(3,4-Dihydroxyphenyl)-2-propen-1-ol; (E)-form, 3'-Me 
ether, 1-O-[ß-D-apiofuranosyl-(1?6)-ß-D-
glucopyranoside]  
 C21H30O12  
   3-(3,4-Dihydroxyphenyl)-2-propen-1-ol; (E)-form, 3'-Me 
ether, 4'-O-[ß-D-apiofuranosyl-(1?2)-ß-D-
glucopyranoside]  
 C21H30O12  
   3-(3,4-Dihydroxyphenyl)-2-propen-1-ol; (E)-form, 3'-Me 
ether, 1-O-[a-L-arabinofuranosyl-(1?6)-ß-D-
glucopyranoside]  
 C21H30O12  
   6-(3,7-Dimethyl-2,6-octadienyl)-5,7-dihydroxy-8-(2-
methyl-1-oxobutyl)-4-phenyl-2H-1-benzopyran-2-one  
 C30H34O5  
   6-(3,7-Dimethyl-2,6-octadienyl)-5,7-dihydroxy-8-(2-
methyl-1-oxobutyl)-4-phenyl-2H-1-benzopyran-2-one; (?)-
(E)-form  
 C30H34O5  
   6-(3,7-Dimethyl-2,6-octadienyl)-5,7-dihydroxy-8-(2-
methyl-1-oxobutyl)-4-phenyl-2H-1-benzopyran-2-one; (?)-
(E)-form, 3-Methylbutanoyl isomer  
 C30H34O5  
   8-(3,7-Dimethyl-2,6-octadienyl)-5,7-dihydroxy-6-(2-
methyl-1-oxobutyl)-4-phenyl-2H-1-benzopyran-2-one  
 C30H34O5  
   8-(3,7-Dimethyl-2,6-octadienyl)-5,7-dihydroxy-6-(2-
methyl-1-oxobutyl)-4-phenyl-2H-1-benzopyran-2-one; (?)-
(E)-form  
 C30H34O5  
   8-(3,7-Dimethyl-2,6-octadienyl)-5,7-dihydroxy-6-(2-
methyl-1-oxobutyl)-4-phenyl-2H-1-benzopyran-2-one; (?)-
(E)-form, 3-Methylbutanoyl isomer  
 C30H34O5  
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475.137 250  1,16-Eicosanediol; (?)-form, Di-O-sulfate   C20H42O8S2  
(continued)   Epiphorellic acid 1   C26H34O8  
   15,16-Epoxy-1,2-dihydroxy-3,13(16),14-clerodatrien-
17,12-olid-18-oic acid; (ent-1ß,2ß,12ßH)-form, Di-Ac, Me 
ester  
 C25H30O9  
   10,14-Epoxy-2,8-dihydroxy-3,11(13)-guaiadien-12,6-
olide; (1a,2ß,5a,6a,8ß,10a)-form, 8-[2-(2-Hydroxymethyl-
2E-butenoyloxymethyl)-2E-butenoyl]  
 C25H30O9  
   1,4-Epoxy-8,13-dihydroxy-3-oxo-1,5,7(11)-
germacratrien-12,6-olide; (4a,5E,8a,10ß)-form, 8-(4-
Acetoxy-3-methyl-2-butenoyl)(Z-), 13-Ac  
 C24H26O10  
   3,4-Epoxy-8,9-dihydroxy-2-oxo-1(10),11(13)-guaiadien-
12,6-olide; (3a,4a,5a,6a,8ß,9ß)-form, 8-(2-Acetoxymethyl-
2E-butenoyl), 9-Ac  
 C24H26O10  
   19,29-Epoxy-1,3,7,12,29-pentahydroxy-14-meliacen-11-
one  
 C26H34O8  
   19,29-Epoxy-1,3,7,12,29-pentahydroxy-14-meliacen-11-
one; (1a,3a,7a,12a,29R)-form  
 C26H34O8  
   14,15-Epoxy-3,5,16,19-tetrahydroxybufa-20,22-dienolide; 
(3ß,5ß,14ß,15ß,16ß)-form, 16-Ac  
 C26H34O8  
   19,29-Epoxy-1,3,7,29-tetrahydroxymeliacane-11,15-dione   C26H34O8  
   19,29-Epoxy-1,3,7,29-tetrahydroxymeliacane-11,15-
dione; (1a,3a,7a,29R)-form  
 C26H34O8  
   8,17-Epoxy-2,9,12-trihydroxy-5,13-briaradien-18,7-olide; 
(2ß,5Z,7a,8a,9ß,12a,17a)-form, 12-Ketone, 2-butanoyl, 9-
Ac  
 C26H34O8  
   Euchrenone a4   C30H34O5  
   Euchrenone a4; (S)-form   C30H34O5  
   Fleminginin   C30H34O5  
   8-Galactopyranosyl-4',5,7-trihydroxyflavone; 6''-O-Ac   C23H22O11  
   Gelliusine E; (±)-form, 5-Deoxy, 6-bromo   C20H20Br2N4  
   8-Glucofuranosyl-4',5,7-trihydroxyflavone; 2''-Acetyl   C23H22O11  
   3',4,4',5,5',9,9'-Heptahydroxy-2,7'-cyclolignan; 
(7'S,8R,8'R)-form, 3',5,5'-Tri-Me ether, 9,9'-di-Ac  
 C25H30O9  
   3,3',4,4',5,9,9'-Heptahydroxylignan; (8R,8'R)-form, 3',4'-
Methylene, 3,5-di-Me ether, 9,9'-di-Ac  
 C25H30O9  
   1,3,5,11,14,19-Hexahydroxybufa-20,22-dienolide; 
(1ß,3ß,5ß,11a,14ß)-form, 1,3,5-Orthoacetate  
 C26H34O8  
   3',4,4',5,9,9'-Hexahydroxy-2,7'-cyclolignan; (7'S,8R,8'R)-
form, 3',5-Di-Me ether, 9-O-(5-hydroxy-4-oxopentanoyl)  
 C25H30O9  
   3',4,4',5,9,9'-Hexahydroxy-2,7'-cyclolignan; (7'S,8R,8'R)-
form, 3',5-Di-Me ether, 9'-O-(5-hydroxy-4-oxopentanoyl)  
 C25H30O9  
   3,3',4,4',9,9'-Hexahydroxylignan; (8R,8'R)-form, 3,3',4,4'-
Tetra-Me ether, 9,9'-di-Ac  
 C26H34O8  
   4'-Hydroxyacetophenone, 8CI; O-[4-Hydroxy-3-methoxy-
E-cinnamoyl-(?6)-ß-D-glucopyranoside]  
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475.137 250  8-Hydroxy-1(10),3,11(13)-guaiatrien-12,6-olide; 
(5a,6a,8ß)-form, [4-Hydroxy-2-(4-hydroxy-2-
hydroxymethyl-2E-butenoyloxymethyl)-2E-butenoyl]  
 C25H30O9  
(continued)   8-Hydroxy-3,10(14),11(13)-guaiatrien-12,6-olide; 
(1a,5a,6a,8ß)-form, 8-[4-Hydroxy-2-(4-hydroxy-2-
hydroxymethyl-2-butenoyloxymethyl)-2-butenoyl](E,E-)  
 C25H30O9  
   Hypholomin A   C26H18O9  
   Isocryptochlorophaeic acid; 4-Me ether   C26H34O8  
   4-Isopropylbenzyl alcohol; O-[ß-D-Glucopyranosyl-
(1?2)-ß-D-galactopyranoside]  
 C22H34O11  
   2-Isopropyl-5-methyl-1,4-benzenediol; 5-O-[a-L-
Rhamnopyranosyl-(1?2)-ß-D-glucopyranoside]  
 C22H34O11  
   2-Isopropyl-5-methylphenol; O-[ß-D-Glucopyranosyl-
(1?2)-ß-D-glucopyranoside]  
 C22H34O11  
   5-Isopropyl-2-methylphenol; O-[ß-D-Glucopyranosyl-
(1?2)-ß-D-glucopyranoside]  
 C22H34O11  
   Kadsulignan A; 6ß-Acetoxy   C25H30O9  
   Kaempferol 3-glycosides; Monoglycosides, 3-O-(2-O-
Acetyl-a-L-rhamnopyranoside)  
 C23H22O11  
   Kaempferol 3-glycosides; Monoglycosides, 3-O-(3-O-
Acetyl-a-L-rhamnopyranoside)  
 C23H22O11  
   Kaempferol 3-glycosides; Monoglycosides, 3-O-(4-O-
Acetyl-a-L-rhamnopyranoside)  
 C23H22O11  
   Kopsaporine; 12-Methoxy, 14,15-dihydro, 15a-hydroxy   C24H30N2O8  
   a-L-Arabinofuranosyl-(1?6)-[ß-D-galactopyranosyl-
(1?3)]-D-galactose  
 C17H30O15  
   a-L-Arabinofuranosyl-(1?6)-[a-D-glucopyranosyl-(1?4)]-
D-glucose, 9CI  
 C17H30O15  
   a-L-Arabinofuranosyl-(1?6)-[a-D-glucopyranosyl-(1?4)]-
D-glucose, 9CI; ß-Pyranose-form  
 C17H30O15  
   a-L-Arabinofuranosyl-(1?2)-[a-D-mannopyranosyl-
(1?6)]-D-mannose  
 C17H30O15  
   a-L-Arabinofuranosyl-(1?2)-[a-D-mannopyranosyl-
(1?6)]-D-mannose; a-form  
 C17H30O15  
   Ligulaverin C; 6-Deacyl, 6-angeloyl   C26H34O8  
   Loxodinol   C25H30O9  
   Luteusin C; Stereoisomer 1, Me ether   C26H31ClO6  
   Mallotophilippen C   C30H34O5  
   Maximowicziol A; 11-Ketone, 4-O-ß-D-glucopyranoside   C25H30O9  
   8-Methoxy-3,4-methylenedioxy-1-
phenanthrenecarboxylic acid; 6-Hydroxy, O-ß-D-
glucopyranoside  
 C23H22O11  
   5-Methyl-2-hexene-1,4,5-triol; 4-(4-Hydroxybenzoyl), 
1,5-dibenzoyl  
 C28H26O7  
   Millewanin D   C30H34O5  
   Munronin F   C25H30O9  
   Murrafoline B   C32H30N2O2  
   Murrafoline B; (±)-form   C32H30N2O2  
   Murrafoline D   C32H30N2O2  
   Murrafoline D; (±)-form   C32H30N2O2  
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475.137 250  Murrafoline G   C32H30N2O2  
(continued)   Murrafoline G; (±)-form   C32H30N2O2  
   Murrastifoline D; 3'-Deoxy   C32H30N2O2  
   Neocalyxin A   C28H26O7  
   Neocalyxin A; 2-Epimer   C28H26O7  
   Nordracorubin   C31H22O5  
   Nordracorubin; (S)-form   C31H22O5  
   Nordracorubin; (±)-form   C31H22O5  
   Nostocyclamide   C20H22N6O4S2  
   3,3',4,4',5,5',9,9'-Octahydroxy-7,7'-epoxylignan; 
(7S,7'S,8R,8'R)-form, 3,4:3',4'-Bis(methylene), 5,5'-di-Me 
ether, 9-Ac  
 C24H26O10  
   3,3',4,4',5,5',9,9'-Octahydroxy-7,7'-epoxylignan; 
(7R,7'S,8R,8'R)-form, 3,4:3',4'-Bis(methylene), 5,5'-di-Me 
ether, 9-Ac  
 C24H26O10  
   3,3',4,4',5,5',9,9'-Octahydroxy-7,7'-epoxylignan; 
(7S,7'R,8R,8'R)-form, 3,4:3',4'-Bis(methylene), 5,5'-di-Me 
ether, 9-Ac  
 C24H26O10  
   Oganomycin GI   C16H18N4O7S3  
   1,3,5,14,19-Pentahydroxybufa-20,22-dienolide; 
(1ß,3ß,5ß,14ß)-form, 19-Aldehyde, 3-Ac  
 C26H34O8  
   3,6,8,12,14-Pentahydroxybufa-4,20,22-trienolide; 
(3ß,6ß,12ß,14ß)-form, 6-Ac  
 C26H34O8  
   3,4',5,6,7-Pentahydroxyflavone; 6,7-Methylene, 4',5-di-
Me ether, 3-O-ß-D-xylopyranoside  
 C23H22O11  
   3',4',5',6,7-Pentahydroxyisoflavone; 3',4'-Methylene, 5'-
Me ether, 6-O-a-L-rhamnopyranoside  
 C23H22O11  
   3',4',5',6,7-Pentahydroxyisoflavone; 3',4'-Methylene, 7-
Me ether, 6-O-a-L-rhamnopyranoside  
 C23H22O11  
   1,3,7,11,12-Pentahydroxy-14-meliacen-28-oic acid; 
(1a,3a,7a,11ß,12a)-form, 7-Ketone  
 C26H34O8  
   Perophoramidine   C21H17BrCl2N4  
   Petromurin C; 5''-Methoxy   C27H26N2O6  
   Phelligridin E   C25H14O10  
   1,18-Phytanediol; Disulfate   C20H42O8S2  
   Picrasin A   C26H34O8  
   Podophyllic acid; (7R,7'R,8R,8'R)-form, N-
Ethylhydrazide  
 C24H30N2O8  
   Poinsettifolin B   C30H34O5  
   4-(2-Propenyl)-1,2-benzenediol, 9CI; Di-O-ß-D-
glucopyranoside  
 C21H30O12  
   5-(2-Propenyl)-1,2,3-benzenetriol; 1-Me ether, 3-O-[ß-D-
apiofuranosyl-(1?6)-ß-D-glucopyranoside]  
 C21H30O12  
   5-(2-Propenyl)-1,2,3-benzenetriol; 1-Me ether, 3-O-[a-L-
arabinopyranosyl-(1?6)-ß-D-glucopyranoside]  
 C21H30O12  
   Protocetraric acid; 1'-O-(3-Carboxypropanoyl)   C22H18O12  
   Puerol A; 4''-Me ether, 2''-O-ß-D-glucopyranoside   C24H26O10  
   Punaglandin 1; Bromo analogue, tri-O-de-Ac   C21H31BrO7  
   Rhinacanthin Q   C28H26O7  
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Names of Putative Compounds Chemical Formula
475.137 250  Robustaol A   C25H30O9  
(continued)   Rubraflavone A; 8-(3-Methyl-2-butenyl)   C30H34O5  
   Saroaspidin C   C26H34O8  
   Scandoside; 6-Butanoyl, Me ester   C21H30O12  
   Scandoside; 6-Epimer, 6-butanoyl, Me ester   C21H30O12  
   4,15-Scirpenediol; 4ß-form, Dibenzoyl   C29H30O6  
   Sclerotiorin; (7S,11E)-form, O-De-Ac, O-(4-carboxy-3-
methyl-2E-butenoyl)  
 C25H27ClO7  
   Sclerotiorin; (7S,11E)-form, O-De-Ac, O-(4-carboxy-3-
methyl-2Z-butenoyl)  
 C25H27ClO7  
   Sclerotiorin; (7S,11E)-form, O-De-Ac, O-(4-carboxy-3-
methyl-3E-butenoyl)  
 C25H27ClO7  
   Sclerotiorin; (7S,11E)-form, O-De-Ac, O-(4-carboxy-3-
methyl-3Z-butenoyl)  
 C25H27ClO7  
   Spinonin; 4'-Me ether   C24H26O10  
   13(16),14-Spongiadiene-2,3,17,19-tetrol; 3a-form, 2-
Ketone, tri-Ac  
 C26H34O8  
   Terretonin D   C26H34O8  
   2,4,6,8,10,12-Tetradecahexaenedioic acid; (all-E)-form, 
1-L-Aspartic acid, 14-L-isoleucine diamide  
 C24H30N2O8  
   5,6,8,13-Tetrahydro-1,7,9,11-tetrahydroxy-8,13-dioxo-3-
(2-oxopropyl)benzo[a]naphthacene-2-carboxylic acid, 9CI  
 C26H18O9  
   3',4,4',5-Tetrahydroxy-2,7'-cyclolign-7-ene-9,9'-dioic 
acid; (7'R,8'S)-form, 9-O-(1S,2-Dicarboxyethyl) ester  
 C22H18O12  
   1,4,6,9-Tetrahydroxydihydro-ß-agarofuran; (1a,4ß,6ß,9ß)-
form, 1-Benzoyl, 6,9-di-Ac  
 C26H34O8  
   1,6,8,9-Tetrahydroxydihydro-ß-agarofuran; (1a,6ß,8a,9a)-
form, 9-Benzoyl, 1,6-di-Ac  
 C26H34O8  
   3,3',4',7-Tetrahydroxyflavone; 3',4'-Methylene, 3-Me 
ether, 7-O-ß-D-glucopyranoside  
 C23H22O11  
   2',4',5',7-Tetrahydroxyisoflavone; 4',5'-Methylene, 2'-Me 
ether, 7-O-ß-D-glucopyranoside  
 C23H22O11  
   2',5,6,7-Tetrahydroxyisoflavone; 6,7-Methylene, 5-Me 
ether, 2'-O-ß-D-glucopyranoside  
 C23H22O11  
   3',4',6,7-Tetrahydroxyisoflavone; 3',4'-Methylene, 6-Me 
ether, 7-O-ß-D-glucopyranoside  
 C23H22O11  
   3,5,11,14-Tetrahydroxy-12-oxobufa-20,22-dienolide; 
(3ß,5ß,11a,14ß)-form, 3-Ac  
 C26H34O8  
   3,5,12,14-Tetrahydroxy-11-oxobufa-20,22-dienolide; 
(3ß,5ß,12ß,14ß)-form, 3-Ac  
 C26H34O8  
  O,O,O',O'-Tetrapropyl 2,2'-(1,2-dimethyl-1,2-
ethanediylidene)bis(phosphorohydrazidothioate)  
 C16H36N4O4P2S2  
  m-Trigallic acid   C21H14O13  
  p-Trigallic acid   C21H14O13  
   2,3,14-Trihydroxy-5,8(17),11-briaratrien-18,7-olide; 
(2ß,3a,5Z,7a,14a)-form, Tri-Ac  
 C26H34O8  
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Names of Putative Compounds Chemical Formula
475.137 250  6,10,14-Trihydroxy-3,7,11,15(17)-cembratetraen-16,2-
olide; (1S,2S,3E,6S,7E,10S,11E,14S)-form, Tri-Ac  
 C26H34O8  
(continued)   5,7,8-Trihydroxyflavone; 5,8-Di-Me ether, 7-O-ß-D-
glucuronoside  
 C23H22O11  
   2,4,5-Trihydroxy-2-(hydroxymethyl)pentanoic acid; 
(2R,4S)-form, 1,4-Lactone, tribenzoyl  
 C27H22O8  
   4',5,7-Trihydroxyisoflavone; 7-O-(6-O-Acetyl-ß-D-
glucopyranoside)  
 C23H22O11  
   1,3,6-Trihydroxy-2-methylanthraquinone; 3-O-(6-O-
Acetyl-ß-D-glucopyranoside)  
 C23H22O11  
   1,3,8-Trihydroxy-6-methylanthraquinone, 8CI; 1-O-(6-O-
Acetyl-ß-D-glucopyranoside)  
 C23H22O11  
   5,6,8-Trihydroxy-28-norisotoonafolin   C25H30O9  
   5,6,8-Trihydroxy-28-norisotoonafolin; (5a,6ß,8a)-form   C25H30O9  
   2,11,12-Trihydroxy-6,7-seco-8,11,13-abietatriene-6,7-dial 
11,6-hemiacetal; 2a-form, Tri-Ac(6a-)  
 C26H34O8  
   4',5,7-Trihydroxy-3',5',8-triprenylisoflavone   C30H34O5  
   4',5,7-Trihydroxy-3',6,8-triprenylisoflavone   C30H34O5  
   Trillenogenin; 1-Ketone   C26H34O8  
   Tryptoquivaline G; Ac   C25H22N4O6  
   Tuliposide E   C21H30O12  
   Vaccariose   C17H30O15  
   Vitexin; 2''-Ac   C23H22O11  
   Vitexin; 3''-Ac   C23H22O11  
   Vitexin; 6''-Ac   C23H22O11  
   14(17)-Vouacapene-1,5,6,7-tetrol; (1a,5a,6a,7ß)-form, 
1,6,7-Tri-Ac  
 C26H34O8  
   Xenione   C26H34O8  
   Xenione; Stereoisomer   C26H34O8  
513.0843 700   
   Agaricoglyceride A; 2-O-Deacyl, 2-Ac   C19H14Cl4O8  
   Aspergillic acid, 8CI; (S)-form, Zn complex   C24H38N4O4Zn  
   Daphmacrine   C32H49NO4  
   Daphnioldhanin F; (-)-form, 25-Ketone, 26-Ac   C32H49NO4  
   Diphlorethohydroxycarmalol   C24H16O13  
   1-Galloylglucose; ß-D-Pyranose-form, 6-O-(4-Hydroxy-
3,5-dimethoxybenzoyl)  
 C22H24O14  
   5-(Hydroxymethyl)-1,2,3-benzenetriol; 1'-O-(3,4,5-
Trihydroxybenzoyl), 2-O-(6-O-acetyl-ß-D-
glucopyranoside)  
 C22H24O14  
   2-Hydroxymethyl-1,4,5,7-tetrahydroxyanthraquinone; 
Penta-Ac  
 C25H20O12  
   2',3,4',5,7-Pentahydroxyflavone; Penta-Ac   C25H20O12  
   3',4',5,5',7-Pentahydroxyflavone; Penta-Ac   C25H20O12  
   3,4',5,7,8-Pentahydroxyflavone; Penta-Ac   C25H20O12  
   3,4',6,7,8-Pentahydroxyflavone; Penta-Ac   C25H20O12  
   Sarain A   C32H51N2O3  
   Stellettazole B   C30H51N6O  
   Tauroacidin A; 9-Deoxy   C13H16Br2N6O4S  
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Names of Putative Compounds Chemical Formula
513.0843 
(continued) 
700  3,4,5-Trihydroxybenzoic acid; 3-Me ether, 4-O-[3,4-
dihydroxy-5-methoxybenzoyl-(?6)-ß-D-glucopyranoside]  




Table A.3. Compounds and corresponding molecular formulae identified as putative 
matches for Compound X as identified by FTMS, assuming molecular ions were potassium 
adducts. 
Peak m/za m/z - K+
Low limit 10 
ppmb range 
(molar mass)





257.0300723 218.0669053 218.0647246 218.069086 0
317.0957864 278.1326194 278.1298381 278.1354007 8
Compound Name 
 4,4'-Dihydroxy-2,7'-cycloligna-7,7'-diene; 4'-Me ether 
 Eupomatenoid 6; Me ether 
 Lewisone 
 Pantetheine 
 Pantetheine; (R)-form 
 3',4',5,7-Tetramethylflavone 
475.1369619 436.1737949 436.1694332 436.1781566 32c
Compound Name 
































 1,7-Diphenyl-3,5-heptanediol; (3S,5S)-form, 1,2:6,7-
Tetradehydro(E,E-), 3-ketone  C19H18O2 
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Table A.3 continued. 
Peak m/za m/z - K+
Low limit 10 
ppmb range 
(molar mass)





475.1369619 436.1737949 436.1694332 436.1781566 32














germacradien-12,6-olide; (1a,4ß,8a,10a)-form, 1-Me 
ether, 8-O-(2-methylpropenoyl), 13-Ac 
 C22H28O9 
 1,4-Epoxy-1,8,10,13-tetrahydroxy-5,7(11)-


























Table A.3 continued. 
Peak m/za m/z - K+
Low limit 10 
ppmb range 
(molar mass)





475.1369619 436.1737949 436.1694332 436.1781566 32
Compound Name Molecular Formula 
 Glaucarubol; 1-Epimer, 2-ketone, 15-Ac 
 Glaucarubol; 2-Ketone, 15-Ac 
 Samaderine Z; 15-Ac 













































Table A.3 continued. 
Peak m/za m/z - K+
Low limit 10 
ppmb range 
(molar mass)





475.1369619 436.1737949 436.1694332 436.1781566 32
Compound Name Molecular Formula 
 Wybutine; (S)-form, 3-ß-D-Ribofuranosyl 
513.084279 474.121112 474.1163708 474.1258532 0
528.0473004 489.0841334 489.0792426 489.0890242 0
565.2863106 526.3231436 526.3178804 526.3284068 1
Compound Name 







 am/z = mass to charge ratio of molecular ion fragments identified by the mass spectrometer 
bppm = parts per million 
cwith the exception of Wybutine, all of these matched at 2 ppm 
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